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Cardiovascular diseases (CVD) are responsible for more deaths than any other disease, 
continue to threaten the quality of life for many, and is a major burden to the health care 
system. The Framingham Heart Study (FHS) identified the major CVD risk factors that 
became essential to effective CVD screening strategies and the Framingham Risk Score 
(FRS), is used to assess CVD risk. Based on the concepts of the health behavior model 
and CVD as a cardiometabolic disorder, multivariate logistic regression analysis was 
used to evaluate the association between fasting blood glucose (FBG) levels and a CHD 
event, and to determine the value of FBG replacing a diagnosis of diabetes (DM2) in the 
FRS. The data set consisted of the 2,677 subjects of the FHS III cohort. In the univariate 
analysis, both DM2 and FBG were statistically significant (both p =.000), but the 
association was stronger for DM2, b = 2.138, OR = 8.483 (95% CI: 4.229, 17.105) than 
for FBG, b = .015, p = .000, OR=1.015 (95% CI: 1.009, 1.022). When adjusted for age, 
blood pressure, cholesterol, and smoking status, only DM2 remained statistically 
significant, OR = 2.295, p = .041, (95% CI: 1.035, 5.087) in the model. The FBG version 
of the FRS did not provide any improvement in performance, as it was marginally 
inferior to the DM2 version. Furthermore, the interactions between FBG and the 
metabolic risk factors were not statistically significant for this given data set. The results 
imply that a diagnosis of diabetes remains the factor of choice for inclusion in the FRS 
model for predicting the 10-year risk of CHD and replacing it with FBG provides little to 
no practical benefit. These findings support the use of CVD risk factor reduction and the 
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Chapter 1: Introduction to the Study 
Introduction 
Diseases involving the heart and/or blood vessels are known collectively as 
cardiovascular diseases (CVDs) and include disorders such as angina pectoris (AP); 
myocardial infarction (MI); stroke; heart failure (HF); peripheral artery disease (PAD); 
and coronary heart disease (CHD, or coronary artery disease or CAD). Every year over 
800,000 persons in the United States, 4 million in Europe, and another 11 million around 
the globe die from CVDs (American Heart Association, Center for Disease Control, and 
Prevention, & National Institutes of Health, 2015; Ferreira-GonzáLez, 2014). In 
particular, CHD, the most common CVD, is responsible for approximately 70% of all 
CVD deaths, and it is the leading cause of morbidity and mortality worldwide (Grimes, 
2012; Jones & Greene, 2013).  
Not only are cardiovascular diseases responsible for more deaths than any other 
disease type, they are a major burden to the society. CVDs cause more physical 
disabilities, are a major financial drain on the healthcare system, and they also contribute 
to many health disparities (World Health Organization, 2016). In the United States alone, 
CVDs claim the lives of 2,200 Americans every day, while another 92 million remain 
alive to deal with the disease and its many related complications ( Benjamin et al., 2017). 
In 2012, those living with cardiovascular disease and its physical, mental and social 
impact, generated $316 billion, in direct health care cost and loss of productivity 
combined ( Benjamin et al., 2017). Consequently, responding to the epidemic of heart 




Given the severity of the threat they pose, there is a concerted effort at reducing 
the incidence and prevalence of CVDs. The American Heart Association uses records of 
risk factors from epidemiological and clinical data to monitor the prevalence and 
incidence of CVD and track the results of prevention and treatment efforts (Goff et al., 
2014). The 2020 Impact Goal remains committed to reducing CVD deaths by 20% and to 
a general improvement in cardiovascular health by 20% by the year 2020 ( Benjamin et 
al., 2017). The Healthy People 2020 initiative uses early risk identification and treatment 
to “improve cardiovascular health and quality of life through prevention, detection, and 
treatment of risk factors” (U.S. Department of Health and Human Services, 2018). 
Critical to any effective early identification and prevention strategy is effective risk factor 
detection and classification.  
Background 
Over half a century ago, the Framingham Heart Study (FHS) expanded the 
understanding of CVDs by identifying the major risk factors involved (Dawber et al., 
1959; Dawber, Meadors, & Moore, 1951). The FHS research continues to today and now 
includes other chronic diseases but CVD remains its primary focus (D’Agostino, Pencina, 
Massaro, & Coady, 2013; Kannel & McGee, 1979; Mahmood, Levy, Vasan, & Wang, 
2014). The major CVD risk factors uncovered by the FHS include gender, age, 
cholesterol level, smoking status, blood pressure, and history of heart disease (Dawber et 
al., 1959; Dawber & Lansing, 1966; Kannel, Castelli, Gordon, & Mcnamara, 1971). 




the role of these risk factors in the long-term development of CVD (Centers for Disease 
Control and Prevention, 2013) 
Most of the established CVD risk factors are modifiable, and it is for this reason 
mainly that CVD is classified as a preventable disease. The CDC reported that 80% of all 
CVD deaths in 2010 were the direct result of these modifiable factors, and as such those 
deaths were considered avoidable (Centers for Disease Control and Prevention, 2013). In 
fact, prevention strategies focused on risk factor reduction have resulted in significant 
decreases in the prevalence, the incidence, the morbidity, and the mortality of CVD (Goff 
et al., 2014; Grundy et al., 2002; Stone et al., 2013). Effective CVD prevention is 
dependent on early detection and prediction, for which accurate and reliable risk formulas 
are essential ( Eichler, Puhan, Steurer, & Bachmann, 2007; Fuster & Kelly, 2010; Keaven 
Anderson, Wilson, Odell, & Kannel, 1991;Wilson et al., 1998).  
One of several CVD risk formulas is the framing risk score (FRS) formulated by 
the Framingham heart study researchers. The initial version, published in 1998, was 
developed using many of the risk factors discovered several decades earlier (Wilson et 
al., 1998). The original FRS formula was used to determine the likelihood of an 
individual developing CVD over a given period, most commonly, 10-year period (Wilson 
et al., 1998). A revised version, released 4 years later, replaced diabetic status with 
dyslipidemia and added hypertension medication to represent a history of heart disease 
(Grundy et al., 2002). This was based on diabetes now being considered a CVD risk 
equivalent, and with the omission, diabetics were now regarded as having a history of 




is now gender specific, and male and female FRS includes measures of age, total and 
HDL cholesterol, systolic blood pressure, and cigarette smoking (Dahlöf, 2010; 
O’Donnell & Elosua, 2008).  
Presently, almost anyone with relevant medical information can obtain a measure 
of their 10-year risk of CVD. The FRS is available in many formats including survey 
questionnaire printouts, as tables and charts for readout, or as computerized programs for 
healthcare professionals, and even as smart phone applications for lay persons 
(D’Agostino et al., 2008; “Framingham Risk Score Calculator for Coronary Heart 
Disease,” 2018). The FRS is the most widely used CVD screening tool in the United 
States (Steyerberg et al., 2010), and has become the heart of the public health response to 
the CVD epidemic (Kones, 2011; Mahmood et al., 2014; Wilson et al., 1998). Since its 
introduction in the late 1990s, alternative CVD risk screening approaches have been 
developed, but the FRS remains the most popular (Günaydın et al., 2016; Tsao, 2015).  
Although the FRS has been an invaluable tool in the task of screening for 
individual CVD risk, it has several noteworthy limitations. First, the experts have 
confirmed that the FRS’s predictive ability is limited to future coronary heart disease 
(CHD) only and does not extend to other coronary events, such as stroke, ischemic attack 
or heart failure (D’Agostino et al., 2013; Root, Hu, & Duncan, 2014). Second, the FRS 
overestimates CVD risk in some populations and underestimates CVD risk in others, 
impeding its usefulness in targeting high risk individuals for prevention treatment ( 




track changes in risk levels over time, also presented opportunities for formula 
optimization (Dahlöf, 2010).  
One of the more popular areas of formula optimization for CVD risk models has 
been the reevaluation of the role of diabetes as a risk factor. There are several reasons for 
this reevaluation but the main two are (a) the changes in the working definition of the 
disease diabetes (new glucose threshold and new diagnostics), and (b) the significant 
increase in the incidence and prevalence of diabetes over the last 50 years (Mayfield, 
1988; Shaw, Zimmet, McCarty, & de Courten, 2000; Wareham, 1998). Reevaluation of 
diabetes was also supported by the discrepancy relationship between observational 
studies, with respect to CVD and diabetes treatment, and findings in clinical trials, at the 
end of the last decade (Qazi & Malik, 2013a). The efforts to abate the increased CVD 
mortality and morbidity of diabetics by treating hyperglycemia has proven ineffective 
(Duckworth et al., 2009; Kelly, Bazzano, Fonseca, & al., 2009; Miller et al., 2008; 
Reaven et al., 2009). This led to the call for more research into the interaction between 
diabetes and cardiovascular diseases and the level of CVD risk possessed by those with 
diabetes. 
The role of the diabetic status as factor in the FRS has undergone several changes 
over the years. Diabetic status was included as binary yes/no variable in the first 
published FRS formula several decades after the FHS was launched (Wilson et al., 1998). 
And, despite subsequent augmentation, namely replacing dichotomous or categorical 
variables (e.g. cholesterol and blood pressure) with their continuous counterparts, 




et al., 2002). However, a diagnosis of diabetes based simply on an arbitrary threshold for 
blood glucose ignores the complexity of the association between glucose levels and CVD 
risk, a complexity that is confirmed in clinical research (Faeh, Rohrmann, & Braun, 
2013; Fawwad, Moin, Siddiqui, Hydrie, & Basit, 2016; Park et al., 2013). But the 
eventual exclusion of diabetes from the FRS has resulted in the loss of significant risk 
information and may have rendered it less effective in predicting heart disease. 
The relationship between blood glucose and the risk of CVD provides important 
CVD risk prediction. Previous research show that blood glucose levels both above and 
below the diabetes threshold are associated with the probability of CVD development 
(Dahlöf, 2010; Kadowaki et al., 2008; Park et al., 2013; Perreault et al., 2014; Valentino 
et al., 2015). It is now accepted that hyperglycemia, hypoglycemia, and glycemic 
variability are all implicated in the macrovascular dysfunction common in diseases of the 
heart and circulatory system ( Benjamin et al., 2017; Saisho, 2014; The Emerging Risk 
Factors Collaboration, 2010; Zhang et al., 2014). Moreover, recent research claims that 
glucose level may be a better predictor of CVD development than is cholesterol level and 
supports its inclusion in CVD risk formulas (Braun, Bopp, & Faeh, 2013; Clark, Perkins, 
Carson, Boyd, & Jefferson, 2015; Lammertyn et al., 2011).  
Unlike a decade ago when the clinical evidence was contradictory, several studies 
now show that the control of blood glucose levels does improve symptoms of CVD (Chi, 
Snaith, & Gunton, 2017; Coch & Green, 2016; Kelly et al., 2009; Xu & Rajaratnam, 
2017). Carter et al (2016) recently found that among the primary risk indicators 




cardiometabolic marker and has the strongest association to high CVD risk in African 
Americans. Prediction models that exclude glucose levels, even at the prediabetes state, 
ignore important CVD risk prediction and stratification information (Huang, Cai, Mai, Li, 
& Hu, 2016). More accurate risk prediction information could ultimately lead to more 
effective early prevention strategies. And it is this theory that was the basis of the 
statistical analysis in my research project. 
Problem Statement 
Despite decades of clinical and epidemiological research, estimating the risk of 
CVD in the general population remains challenging. The FRS, the most commonly used 
prediction tool, has many known limitations with regard to precision and accuracy 
(Brindle et al., 2005; Eichler, Puhan, Steurer, & Bachmann, 2007). Even with its 
widespread use, the FRS is far from infallible, frequently generating overestimations or 
inconsistent results, with significant classification errors, which has been reported as high 
as 37% on one occasion (D’Agostino et al., 2008; Kones, 2011). A more effective and 
accurate risk assessment tool is critical to an improved public health response to the 
burden of CVDs (Goff et al., 2014; Kones, 2011). 
Recognition of CVD as a cardio-metabolic disease can lead to important 
improvements in the risk prediction effort. Some of the most key CVD risk factors (BMI, 
high cholesterol, and high blood pressure), along with insulin resistance and 
hyperglycemia, are all symptoms of metabolic syndrome (MetS), which is itself a most 
effective predictor CVD risk (Clark et al., 2015; D’Agostino et al., 2008; Goff et al., 




such as blood glucose levels as a risk factor, may provide valuable risk prediction 
information (Cockram et al., 2001; D. Lloyd-Jones et al., 2010). In this research I aimed 
to demonstrate the utility of blood glucose levels in improving the discriminatory power 
and classification ability of the FRS predicting the most injurious of CVDs, CHD. 
Purpose 
This study investigated the effect of blood glucose (BG) levels on the 
performance of the FRS formula. The approach involved generating an alternative 
version of the FRS formula, in which the binary variable diabetic status was replaced 
with continuous variable, BG levels values and evaluating the prediction performance of 
the FRS version. The coefficients or odds ratio (OR) of the two risk factors (BG and 
diabetic status), as well as the overall performance of respective multiple logistic 
regression (MLR) models was assessed for both. The role of the comorbid, metabolic risk 
factors (BMI, cholesterol, blood pressure), was also examined for any interaction with 
and then their effect on the predictive role of blood glucose level on the model’s 
performance. The objective was to produce a more accurate, and therefore reliable 
algorithm for predicting CHD event probability among asymptomatic individuals (see 
D’Agostino et al., 2013; Van Staa et al., 2014). The formulas were based on the 10-year 






I sought to answer the following three research questions: 
RQ1: Is the relative risk for glucose level higher than that for diabetic status in the 
CHD 10-year risk prediction? 
H01: There is no difference between the relative risk for glucose level and that for 
diabetic status in the CHD 10-year risk prediction.  
Ha1: The relative risk for glucose level is higher than that for diabetic status in the CHD 
10-year risk prediction. 
RQ2: Is the measure of accuracy for glucose level higher than that for diabetic 
status in the CHD 10-year risk prediction formula? 
H02: There is no difference between the measure of accuracy for glucose level and 
diabetic status in the CHD 10-year risk prediction formula. 
HA2: The measure of accuracy for glucose level is higher than that for diabetic status in 
the CHD 10-year risk prediction formula. 
RQ3: Is the measure of accuracy for glucose level independent of ‘BMI’, 
cholesterol level or blood pressure level in the CHD 10-year risk prediction formula? 
H03: The measure of accuracy for glucose level is independent of ‘BMI’, cholesterol 
level or blood pressure level in the CHD 10-year risk prediction formula. 
HA3: The measure of accuracy for glucose level is dependent on BMI, cholesterol level or 





Health Behavior Model  
The concepts on which this study is based are the health behavior model (HBM) 
and the cardiometabolic model of heart disease. The former is borrowed from the social 
sciences and is very commonly used in health care research and in developing public 
health strategies (Esparaza-del Villar et al., 2017). There are three main supposition on 
which the HBM is based: perceived vulnerability, perceived severity, and perceived 
efficacy (Janz & Becker, 1984). According this model, an individual’s health behavior is 
motivated by their belief and that belief is based on the information and level of health 
education to which they have been exposed or are in their awareness. HBM suggests that 
proper knowledge of the association between risk factors and the related diseases is 
critical to heart healthy behavior (Khorsandi, Fekrizadeh, & Roozbahani, 2017). The 
identification of the CVD risk factor, dysglycemia, and the level of risk they present is 
the goal of this study. 
Cardiometabolic Model of CVD  
In the cardiometabolic model, there is a close relationship between the elements 
involved in metabolic disorders and those involved in heart disease (Brunzell, Davidson, 
& Fuberg, 2009). It is already accepted that a diagnosis of diabetes incurs a two-four-fold 
increase risk of heart disease, depending on gender (Booth, Kapral, Fung, & Tu, 2006; 
Conroy et al., 2003; Fox, 2010; Sarwar et al., 2010). I focused on one of the overlapping 
risk factors, namely dysglycemia, and its inclusion in the CVD risk prediction formula as 




blood vessels of the heart and this is usually the initiation of or exacerbation of other 
factors that lead to CHD (Jackson et al., 2016; Kozakova et al., 2017; Saisho, 2014). This 
analysis attempts to take a closer look at this relationship between glucose level and CHD 
by measuring its strength the relationship and testing its utility in the CHD prediction 
formula. 
Nature of the Study 
This research is a quantitative study using statistical analysis of an existing data 
set to evaluate the answers to the research questions. The data set is from the third cohort 
of the FHS clinic data, collected from over 4,000 of the descendants of the first cohort 
that began in 1964 (Framingham Heart Study Longitudinal Data Documentation, 2004). 
More details will be included in Chapter 3. The variables of interest are fasting blood 
glucose (FBG) and diabetes diagnosis (DM2) and they were compared for their predictive 
ability and their interaction other metabolic comorbidities (cholesterol, blood pressure, 
BMI), for their effect on the relation to the outcome of a CHD event (Rudestam & 
Newton, 2014). The methodology involves both univariate and MLR analyses of the FHS 
data set as secondary data. The Framingham risk score (FRS) is the formula that 
describes the relationship between the variables, developed by the FHS researchers based 
on the many risk factor they discovered, and is a multivariable logarithm of  the 
probability of developing coronary heart disease. The same latest version of the 10-year 





Assumptions, Limitations and Delimitations 
Assumptions 
The FHS is a seminal epidemiological study in the fields of public health and of 
medicine and has provided invaluable insight into the factors involved in the 
development of cardiovascular diseases (O’Donnell & Elosua, 2008). The subsequently 
derived FRS has proven instrumental in predicting cardiac events for many at risk but 
asymptomatic members of the population (O’Donnell & Elosua, 2008). I assumed that 
the data FHS collected was accurate and included objective responses from the 
participants, competence on the part of the health care workers’ in conducting surveys 
and in performing examinations, and accurate recording and documenting of the relevant 
information. 
Despite the limitations and the challenges to the internal and external validity of 
the original Framingham cohort, the study successfully identified several major CVD risk 
factors. The researchers were careful to point the steps needed for internal and external 
validation that other researchers should put in place (O’Donnell & Elosua, 2008; Pencina 
et al., 2009). These factors do provide general applicability to similar demographics, even 
if calibration is required in cases of the nonuniform distribution of variable among certain 
groups or for groups with risk factor prevalence that are different from the FHS 
(Hermansson & Kahan, 2018; Tsao, 2015)(Moons et al., 2012). The foundation laid by 
the FHS continues to be the benchmark for CVD research, but the limitations of the tools 
and the persistence of the disease necessitates an ongoing effort at improving on CVD 





Despite the great successes of the FHS, the usefulness of the FRS, and the many 
effective succeeding projects, there are shortcomings that must be addressed (Schlendorf, 
Nasir, & Blumenthal, 2009). First, the outcome of the original cohort focused solely on 
CHD and therefore the data does not extrapolate well in the prediction of other coronary-
related events (Mahmood et al., 2014). Second, given that several groups were 
underrepresented in the original cohort, use of the FRS is less than ideal for certain 
groups like for young people or for ethnicities other that are not whites of European 
descendent (Hemann, Bimson, & Taylor, 2007). Thirdly, the original delineation of no 
prior CVD events and the challenges to internal validity (the response rate, recall bias, 
mortality/attrition, etc.) resulted in a sample that was healthier than the general 
population (Mahmood et al., 2014).  
Notably, the initial FHS was conducted when diabetes was less prevalent, and the 
diabetes protocol used was different from the present. The previous criterion for a 
diagnosis of diabetes was a random blood glucose level of 200 mg/dL or more, but the 
current criterion is a fasting blood glucose of 125 mg/dL or more (Framingham Heart 
Study Longitudinal Data Documentation, n.d.). As a result of the difference in diabetes 
diagnosing, the FRS’s discriminatory powers within current populations, where diabetes 
is now more prevalent, is compromised. Other adverse features of the original cohort 
include the absence of factors like metabolic risk factors such as C-reactive protein 
(CRP) levels and coronary artery calcium (CAC) (Kones, 2011). These issues, combined 




year period, all leave opportunity for optimization of the FRS formula (Schlendorf et al., 
2009). This optimization can take many different directions, but this study focuses on the 
role of fasting blood glucose levels (FBGs) in CVD risk estimation.  
Delimitations 
The FHS researchers considered the long-term epidemiological study design most 
suitable for studying the lifestyle and environmental factors involved in the development 
of cardiovascular disease (O'Donnell & Elosua, 2008). The participants were restricted, 
due to the logistics of the early stages of the study, to adults living in the town of 
Framingham, Massachusetts (Dawber & Lansing, 1966; Mahmood et al., 2014) The 
middle-class white, mostly of European descent, residents of this town were believed 
(erroneously) to be geographically, socioeconomically, and environmentally 
representative of the rest of the country (Mahmood et al., 2014). The variables measured 
and recorded, including age, gender, serum cholesterol, diastolic and systolic blood 
pressure, glucose, and diabetes, were predetermined by the study leaders as potential risk 
factors relevant to the outcome (Dawber et al., 1951).  
The original cohort sampling spanned 5 years from October 1948 to 1953 and 
potential candidates were between the ages of 20 and 70 years (Dawber & Lansing, 
1966). From that group, two-thirds of the all the families in the town were selected at 
random, and all eligible members in those families were invited to participate. 
Subsequently, there were only two edibility criteria- being 30 to 59 years old and having 
had no history of cardiovascular disease (Dawber & Kannel, 1966). Of the 6,507 invited 




rate (Tsao, 2015). The researchers believed that this was an adequate sample size for 
generating reliable results, but there were still other challenges to the internal and 
external validity of the results (Mahmood et al., 2014). The internal and external validity 
of the data collected will be discussed further in chapter three. 
Significance of the Study 
The uncertainty surrounding the pathophysiology of CVD, and its often-
subclinical symptomology, serve to complicate most detection and prevention strategies 
(K. M. Anderson, Wilson, Odell, & Kannel, 1991; Kones, 2011). Comorbidity between 
the risk factors and the varying prevalence rates among the different populations both 
challenge any effort at risk assessment (D’Agostino et al., 2013; Haregu et al., 2016; 
Scheerbaum et al., 2017). The limitations of the current screening tools —inadequate 
scope, insufficient sensitivity, and sometimes, imprecise results— continue to underscore 
the need for risk estimation augmentation (Kones & Rumana, 2014; D. Lloyd-Jones et 
al., 2010). This research is a part of the need for augmentation research that advances the 
effectiveness of risk prediction formula. 
The increased prevalence of metabolic diseases, which do strongly predispose to 
heart disease, makes both metabolic and diabetic factors essential CVD risk factors. 
Glucose is a most fundamental maker for cardio-metabolic given its significant 
relationship to both developing diabetes and developing CVDs (Haregu et al., 2016; 
Huang et al., 2016; Park et al., 2013; Valentino et al., 2015). As such, glucose should be 
an important predictor of cardiovascular health as well. This dissertation research will 




and its potential for improving the performance of the FRS-CHD risk assessment 
formula.  
Positive Social Change 
This research focuses on glucose as a major risk factors associated with 
cardiovascular disease and aims to further elucidate its role in CVD risk prediction. The 
findings will impact the way cardiovascular disease is screened for in the field and the 
way it is treated in the both the outpatient and hospital setting (Hosseini, 2015). 
Secondly, it will help guide the physicians’ decisions about where and how to direct often 
limited resources in CVD prevention and treatment efforts, especially for those at high 
risk (Hosseini, 2015). Finally, the information generated may influence health education 
and literacy efforts among the low and moderate-risk population, providing greater 
incentive for behavioral change adoption (see Rosenstock, 1974). 
I was motivated to complete this study by the burden that exists for more effective 
screening tools and for a greater efficiency and wider applicability of the CVD screening 
protocols (see Kones, 2011; Lloyd-Jones et al., 2010; Roger et al., 2012). The results 
could be used to support treatment regimen and the education of the public about the 
effectiveness of the positive lifestyle and behavioral changes effective in protecting 
against this deadly disease (see Goong et al., 2016). This research may provide much 
needed insight about cardiometabolic pathophysiology that informs future 
epidemiological and clinical research (see Dahlöf, 2010; Kones, 2011). The objective is 




greater quality of life and heart health for those at risk, as well as the afflicted by CVD 
and those who care for them. 
Summary 
CVD is currently the deadliest of all diseases and it is a major burden on the 
healthcare system. The FHS uncovered the many CVD risk factors and shifted the 
emphasis from treatment to prevention. The FRS is a multivariate logistic regression 
formula used to predict the probability of developing CHD and has been used effectively 
in reducing the incidence and prevalence of the CHD. Despite its effectiveness and 
widespread use, the FRS has some notable limitations that necessitate optimization. By 
nature, CVD is believed to be a cardiometabolic disease, as many metabolic markers are 
strongly associated with the disease outcome. I hypothesized that replacement of the 
dichotomous variable of diabetic status with that of the continuous variable glucose levels 






Chapter 2: Literature Review 
Introduction and Literature Review Strategy 
The purpose of this literature review is to detail the burden of CVD, both past and 
present, and to establish the need for ongoing CVD research, specifically in area CVD 
risk assessment. Although, there has been a decline in the incidence and prevalence of 
CVD over the last 7 decades, it remains the leading cause of death in most nations 
(Emelia J. Benjamin et al., 2017). This decline is largely the result of the identification of 
the major risk factors followed by concerted and successful efforts in reducing the 
prevalence of these risk factors, mainly that of cigarette smoking . However, the increase 
in obesity and other metabolic disorders pose new threats to cardiovascular health . Other 
studies have looked at the role of various risk factors in risk assessment models, but none 
have focused the role of glucose level in the most common risk assessment formula, the 
FRS.  
This second chapter of the dissertation will begin with the delineation of the 
pathophysical model and the conceptual framework on which this research is based. This 
will be followed by a discussion of the history and epidemiology of heart disease and 
how it went from being a rare disease to an epidemic. Next will be an account of the 
research into heart disease and how the FHS got its start and how it became a seminal 
study, not just in heart disease but in public health in general is then presented. The first 
half of chapter will close out with a description of how the CVD risk factors were 
discovered and how their discovery influenced the CVD screening and prevention 




The second half of this chapter will focus on the multivariate risk model that came 
out of the FHS FRS. Each of the risk factors included in the FRS and their role in CVD 
screening is described in detail. The next section will focus on the disorders of 
carbohydrate metabolism and how they are related to the development of heart disease. 
Glucose level, as the main metabolic marker, will be a highlighted with information 
about how it is measured, how it affects the metabolic system, and its role in screening 
for CHD. The discussion will also report on the current state of glucose lowering therapy 
in CHD prevention therapy. The chapter will end with a discussion on the main risk 
assessment tools, their formula performance evaluation and their optimization over the 
years. 
The literature search for this chapter was conducted using several electronic 
databases that cover research in the areas of medicine and health. These included 
PubMed, Medline, CINAHL, ProQuest, Springer, Google Scholar, and Elsevier. The 
keywords used for searching these databases include cardiovascular disease, CVD, 
coronary heart disease, CHD, CVD risk factor, diabetes, blood glucose, blood sugar, 
pre-diabetes, metabolic syndrome, CVD risk assessment, and CVD risk tools. The 
Boolean operators (AND, OR, NOT) were used to ensure the relevance of the returned 
journal articles. For articles not available online, I made requests to the Walden 
University Library staff and was either provided with the article or directed to an 
alternative available source. For current epidemiological data on heart disease and related 
risk factors, I used the websites of scientific and governmental intuitions such as the 




Given the nature and importance of the topic of heart disease, there was an 
abundance of available sources. However, a critical review allowed for restriction to 
articles that had relevance to the objective of the research. Articles chosen focused on the 
most common and the most dangerous of the CVDs, CHD and its risk factors, the tools 
for CHD assessment, and the role of blood glucose as a risk factors and in risk 
assessment tools. Efforts were made to obtain the primary research article or the original 
report of the findings, and to restrict use of only research conducted by or associated with 
reputable institutions. On obtaining access to the articles, the abstract was perused to 
determine the relevance of the article and if it appeared relevant then the full text was 
reviewed. Additional articles were found in the references of the articles returned from 
the original search. All articles deemed important were then saved to a Mendeley account 
where they were tagged and filed for later reference and citation in the document. 
Theoretical Framework 
Health Behavior Model 
The theoretical framework used for this research is the health behavior model 
(HBM), which was developed using theories from social and behavioral sciences 
(Esparaza-del Villar et al., 2017; Janz & Becker, 1984). HBM was first used in the 1950s 
by the U. S. Public Health Service in their efforts to curb the spread of tuberculosis (TB) 
(Esparaza-del Villar et al., 2017; Hosseini, 2015; Rosenstock, 1974). It remains one of 
the most popular conceptual frameworks for understanding changes in or explaining and 
predicting acceptance of new health behaviors (Janz & Becker, 1984). It has been 




osteoporosis prevention, Hepatitis A & B vaccination, and Pap smear testing (Esparaza-
del Villar et al., 2017). 
The HBM is based on three main components: (a) perceptions of susceptibility or 
vulnerability to the condition or disease; (b) perceptions of the severity of the disease and 
its consequences; and (c) perceptions of the effectiveness of action to avert or ameliorate 
the disease condition (Janz & Becker, 1984). The other tenets of the model include the 
perceived barriers to selected actions or action, cues-to or triggers-to these particular 
actions, and self-efficacy or confidence to carry out the chosen actions (Hosseini, 2015). 
The energy or force driving the new behavior comes from the perceptions of severity and 
susceptibility, while the choice of behavioral path is influenced by subjective barriers and 
any feelings or lack thereof, of self-efficacy (Janz & Becker, 1984). Essentially, a person 
health behavior is driven by their own perceived susceptibility and whether acting will 
relieve their susceptibility. 
The general tenet of the HBM is that people are only motivated to make changes 
in their behavior, as it relates to health, in response to some perceived personal threat or 
impending illness (Esparaza-del Villar et al., 2017; Janz & Becker, 1984). Knowledge of 
the threat, and the belief that it will be averted by certain actions, is the impetus for the 
behavioral changes. Conversely, ignorance of the association between the disease and its 
risk factors or the impact of related behavioral changes causes skepticism about the 
actions being promoted (Khorsandi et al., 2017). According to HBM, subjects who are 




In the HBM model, health behavior is closely related to health belief, making 
knowledge the most important factor in motivation towards change (Rosenstock, 1974; 
Janz & Becker, 1984). The HBM guides much of the research and the communication of 
relevant information about the susceptibility to CVD, the severity of its consequences, 
and the effectiveness of risk factor averting behavior. Behavioral changes and lifestyle 
modifications have been shown to reduce the risk of developing CVD as well as 
minimize the severity of the symptoms (Esparaza-del Villar et al., 2017; Goong et al., 
2016; Khorsandi et al., 2017). The research objective for my study is to strengthen the 
link between glucose level and heart disease will increase attention to this risk factor and 
promote the adoption of related health behaviors. 
Cardiovascular Framework 
The conceptual model that undergirds this study is the relationships between the 
established risk factor and the prediction of CVD risk (see Mozaffarian, Benjamin, Go, et 
al., 2015). The covariates and commodifiers that have an impact on the outcome are 
included in the model (see Figure 1) as well as the complex interactions among these 
health determinants and how they are mediated through the specific metabolic risk factors 
(see Brunzell, Davidson, & Fuberg, 2009; Nguyen et al., 2012; Wilson & Meigs, 2008).. 
Understanding what biochemical factors predates CVD can provide insight into the 
etiology of the disease development. Insight into the nature of these factors, their 






Figure 1. Cardiometabolic model of CVD development. 
Heart disease is a disease of the vascular system, detected as the arteries develop 
atherosclerosis and become clogged with fatty substances or plaques made up of low-
density lipoproteins (LDL) and other material . However, it is now accepted knowledge 
that the atherosclerosis is preceded by damage to the walls of the blood vessels, and the 
cause of this damage may be the root cause of the disease (Cockram et al., 2001; Jackson 
et al., 2016; Kozakova et al., 2017; Saisho, 2014). Increases in blood sugar concentration 
have been shown to be associated with significant damage to the blood vessel walls 




major contributor to atherosclerosis and the subsequent heart disease. This process 
explains the connection between diabetes, and more specifically, hyperglycemia and 
cardiovascular disease and is basis for cardiometabolic disease theory of CVD.  
Based on the medical model of cardiometabolic disease development combined 
with the principles of the HBM, I investigated the association between the glucose level 
and the development of CVD with the objective of informing and promoting heart 
healthy behavior. I focused on the role of blood glucose as a CVD risk factor and how it 
affects the performance of a risk assessment algorithm, the FRS. These findings provided 
evidence in support of an emphasis on dysglycemia as a marker for metabolic disorder 
and a predisposition to CVD. Ultimately, the purpose of the study is to advocate for the 
inclusion of glucose level in risk detection formula tools and to encourage glucose 






History and Epidemiology of CVD 
Discovery and Rapid Rise of CVD 
A little less than 100 years ago a new era of public health emerged (citation), and 
it presented novel challenges to the field. The patterns of old diseases were replaced by 
unfamiliar ones and a different set of problems confronted public health practitioners 
(U.S. Department of Health and Human Services, 2005). No longer were infectious and 
communicable diseases the major global threat they had been for centuries; the greater 
danger now lay in noncommunicable diseases (Rosen , 1958). Optimism over the success 
of vaccination, improved sanitation, and antibiotics eradication of diseases like small pox 
and tuberculosis was replaced by the confusion over a new epidemic of chronic non-
contagious health issues (Nieto, 1999a).  
It all began with shifts in the causes of morbidity and mortality brought on by the 
emergence of new noncommunicable disease. The cause of the increase of these diseases 
was  unhealthy behaviors and practices . These newly-discovered diseases would 
eventually become known as lifestyle diseases due to their most common trait being a 
susceptibility to lifestyle changes and behavior modifications (Moore, Chaudhary, & 
Akinyemiju, 2017). One of those diseases, heart disease, quickly became seen as the 
deadliest (Nieto, 1999; Ockene, Daley, & Tran, 2014). But this shift in the cause of 
morbidity and mortality occurred gradually.  
Physicians became aware of heart disease somewhere between the middle of the 
19th century and the end of World War I (citation). Between 1900 and 1930, CVD moved 




Goldberg, & Weinstein, 2014). Today, CVD accounts for one out of every three deaths in 
the United States and in Europe  Benjamin et al., 2017; Go et al., 2014; (Kannel & 
Boston, 1990; Mozaffarian et al., 2015 ).  
The first anecdotal case of heart disease was mentioned in a 1859 report at the 
Swedish Medical Society meeting, when the pathological features of myocardial 
infarction (MI) were described (Jones & Greene, 2013). By 1923, angina pectoris, still 
considered very rare with roughly one case per month, was being documented as 
resulting from the later stages of infectious diseases like rheumatoid fever and syphilis 
(Jones & Greene, 2013). But by the 1920s, cases specifically identified as CVD were 
now ubiquitous and the mortality rate for these diseases rose so sharply that the death rate 
was doubling approximately every 5 years (Grimes, 2012).  
During the 1930s and the 1940s, more cases of CVD, specifically chronic heart 
disease (CHD), were being readily recognized and classified Grimes, 2012; O’Donnell & 
Elosua, 2008; (Stehbens, 1995). At around the middle of the 20th century, CVD deaths 
numbered twice those of TB and it was fast becoming a major public health concern 
(Grimes, 2012). By the last quarter of the century it was so prevalent and deadly that 
650,000 CHD deaths were reported in 1978 alone (Levy, 1981,). It was this dramatic 
change in the main causes of death, led by CVD, that caught the attention of public health 
professionals and epidemiological research efforts on CVD were subsequently launched 
(O’Donnell & Elosua, 2008). 
Top on the list of research objectives was identifying the causes of heart disease. 




like the increase in smoking, more sedentary lifestyles, and increased consumption of 
processed food, especially sugar (Rosen, 1958). Most notably, smoking alone saw an 
eight-fold increase simultaneous to the rapid increase in CVD deaths . The incidence of 
smoking in the American population jumped from 5% in 1930 to 42% in 1965 and was 
believed by many to be the main reason for the of CVD rise (Dalen et al., 2014). Others 
believed the eradication of other deadly diseases and changes in the diagnosis and 
reporting practice for CVD resulted in an apparent increase (Nieto, 1999). Later research 
would confirm the role of smoking (cigarette and tobacco) as a major risk factor in the 
development of cardiovascular and in other lifestyle diseases . Smoking cessation would 
mark the beginning of heart disease prevention and the curb of the rising CVD rates .  
The Declining Rates of CVD 
The rapid increase in the prevalence of cardiovascular diseases during the 1940s 
and 1950s began slowing down in the 1960s (Dalen et al., 2014; Dawber & Lansing, 
1966). By the late 1964 the disease incidence peaked and then slowly declined in the 
latter half of the decade (Dalen et al., 2014; Dawber & Lansing, 1966). The CVD death 
rates in the US continued to decline, resulting in a 50% decrease over the next 30 years 
(Jones & Greene, 2013). As the CVD rates declined, there was much speculation about 
the reason for the decline. The combined effect of personal and communal behavioral 
changes, the increase in health literacy, the improved medical therapies, and supportive 
public policy were all credited (Dalen et al., 2014). Some believed that it was the 
successful combination of primary (risk factor reduction) and secondary (medical 




Others attributed it to the reduced prevalence of atherosclerosis that coincided with a 
drop in cigarette smoking (from 42% to 18% between 1965 and 2012) following the 1964 
Surgeon General’s report on the dangers of smoking (Dalen et al., 2014).  
The CVD rate decline in the US and Europe was hailed as a victory for public 
health. In 2011 some experts predicted, based on age-standardized extrapolations, that the 
disease would come to an end in another 5 years (Grimes, 2012)(Grimes, 2012). But that 
did not happen, as the declining CVD rates slowed considerably and eventually reversed, 
with CVD rates rising in most developing countries (Bragg et al., 2014; Mensah et al., 
2015; Reddy & Satija, 2010). Surprisingly, the continued downward trend in cigarette 
smoking was not matched by any further decreases in incidence of CVD (Jones & 
Greene, 2013). The experts, baffled by the trend reversal, redoubled their efforts on 
continued surveillance and risk factor modeling for the cardiovascular disease complex 
(Grimes, 2012). 
Origins of the Framingham Heart Study 
In the early days of the disease, circa 1930s, the rapid rise in CVD mortality and 
morbidity made the disease a top priority in the public health discourse. The consensus 
among both health and political leaders was that the situation critically demanded action 
(Tsao, 2015). That period in history was marked by very little understanding of the cause 
of the disease and even less knowledge of how to respond to the crisis. During this period 
of confusion, almost every other death was in some way related to CVD (Mahmood et al., 
2014). It was evident to those in the know that a CVD epidemic was in full force and it 




During that time, it seemed no one was protected from the threat of heart disease. 
Not only were average individuals being affected, but even the most powerful members 
of the community were at risk as the disease was also impacting the top echelons of 
society. In 1944, a diagnosis of CVD was confirmed in the nation’s leader, Franklin D. 
Roosevelt, who along with his disability, had been living with the major indicators for 
years (Rosen G, 1958). President Roosevelt endured many symptoms of CVD during the 
later years of his life, eventually succumbing to a premature death in 1945 when his 
blood pressure rose dangerously to 300/190 and he suffered a fatal stroke at the age of 63 
(Mahmood et al., 2014).  
 While still in power however, it was President Roosevelt’s administration who 
established the National Institutes of Health (NIH) as a federal agency in 1940; an act 
contemporaneous with the growing threat to the nation’s heart health (Mahmood et al., 
2014). In 1948, Roosevelt’s successor Harry S. Truman established the National Heart 
Act (NHA), which funded the establishment of the National Heart, Lung & Blood 
Institute (NHLBI) that same year (Mahmood et al., 2014). The hope was that the NHLBI, 
in response to the dramatic increase in CVD mortality, would somehow be able to 
unravel the complex etiology of CVD and devise a solution to the epidemic (Lansing, 
1961; Jones & Greene, 2013; Mahmood et al., 2014). The benefits of FDR’s foresight in 






Figure 2. The history of FHS. Graphical representation of the history of FHS. Reprinted 
from “The Framingham Heart Study and the epidemiology of cardiovascular disease: a 
historical perspective.” by S. S. Mahmood, D. Levy, R. S. Vasan, & T. J. Wang, 2014, 
The Lancet, 383(9921), p 999-1008. 
Not long after its formation in 1948, the federally funded NHLBI joined with 
academic researchers, first from Harvard University and then later from Boston 
University, to launch the Framingham Heart Study (Tsao & Vasan, 2015a). Improving 
insight into the etiology, finding ways to effectively treat, and curb the spread of the 
disease were the objectives (Mahmood et al., 2014; Tsao, 2015). The long natural history 
of the disease necessitated a prospective, observation-type, cohort study. The data 
collection included, but was not limited to, information on: consent, family history, 
medical history, current symptoms, medication, personal and dietary habits, weight, 




syphilis), and urinalysis (Dawber et al., 1951). For each case, collected data were 
eventually compared to the original clinical findings of the attributes associated with the 
development of CVD, with attention paid to the most common CVD subtype- CHD (Tsao 
& Vasan, 2015a).  
FHS Through the Years 
The FHS began in 1948 with 5,209 participants. The off springs’ of the 1st of the 
2nd generation (children and grandchildren of the original cohort participants) made up 
the 2nd and 3rd FHS cohort (Mahmood et al., 2014; Tsao & Vasan, 2015). These groups 
provided additional understandings, including which individuals were susceptible, the 
effects of shared environments, and most importantly, familial and multigenerational trait 
aggregations (Mahmood et al., 2014; Long & Fox, 2016). The smaller OMNI1 and 
OMNI2 groups, started in 1994 and 2003 respectively, focused on increasing the racial 
and ethnic diversity of the participant pool beyond the mostly white (of European 
descent) participants that made up the first three (Long & Fox, 2016; Tsao & Vasan, 
2015a)  
The first published report from the biennial FHS examinations described the 
extent of the CVD disease, as well as the associated personal and environmental traits 
(Dawber, George, & Mann, 1957). The second FHS report, based on data from 6 years of 
observation (3 biennial examinations), looked at the role of nationality, education, 
smoking and drinking habits (Dawber et al., 1959). By the 3rd cohort, more tests like the 
12-lead ECG, cardiovascular imaging procedures, and biomarkers were added to the 




metabolic factors: elevated blood pressure, obesity, and cholesterol level (Tsao & Vasan, 
2015). The second follow-up on the original group, implicated the additional factors of 
age and gender (Tsao & Vasan, 2015; Long & Fox, 2016). In the late 1950s, more data 
analysis determined that cigarette smoking had a major effect on the CVD mortality rate 
(Nieto, 1999b), and that it synergistically amplified other factors, as smokers tended to 
also have higher cholesterol levels (Tsao, 2015).  
The FHS revolutionized the field of epidemiology and birthed the term “risk 
factors” (Tsao, 2015). The earliest findings of the FHS study indicated that CVD was 
multifactorial (Dawber, George, & Mann, 1957; Dawber et al., 1959). It also caused the 
shift in emphasis from secondary prevention and treatment to that of screening and of 
primary prevention efforts (Ockene et al., 2014). The FHS results served as the 
foundation for primary prevention projects and became an integral part of the CVD 
practice guidelines and treatment strategies (D’Agostino et al., 2013). The FHS 
originated the multivariate risk factor approach and its tool eventually became known as 
the Framingham Risk Score (FRS) risk formula (Mahmood et al., 2014; Tsao, 2015). 
The FHS has served as a template for many longitudinal cohort studies and its 
protocol has become a widely accepted standard in the field of epidemiology (Kim, 2016; 
Tsao & Vasan, 2015a). The FHS project has grown steadily over the last five decades 
from the original 5,200+ to over 13,000 participants today in the core cohorts and several 
auxiliary projects. The expansion has included ‘risk marker’ measurements such as 
homocysteine, fibrinogen, lipoprotein lipase, and c-reactive protein and investigation of 




all the novel projects thus far, the most effective CVD health promotion has been those 
that focus on identification and reduction of the traditional major risk factors. 
The Creation of the Framingham Risk Score 
Primary Prevention and CVD Risk Reduction 
Over the years, evidence has confirmed that primary prevention focused on risk 
factor reduction lowered the frequency of coronary arteriosclerosis and decreased the 
CHD death rate (Dalen et al., 2014; Ray et al., 2014). Primary prevention, unlike 
secondary prevention, is administered prior to the onset of the disease with the goal of 
preventing of the disease from occurring. Secondary prevention, on the other hand, can 
involve drug administration, surgery to reverse an already existing condition, or any 
treatment administered after a confirmed diagnosis to minimize complications, 
reoccurrence, or death (Stone et al., 2013). The most common and most effective primary 
prevention effort focused on smoking cessation, but primary prevention can also include 
healthy eating and exercise programs (Grundy et al., 2002; Roger et al., 2012). The 
importance of primary prevention and early intervention is underscored by the report that 
over 1/3 of the victims of myocardial infarctions die within 24 hours or they develop 
debilitating chronic heart failure, angina or have a cardiac arrest (Grundy et al., 2002). 
Primary prevention involves screening and early detection of the antecedent risk factors 
and applying specific therapies that have been shown to significantly reduce the risk of 
developing heart disease and CVD (Jones & Greene, 2013). Primary prevention starts 




and for this CVD risk models are most effective tools (Tomasik, Krzysztoń, Dubas-
Jakóbczyk, Kijowska, & Windak, 2015).  
Disease Modeling and the Framingham Risk Score 
The science of CVD risk modeling began in the 1950s with the introduction of the 
term ‘risk factors’ in the first FHS report and has progressed to the several dozen models 
in use today. The original risk estimation was based on a basic combination of risk 
factors into discriminant analysis tables, without any account for the severity or relative 
role of each risk factor. This rudimentary tool focused mainly on the four major traits: 
hypertension, high cholesterol and diabetes (D’Agostino et al., 2013; Mahmood et al., 
2014). Risk assessment models subsequently progressed to the use of cross-classification 
combinations, but they were difficult to understand and even more challenging for the 
physicians to use (Mahmood et al., 2014). By 1976, the first Framingham Risk formula 
being used were based on seven factors (age, total cholesterol, weight, ECG abnormality, 
hemoglobin, cigarettes smoked, and systolic blood pressure) with crude relative risk 
values for blood pressure and cholesterol (Truett, 1976 in Mahmood, 2014). By 1998, in 
the second iteration of the FRS, a more sophisticated multivariable logistic regression 
formula had been devised to calculate an individual's risk score (Mahmood, 2014). The 
critical importance of these tools in dealing with CVD morbidity and mortality and the 
millions of dollars in healthcare cost potentially saved, resulted rapid distribution of the 
different versions of this formula. Many versions are still in use and  frequently updated 




CVD is a multifaceted disease and as such requires a complex risk assessment 
formula that incorporates several risk factors. Using the FRS, an individual’s calculated 
risk score (as a percentage) can be in either four categories: low, moderate or 
intermediate, moderately high, and high, depending on the established threshold values. 
The ATP III (Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III) guidelines classify people into categories that depend on both 
their 10-risk score and the presence of certain risk factors. The four are: high risk (FRS 
over 20% and CHD or a CHD equivalent or 2 or more risk factors); moderately high risk 
(FRS between 10% and 20% and 2 or more risk factors); moderate risk (FRS below 10% 
and 2 or more risk factors), and low risk (0 or 1 risk factors) (Pedersen, 2002). Over the 
years, the FRS has proven to be an important tool in CVD research, especially the ones 
with disease incidence and risk factor similar to that of Framingham, MA, 60 years ago 
(Eichler et al., 2007; Fawwad et al., 2016; Feresu, Zhang, Puumala, Ullrich, & Anderson, 
2008; Rodondi et al., 2012; Yeung, Yuan, Hui, & Feresu, 2016; Yosaputra, Kholinne, & 
Susanto Taufik, 2010).  
Unfortunately, in instances where the disease pattern changes (e.g., increase in 
diabetes prevalence) or the risk frequencies are different (e.g., low-income, minority, 
etc.) the FRS may fail to identify those who need preventative therapy (P Brindle et al., 
2005). Refining the FRS has taken many forms mainly the revaluation of current 
variables or the addition of novel risk factors and biological markers, many of which 
require expensive equipment. The changing (arbitrarily chosen) thresholds, , risk factor 




ratio of any of those changes are important considerations (D’Agostino et al., 2013). 
Finally, simply using the disease incidence and prevalence data for a given population to 
recalibrate and improve the formula’s performance is the most common ways of 
remodeling CVD risk formula to improve its accuracy and precision (D’Agostino, 
Grundy, Sullivan, & Wilson, 2001a).  
The Most Common Outcome for the FRS: CHD 
Cardiovascular disease can be divided into three main classes: congenital heart 
disease (i.e., genetic factors or birth defects); disease caused by microorganism (e.g., 
rheumatoid heart disease); and heart disease resulting from atherosclerotic or 
hypertensive disorders. Of the many forms of atherosclerotic heart disease, coronary 
heart disease (CHD) is the most common and is the leading cause of sudden cardiac 
arrest (Dalen et al., 2014). Coronary heart disease (CHD) is the term used to describe the 
narrowing of the arteries that supply blood to the heart and is leading cause of CVD 
morbidity and mortality, as 6.2 million are hospitalized and 400,000 die from CHD every 
year (Kones, 2011). The prevalence of CHD, also referred to as coronary artery disease 
(CAD), equals the sum of the prevalence of all other CVDs and accounts for 64% of all 
CVD related deaths (Dalen et al., 2014). It is because of numbers like these that point to 
the greater threat of CHD, that most CVD risk formulas focus of CHD prediction. 
CHD is caused by the narrowing of the arteries when plaque accumulates on the 
vessel walls. Plaque, made up mostly of cholesterol, builds up on the walls of the arteries 
and reduces the supply of blood to the muscles of the heart (Kannel, Castelli, et al., 




begin to die. The death of cardiac tissue is experienced as chest pain and shortness of 
breath, the symptoms of angina pectoris (Bennet, Di Angelantonio, et al., 2008). 
Ultimately, if the blood flow is completely occluded by fatty deposits or clotted blood, 
nutrients and oxygen supply ceases, the muscle tissue dies, and a heart attack occurs. 
Unfortunately, some 735,000 Americans experience a heart attack every year 
(Mozaffarian, Benjamin, Go, et al., 2015). 
The FHS group of researchers provided the very important insight that CHD 
disease is always preceded by a condition of atherosclerosis (Dawber & Lansing, 1966;. 
The belief then became that CHD was caused by a buildup of plaque in the arteries of the 
circulatory system, a process usually starting in the second and third decade of life and 
progressively worsening with time (Ockene et al., 2014). Later research revealed, when 
this atherosclerosis is exacerbated, the vessels walls become inflamed and the plaque 
ruptures; the debris forms a clot that completely occludes blood flow, resulting in a heart 
attack or a stroke (Cockram et al., 2001; Hosseini, 2015; Ockene et al., 2014). This had 
been the main etiological concept of heart disease for many decades 
However, due to the invention of high-tech imaging tools, a better understanding 
into the development of CHD was been gained. It is now known that the disease does not 
begin with atherosclerosis, but is accurately is preceded by damage to the endothelial 
walls of the coronary arteries (Grundy et al., 2002; Pedersen, 2002; Zhang et al., 2014). 
The plaque deposits at the injury site are attempts by the body to repair the damage to the 
endothelium and is it made up of cellular waste, calcium, fibrinous clotting material, and 




of the body’s arteries, it is referred to as atherosclerosis and plaque accumulation 
specifically in the arteries of the heart, is diagnosed as coronary artery disease (CAD) or 
CHD (Hutcheson & Rocic, 2012). So, heart disease is more a disease of blood vessel 
damage than it is of atherosclerosis. But what causes the damage to the walls and what 
risk factors account for this threat? 
Components of FRS: The CHD Risk Factors 
The risk factors that are involved in the development of CHD fall into four main 
categories: genetic, physiological, behavioral, and environmental (Kones, 2011). The 
non-modifiable factors are genetic or physiological and include age, gender, and family 
history of CHD. The other factors are behavioral or environmental and therefore 
modifiable, and they include: smoking status, cholesterol levels, blood pressure, diabetes, 
and obesity (Hobbs & Hobbs, 2004). The major predictive risk factors such as high 
cholesterol, diabetes, and high blood pressure are linked to diet and level of physical 
activity and smoking directly to the individual’s choices, making them all behavioral. 
The more recently discovered, less established, factors include biological markers 
such as C-reactive protein (CRP), lipoprotein A (lpA), low density lipoprotein (LDL), 
fibrinogen, and triglyceride (TG) levels (D. Lloyd-Jones et al., 2010) (Bennet, Di 
Angelantonio, et al., 2008). Also included in this category are imaging factors like 
coronary artery calcification (CAC), carotid intima media thickness (CIMT), and 
coronary angiography- all measured by MRI or CT scans (D. Lloyd-Jones et al., 2010) 
(Ray et al., 2014). The sophisticated technology required for these markers makes testing 




offer very little improvement in the performance of the predictive models based on 
established risk factors (Tsao & Vasan, 2015a).  
In the US, screening for primary prevention purposes uses the latest version of the 
multivariable FRS to estimate the risk of CHD. The FRS combines measures of the more 
classical risk factors (i.e., age, gender, total cholesterol, tobacco use, HDL-C, TC, 
systolic blood pressure, and treatment status or CHD history) into an equation that 
calculates the risk score. Of the modifiable risk factors, high cholesterol is considered the 
strongest predictive factor, (after smoking), followed by diabetes, and high blood 
pressure. These modifiable risk factors are the focus of primary prevention efforts that 
include smoking cessation, and the lowering of blood pressure and cholesterol levels and 
reducing measures of obesity. This research aims to show that blood glucose level 
stabilization may also be critical to CVD prevention. 
Cigarette Smoking  
Smoking cigarette or tobacco is a major CVD risk factor, which was overlooked 
in the first report, but later confirmed as having the strongest association to CVD in the 
second FHS report (Dawber et al., 1959). Clinical research showed that the effect of 
smoking habits are  associated with reduced heart rate, decrease oxygen capacity of the 
lung, increase blood clotting and chronic damage to the endothelium of the blood vessels 
(Ockene et al., 2014). Nicotine, the accompanying toxins, and the free-radicals generated 
from smoking all cause direct damage to the tissues, including those of the cardiovascular 




formation blood clots (Ockene et al., 2014). These structural and functional damage to 
the blood vessels are what lead to atherosclerosis and eventually cardiovascular disease. 
After much debate between the government, the policy makers, and the tobacco 
industry, the Surgeon General officially reported, in 1964, that smoking was dangerous 
for the smoker’s health (Dalen et al., 2014). The report stated that smoking causes lung 
cancer and was linked to heart disease, but the impact of this information on subsequent 
CVD surveillance measures was not immediate. Slowly, over many decades, the 
prevalence of smoking dropped from 42% in 1965 down to 18% by 2012 (Dalen et al., 
2014). This decline was eventually reflected in the decline in CVD prevalence, and by an 
even larger decline in the incidence of heart disease in the population (Tsao & Vasan, 
2015a). Now cigarette smoking, though the strongest risk factor, is no longer the most 
prevalent as other risk factor have become more common. 
Unlike hypertension and hypercholesterolemia, cigarette smoking was found to be 
independent of other risk factors (Lansing, 1961). Of the many reversible risk factors, 
smoking has the biggest impact as it confers a 6-fold increase in men, and a 3-fold 
increase in women in the risk for MI, compared to non-smokers (Amsterdam, 2011). As 
with other risk factors, the duration and the intensity of smoking impact the degree of the 
risk, as former smokers who are now non-smokers have worse risk profile than those who 
never smoked, and the more packs per day the more severe the risk (Fuster & Kelly, 
2010). A habit of cigarette smoking is still associated with the risk of Myocardial 
Infarction and sudden death due to CVD and smokers are 2-4 times as likely to have a 




Over the last four decades, CVD mortality has decreased by one third and the 
related symptoms have decreased by one half, due in large part to the reduced prevalence 
of smoking (Dalen et al., 2014). When a person stops smoking the damaging substances 
are eliminated and the many hazardous effects minimized and the risk is gradually 
reversed (Jones & Greene, 2013). Consequently, widespread smoking cessation leads to a 
considerable reduction in heart attacks and cardiac death rates. Reduced prevalence of 
smoking when accompanied by dietary changes was found to amplify the benefits of 
smoking cessation (Huxley, Woodward, Huxley, & Woodward, 2011). 
Hypercholesterolemia  
Although smoking and hypertension were among the first factors found to have a 
high correlation to CVD, cholesterol was the first predictive factor uncovered in 
analyzing the data (Dawber & Lansing, 1966). Cholesterol values describes the 
concentration of fat molecules or lipoprotein dissolved in the blood. In the early days, 
when the cross-classification tables were used for risk assessment, total serum cholesterol 
had three levels- low, moderate, and high, corresponding to <225 mg/dL, 225-274mg/dL, 
and > 275 mg/dL respectively (Truett, Cornfield, & Kannel, 1967). More recent risk 
assessments use slightly different values: normal cholesterol levels are <200 mg/dL, 
borderline is 200-239 mg/dL, and high is >240 mg/dL (Wilson et al., 1998). According to 
the latest ATP III report 39.7% of Americans have a total cholesterol >200 mg/dL with 
11.9% >240 mg/dL (Emelia J. Benjamin et al., 2017). In modern risk calculations, the 
cholesterol level value, instead of the categories, are entered into the formula for risk 




as the RR ranges from 2.83 t0 4.46 depending on the cholesterol level and is even higher 
if diabetes is also present (Bertoluci & Rocha, 2017; Dahlöf, 2010)  
During the 2nd generation of the FHS in 1971, the FHS lab was technologically 
advanced enough to separate the blood lipids in to high density lipoproteins (HDL), low 
density lipoproteins (LDL) and lipoprotein A (LpA) (Tsao & Vasan, 2015a). This 
allowed for the determination that LDL blood lipids are the pre-disposing risk factor 
contributing to plaque buildup in the coronary arteries. The discovery that LDL (and not 
HDL) was the blood lipid most predictive of the development of CVD, resulted in the 
substitution of the ratio of “total cholesterol to HDL” (Tot Chol/HDL) measure instead of 
the “total cholesterol” in risk calculations (Tsao & Vasan, 2015a). When assessing LDL 
separately, the optimal level is <100 mg/dL, moderate is 100-129 mg/dL, borderline high 
is 130-159 mg/dL, high is 160-189 mg/dL, and very high is >190 mg/dL (Hosseini, 
2015). High or very high levels of unhealthy LDL are found in 33% of Americans 
(Pedersen, 2002). 
More recent research led to the understanding that not only was the HDL 
component of total cholesterol not implicated in the development of atherosclerosis, but it 
was in fact beneficial to CVD health. HDL has been shown to protect of the endothelial 
surface of the cell wall, to reduce LDL oxidation, and to help maintain the cells 
sensitivity to insulin of the cells (Kones, 2011; Ray et al., 2014) HDL lowers CVD risk 
and is recommended to be ideally > 60 mg/dL, while <40 mg/dL is considered low and 
unhealthy (Hosseini, 2015). Epidemiological research has indicated that some 18.7% of 




The difference in the roles of HDL and LDL may explain why total cholesterol as 
a risk factor only accounted for 50% or the CVD prevalence in previous data analysis. 
Some individuals had the ‘high’ cholesterol, but had no CVD and others had CVD yet 
were free of traditional hypocholesterolemia (Nieto, 1999b). High HDL concentration is 
now known to be associated with a lower incidence of CVD and is regarded as a negative 
risk factor (Pedersen, 2002). To account for this discovery, researchers decided to use the 
Total Cholesterol to high density lipoprotein (Tot Chol/HDL) ratio in the Framingham 
Risk Score. Eventually, the HDL/TC ratio was replaced by two distinct variables, total 
cholesterol (TC) and the high-density lipid cholesterol (HDL) (Wilson et al., 1998).  
The drop in the incidence of smoking caused hypercholesterolemia to the become 
the most important CVD risk factor, but the prominence of cholesterol as a risk factor has 
been challenged by recent research. According to Grimes (2012) the administration of 
statin drugs did not cause the drop in the CVD death rate as the decline started before 
statins were introduced 1994, and clinical trials showed benefits in only 2% of the 
sample, with aspirin and streptokinase therapy benefiting only 5%. Similarly, in clinical 
trials, aspirin, streptokinase, ezetimibe, and other cholesterol/plaque reducing 
pharmaceuticals lowered cholesterol levels, but had very little (< 5%) or no clinical 
benefit (Grimes, 2012). Additionally, the association between lowering of high 
cholesterol and the reduction in CHD deaths was only experienced for young men, but 





There is a powerful association between hypertension and heart disease, and it 
was one of the earlier traits identified by the FHS. High blood pressure (HBP) is 
diagnosed as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure of ≥90 
mm Hg (Goff et al., 2014). HBP is regarded as a leading independent risk factor for CVD 
and is believed to result from the efforts of the heart to move blood through blood vessels 
that have been narrowed by plaque buildup (Xu, 1991). As the condition of 
atherosclerosis progresses and the narrowing of the arteries worsens, the vessel diameters 
decrease, the heart is required to work harder and blood pressure goes up in response 
(Hollander, 1976). This continual over exertion of the cardiac muscles sets up the 
conditions for heart failure (stressed enlarged heart muscles), which can progress to heart 
attack or stroke if the blood supply is eventually obstructed. (Renna, 2013). 
Hypertension or HBP has a prevalence of 34% in adults, affecting over 90 million 
in the US, and 972 million globally (E J Benjamin et al., 2017). Rates in subpopulations 
can vary- African Americans have HBP rates of almost 46%, while children have 11% 
HBP rates. Of those with a first heart attack, 69% were hypertensive and 77% of stroke 
patients and 74% of those with congestive heart failure had blood pressures over 140/90 
mm Hg (Mozaffarian, Benjamin, Go, et al., 2015). While hypercholesterolemia may be 
regarded as the leading risk factor for CHD, hypertension is significantly correlated with 
the other subtypes of CVD and is the leading risk factor for MI, HF, AF, PAD, stroke and 




The finding that an elevated systolic blood pressure (Sys BP) was more predictive 
than elevated diastolic blood pressure (Dia BP) of a CHD event was a most important 
FHS discovery (Dawber & Lansing, 1966). As a result, systolic and diastolic BP was 
replaced by only ‘Sys BP’ as a risk factor in the FRS formula (Kannel, 1971). The FHS 
researchers determined that the association between Sys BP and the risk of developing 
CVD was continuous and graded no matter the level of BP or the age of the subject 
(Kannel, Vasan, & Levy, 2003). Elevated Sys BP (> 140 mg Hg) is directly related to 
both obesity and hypercholesteremia and the severity of the risk is dependent on the 
presence of other CVD risk factors (Tsao & Vasan, 2015a). One study found that for 
blood pressure measures that are above normal, every reduction in the BP by 10 mmHg 
reduced the risk of CHD or stroke mortality by 15% (Bertoluci & Rocha, 2017). 
Type 2 diabetes (T2DM).  
Type 2 diabetes mellitus (T2DM) is a condition of impaired carbohydrate 
metabolism. T2DM caused by an inability of cells to respond to insulin, results in 
elevated levels of glucose concentrations in the blood. Insulin is a pancreatic hormone 
that facilitates the entry of glucose into cells to be used for energy production. When the 
supply of glucose is excessive, the high glucose concentration triggers an overproduction 
of insulin from the pancreas, in an attempt to shuttle the surplus glucose from the blood 
into the cells (Faerch, Bergman, & Perreault, 2012; Roberts, Hevener, & Barnard, 2014). 
But this excess of glucose is harmful to the cells and they respond by removing their 
insulin receptors from their cell membrane to minimize glucose influx (Roberts et al., 




to respond to insulin and they are become effectively ‘insulin resistant’ (Roberts et al., 
2014). At the same time the pancreas, which has been pumping out extra insulin to deal 
with the rising glucose concentrations, becomes overworked and eventually shuts down 
(Sah, Singh, Choudhary, & Kumar, 2016). With less insulin being produced and cells in a 
state ‘insulin resistance’, dissolved glucose accumulates in the blood and abnormally high 
blood glucose levels or hyperglycemia persists.  
Epidemiological and clinical studies now indicate that one of the consequences of 
prolonged hyperglycemia is CVD. High concentrations of glucose are damaging to the 
cells and tissues of the body (Faerch et al., 2012; Laakso, 2015; Tostes & et al., 2009) 
Excessive glucose causes glucose molecules to attach to the protein structures of cells, 
the severity and duration of which can be measured by the hemoglobin A1 C (HbA1C) 
test (Huang et al., 2016). High concentrations of glucose also cause the cells of the 
epithelium of the blood vessels to lose their integrity and become damaged (Laakso, 
2015). It is this damage to coronary blood vessels that initiates cardiovascular disease. 
Advances in imaging technology have revealed that CVD is preceded by damage 
to the arteries that carry blood to the organs and tissues of the body. One of the ways the 
body tries to deal with this damage is by generating a blood clotting mechanism with 
patches of fatty deposits at the site of injury (D. Lloyd-Jones et al., 2010). Unfortunately, 
this ‘patch work’ becomes excessive with ongoing damage (persistent insulin resistance 
and resulting hyperglycemia) and it leads to a build-up of plaque on the walls of the 
arteries (Clark et al., 2015; Kishore, Kim, & Crandall, 2012) The plaque buildup may 




blood flow at the site, or break off and travel to other smaller spaces and occlude blood 
flow there (Hutcheson & Rocic, 2012; Long & Fox, 2016). If this happens in the heart, 
angina and heart attacks results; if the clot travels to the brain and obstructs blood there, 
the person suffers an ischemic stroke. Hyperglycemia, and the accompanying 
hyperinsulinemia, is believed underly the exacerbation of the many pathologies and 
morbidities of CVD (Hobbs & Hobbs, 2004). 
CHD Risk Assessment Tool  
CHD Risk Tool Performance 
Accurate prediction of threat and effective disease prevention and treatment 
strategies depends on well-designed risk estimation models. The widespread use of tools 
like the FRS and others is a testament to this. A risk formula combines the major risk 
factors into an equation that returns an estimation of the risk as the probability of a 
disease event happening. The CVD risk formulas typically calculate the probability of 
developing CVD events within a given period, usually “10-years” but sometimes “20-
years”, “30-year” or even “life-time”. Ideally, the use of baseline relative risk and the 
levels of exposure of the risk factors used in these tools should be specific to the 
population under investigation, otherwise additional calibration adjustment is required 
(Eichler et al., 2007).  
A more trustworthy stratification can be achieved by changing the disease range 
and using alternative thresholds for the categorization of different levels of predicted risk. 
Incorporating additional variables or replacing old ones with newer, more strongly 




applicability and utility of prediction tools, the ability to adequately discriminate (to 
differentiate between those with CVD outcome from those without) and to sufficiently 
calibrate (agreement between the prediction and the observation) are essential. In most 
cases, regression statistics are used to generate the model and the corresponding AUC or 
c-statistic are used evaluated the model’s performance (Elosua, 2014).  
The FRS Tool and its Performance Limitations 
The Framingham Risk Score tool has endured the test of time and is credited with 
popularizing the concept of risk prediction (Bitton & Gaziano, 2010). Because of these 
tools like the FRS physicians no longer must rely on their experience and judgment in 
assessing the CVD risk of their patients. Instead they can use the risk prediction function 
to more adequately screen and sort patients, more responsibly allocate resources and 
more effectively manage the treatment modalities (Günaydın et al., 2016). For a great 
many people, the FRS is still the most effective way for predicting the likelihood of 
developing CHD as well as screen for the presence and severity of the disease 
(D’Agostino et al., 2013). 
However, as beneficial as the FRS is, it has its some limitations and these 
limitations serve as the main driving force behind of risk score optimization efforts. 
Earlier research on the risk factors led to changes such as the removal of HDL from 
cholesterol measures and the use of only diastolic blood pressure values. Other changes 
such as generating gender specific versions of the formula or the labelling of diabetes as a 




of the tool became more widespread there were reports of more fundamental issues with 
the tool’s performance. 
The main limitations of the FRS relate to the less than ideal discrimination and 
classification power. A comprehensive study conducted by the FHS team evaluated the 
performance of the FRS amongst six ethnically different groups across the US. 
Evaluating the classification and calibration ability of the FRS to predict the relative risk 
associated with CHD revealed that the tool had an AUC score between 60-70% 
(D’Agostino et al., 2001a). By their own standard any risk assessment tool with an AUC 
score below 70% is considered suboptimal and should be amended (D’Agostino et al., 
2013). And although, the FRS has been updated since that 2001 report, the issues with 
under or overestimation and inadequate classification persist (Çevik, Özcan, & Satman, 
2015; Günaydın et al., 2016; Van Staa et al., 2014). 
The white middle-class cohort from which the original formula was designed 
limited its generalizability to more ethnically diverse populations. Studies conducted by 
the NHLBI have determined that the FRS, even after recalibration, tended to 
underestimate the risk in populations that have very low incidences of CVD, such as 
Japanese, East-Indians and Native-Americans (D’Agostino et al., 2008; N. Garg et al., 
2017; Kones, 2011; Reddy & Satija, 2010). Additional studies reported on the 
misclassification and overestimation in high-risk groups or those in the lower 
socioeconomic class in the US and among European populations in general (Eichler et 
al., 2007; Günaydın et al., 2016; Pike et al., 2016). These findings were concerning and 




Other Tools Developed in Response to the FRS Limitations 
The next section describes the three most common (after the FRS) CVD risk 
estimation models being used in the field of CVD screening and prediction. These tools 
were developed from the FRS and came about in response to its limitations. Despite the 
recalibration and other adjustments made to the FRS, the inaccuracy was problematic, 
and researchers wanted risk formulas that was more representative of how the disease 
manifested for their patients. The desire for tools that specifically represented the CHD 
risk in their respective countries and communities resulted in the development of the 
QRISK, the SCORE, and the ASSIGN. 
QRISK: the QResearch database CVD risk score. QRISK was in response to 
the challenge of using the FRS in Europe, namely European ethnic diversity and 
differences in CVD prevalence. The UK-NICE (National Institute for Health and Clinical 
Excellence) developed a revised version of the FRS, called FRS-NICE. The FRS-NICE 
added the risk factors BMI, family history of CVD, treatment for hypertension, and social 
deprivation to the FRS and raised the threshold for the high-risk category (Collins & 
Altman, 2012). Applying the FRS-NICE reduced by half the number of patients being 
recommended for primary prevention and thereby reduced the expense and many-side-
effects associated with statin, the cholesterol-lowering drug, usage (Collins & Altman, 
2012).  
The SCORE (Systematic Coronary Risk Evaluation). SCORE, the second 
most common European risk assessment tool, began in 1994 as a collaboration between 




from 12 European cohorts and their 205,178 patients (Tomasik et al., 2015). The six risk 
factors used were: total cholesterol, TC:HDL ratio, age, gender, smoking status, and 
systolic BP with a 10-year CVD outcome prediction. The larger cohort, the easy-to-read 
charts, the inclusion of endpoints other than mortality, and the use of the respective CVD 
rates for each region did improve the risk estimation and prediction. This simplified 
prevention method assignment and patients were more appropriately categorized for 
application of education, lifestyle changes, or medication (Conroy et al., 2003).  
ASSIGN (Assessing cardiovascular risk, using SIGN). ASSIGN is the CVD 
screening tool developed by the Scottish Heart Extended Cohort (SHHEC) from survey 
data, collected from 1944 to 1995 from clinic patients between 25 and 74 without a 
history of CVD (Woodward, Brindle, & Tunstall-Pedoe, 2007). Like the QRISK, the 
outcome was based on mortality and morbidity measures as well as both CHD and CAD 
as this was the most common CVD and the leading cause of death among the Scotts. The 
ASSIGN successfully improved upon the sensitivity and specificity of the FRS and 
alleviated the disadvantages suffered by high-risk minorities who were previously 
insufficiently allocated for preventive care (Tunstall-Pedoe, 2011).  
Comparing the Common CVD Risk Formulas. Choosing between models is an 
important task for many personnel and organizations involved in CVD screening. There 
are several studies comparing the performance of the more common models of risk 
estimation. One such study compared the performance of the FRS (US based), the 
ASSIGN (Scottish), and the QRISK2 (England and Wales) on the same data set. There 




challenged by the different thresholds (Van Staa et al., 2014). The social-deprivation term 
in ASSIGN did not work for non-UK populations but the region-specific data and CVD 
history information made the QRISK most accurate overall (Van Staa et al., 2014). 
Recently Gunyadin (2016) compared the performance of the SCORE relative to 
FRS to determine which was better at predicting CVD. They used the SYNTAX test, an 
angiograph measurement of the number of lesions inside the coronary arteries, for a non-
formula estimation of CVD risk. According to the results, the SCORE provided better 
discrimination among men and diabetic patients, but not among the obese or those with a 
family history of CVD. Although, both models predicted a similar level of CHD severity 
risk (based on the AUC evaluation), the only factors found to be statistically significant 
in the SCORE model were ‘blood pressure’ and ‘total cholesterol’ (Günaydın et al., 
2016). 
Performance Evaluation of CHD Risk Tools  
It is important that prediction models that have been developed, redesigned, or 
extended continue to be adequately reevaluated as these tools are used for making 
important decisions, both diagnostically and prognostically. In the field of medicine, 
where decisions are usually binary in nature and require an estimation of absolute risk, 
logistic regression models have proven effective (Sperandei, 2014). Determining whether 
these formulas' predictions can be extended to the other sample population is vitally 
important. The calibration ability or the difference between the predicted outcome and 
the actual outcome reflects most how well the model describes the data. Making changes 




 For CVD risk prediction, the models are formulas that combine the major risk 
factors generates prediction probability as an attributable risk value. There are many 
methods for evaluating the performance of these prediction formula and by convention, 
quantifying the performance with known-outcome data sets works best. For logistic 
regression formulas, where the outcome is dichotomous, the model’s performance is 
evaluated based on four main metrics: (i) the coefficient of the independent variable 
(which reflects the strength of the association), (ii) the confidence interval of the 
independent variable (which gives an indication of the importance of the variable to the 
prediction relationship), (iii) the accuracy of probability of the dependent variable, and 
(iv) the goodness of fit of the formula in both its discriminating and its calibrating 
abilities (P Brindle et al., 2005; D’Agostino et al., 2001a; Giancristofaro & Salmaso, 
2003).  
For models whose performance evaluation determined that they need to be 
optimized, there are several ways of doing so. Models can be optimized by adding new 
markers that extend to the formula but adding this new variable must provide a higher 
degree of accuracy (Root et al., 2014). Models can also be optimized by altering the 
variables already in use so that there is an increase in the additional risk information 
provided (Rodondi et al., 2012). Ideally this altering of the variable should have a 
generate an increase in the predictive power. In either case, the new formula is evaluated 
against the performance of the old one based on the same principles used in the original 




Improving the performance of multivariable risk assessments is vital to patients’ 
classification and treatment guidelines and users should be confident of the tools 
applicability and generalizability. This study will compare the predictive performance of 
the FRS model that uses ‘diabetic status’ as a marker against the one that uses ‘glucose 
levels’. First the relative risk and the confidence intervals of each marker will be 
computed and compared, then the attributable risk as a probability for each the two 
formulas. The predicted probability will be compared with the observed probability of the 
data compared as discriminating ability in the AUC to determine which is the better fit of 
the data. Finally, the co-variates will be added to the analysis and the effect on the AUC 
of the ‘glucose level’ formula will be assessed. 
Glucose and the Crisis of Metabolic Disorders  
Spectrum of Metabolic Disorders 
Diabetes describes persistent elevated blood glucose levels produced by impaired 
carbohydrate metabolism. Diabetes is, however, one of many states that are part of a 
continuum of metabolic abnormalities and body weight issues; beginning with mild 
insulin resistance, moving to being overweight, then to full-blown insulin resistance and 
obesity, followed by pre-diabetes, and finally ending with diabetes (Long & Fox, 2016). 
Collectively these disorders, referred to as ‘diabesity’ by Dr. Hyman, are known as 
metabolic disorders or impaired glucose tolerance problems, most of which go 
undiagnosed and therefore ignored (Hyman, 2012). The rapid rise of metabolic disorders 




2010). More recent research indicates that in 2012 one in every two Americans (52%) 
was already either pre-diabetic or diabetic (Menke, Casagrande, Geiss, & Cowie, 2015). 
Cardiovascular diseases are part of a larger group of cardiometabolic diseases that 
share clinical markers, that can co-occur, and are interlinked in their development 
(Assmann, Schulte, & Seedorf, 2008; Bertoluci & Rocha, 2017; Long & Fox, 2016; 
Srikanthan, Feyh, Visweshwar, Shapiro, & Sodhi, 2016; Wilson & Meigs, 2008). The 
high probability of co-morbidity necessitates an integrated approach to risk assessment 
that combines ‘cardio’ factors and ‘metabolic’ factors of diseases such as CVD. One 
cross-sectional study of 5,190 Kenyans looked at the most common cardio-metabolic 
markers and concluded that central-obesity (i.e., abdominal obesity), hypertension, 
hypercholesterolemia, hypertriglyceridemia, and hyperglycemia were all inter-linked 
(Haregu et al., 2016). Assmann et al., (2008) argued that including metabolic markers 
significantly improved the accuracy of CVD risk assessment tools. A decade ago, the 
FHS researchers concluded that metabolic risk factors, not diabetes only, should be part 
of the screening and prevention strategies for CVD (Wilson & Meigs, 2008).  
Overweight, Obesity, and BMI  
Metabolic disorders usually begin with some form of insulin resistance and if 
unchecked progresses through to several stages of metabolic disorders eventually end in 
diabetes. The hormone insulin is responsible for the movement of glucose into the cells 
as described above. It is also involved in the production of fat- both in the liver and the 
fat cells around the body (Sah et al., 2016). Insulin production by the pancreas and 




glucose in the blood into fat cells where it can be stored (Roberts et al., 2014; Srikanthan 
et al., 2016). The accumulation of fat tissue around the vital organs begins the overweight 
status that eventually leads(Roberts et al., 2014) to central or abdominal obesity. 
Overweight is usually the first recognizable sign of hyperglycemia, insulin resistance and 
metabolic dysfunction (Hyman, 2012; Roberts et al., 2014; Srikanthan et al., 2016).  
Overweight status is determined by the height to weight ratio or body mass index 
(BMI) and is calculated by dividing the subject's weight by the square of their height 
(Kg/m2) (Çevik et al., 2015). A BMI over 25 but less than 29.9 is considered overweight 
and affects approximately 35% of the American population (Go et al., 2014). Sometimes 
the BMI measures are misleading, and waist to hip ratio is used to be a more accurate 
estimation of an individual’s obesity level (Reddy & Satija, 2010). However calculated 
though, more than half (53%) of Americans have visceral or abdominal obesity, and 3 
billion around the globe are dealing with excess body fat (Kones, 2011). 
If overweight condition is not adequately managed the next state, in the metabolic 
disorder continuum- obesity, happens. Obesity, measured by a BMI of 30 or above, is 
considered the leading cause of preventable death and afflicts 35% of the Americans 
(Nichols, 2012). Obesity is a serious medical condition that causes hypertension and 
atherosclerosis making it a major CVD risk factor, but it also predisposes individuals to 
respiratory problems, sleep disorders, and even cancer (Long & Fox, 2016). Increased 
BMI is correlated with hypertension, T2DM, congestive heart failure, and the onset of 
atrial defibrillation, and obesity was found to be double the risk of CVD in the original 




and sudden death by cardiac arrest (Long & Fox, 2016). Obesity serves an independent 
risk marker for glucose intolerance and a corresponding increased risk of CVD (Long & 
Fox, 2016). The rate of obesity and overweight status has been increasing - between 1950 
and 2000 the proportion of Americans who are overweight rose from 15 to 30%, while 
obesity rose from 3.9 to 14% (Long & Fox, 2016). Today, as many as 70% of American 
adults are either overweight or obese (Kones, 2011) and over 80% of overweight patients 
have at least one of four major CVD risk factors- hypertension, elevated triglycerides, 
low HDL, or impaired glucose tolerance (Nichols et al., 2012). 
Pre-Diabetes  
The order of progression through the metabolic continuum is not pre-set, obesity 
can be preceded by or followed by conditions of pre-diabetes. Pre-diabetes, or 
intermediate hyperglycemia refers to the condition where the blood glucose is higher than 
normal but not high enough to be diagnosed as diabetic (Huang et al., 2016). Pre-diabetes 
is diagnosed with a fasting blood glucose level from 100 to 125 mg/dL (5.6 to 6.4 
mmol/L) and is accompanied by an established insulin resistance (Farooq Al-Azzawi, 
2015; Tabák, Herder, Rathmann, Brunner, & Kivimäki, 2012). Prediabetes is strongly 
associated with other CVD risk factors such as obesity (especially central or visceral 
obesity), high levels of LDL cholesterol, high triglycerides, and high blood pressure 
(Tabák et al., 2012). Pre-diabetes was found to confer a 12.7 to 22.3 fold higher risk of 
developing diabetes, depending on the duration, which is strongly associated with an 
increased incidence of CVD (Tsao & Vasan, 2015; Long & Fox, 2016)(Fox, 2010). 




determined to be pre-diabetic (Menke et al., 2015). Currently, there are over 84 million 
people living with pre-diabetes and over 90% of them are undiagnosed (Center for 
Disease Control & Prevention, 2017). 
Metabolic Syndrome  
Another condition that is clustered with obesity and pre-diabetes is that of 
metabolic syndrome (MetS). MetS is defined as a combination of three or more of the 
seven risk factors that include prediabetes, diabetes, central obesity, high blood pressure, 
high triglycerides, high levels of LDL, and low levels of HDL (Grundy et al., 2008). A 
co-existence of these inter-related parameters produces a synergistic effect that 
significantly increases the likelihood of CVD (Farooq Al-Azzawi, 2015). MetS was 
found to confer a 7-fold higher risk of T2DM and to double the risk for CVD mortality, 
all-cause mortality, myocardial infarction and stroke (Hutcheson & Rocic, 2012). Despite 
the dominance of factors such as HDL and BP, when MetS is included in the prediction 
formula, the probability of CHD increases from 37.4% to 54.7% (Bertoluci & Rocha, 
2017). MetS, found in 35% of the adult US population or 50% for those over 60 years, 
has a rapidly rising prevalence, driven mainly by the increase in insulin resistance and 
obesity (Aguilar, 2015).  
Type II Diabetes 
At the end of the metabolic disorder spectrum is T2DM, a state of persistent 
hyperglycemia. Unlike Type I Diabetes, in which hyperglycemia is caused by an 
autoimmune-based insulin insufficiency, T2DM is caused by a acquired insulin resistance 




T2DM is diagnosed by a fasting blood glucose (FBG) level above 125 mg/dL or 
6.9 mmol/L (Center for Disease Control & Prevention, 2017). In 2009, there were over 
110 million Americans, and another 130 million worldwide, living with T2DM and it was 
predicted to rise to 180 million by the year 2030 (Fuster & Kelly, 2010). The incidence of 
T2DM increased so rapidly, that the projection was changed to 239 million people 
affected worldwide by 2030 (Shaw, Sicree, & Zimmet, 2010). The latest report from the 
International Diabetes Federation (IDF), states that there are 425 million diabetics on the 
planet (half of which are undiagnosed) and it is predicted to increase to 552 million by 
2030 and 629 million by 2045 (International Diabetes Federation, 2017).  
T2DM, though very common, is a serious illness and is a major cause of chronic 
disease, disability, and death. T2DM is associated with heart disease and stroke, and is 
the leading cause of kidney failure, lower limb amputation and new cases of blindness 
(Dauriz et al., 2015; Sarwar et al., 2010) Despite the decline in CVD related deaths, 
diabetics included, there are still a large number who survive and continue suffer the 
many complications of the combination of both diseases. T2DM can double, triple or 
quadruple (depending on age and gender) the risk of CVD mortality as well as increase 
the risk of chronic heart disease and ischemic stroke (Bertoluci & Rocha, 2017). T2DM 
and pre-diabetes are associated with many issues arising from damage of the 
microvascular vessels which including, retinopathy, neuropathy, and nephropathy, but 
CVD remains is the primary cause of death in diabetics (Tabák et al., 2012).(Bertoluci & 




Diabetic Status in the FRS 10-year Risk Assessment 
Early scrutiny of the FHS data identified diabetes is one of the strongest CVD risk 
factors, but it would take several rounds of revisions before it would be included as a risk 
factor in the FRS assessment formula. In the early 1930s and 1940s, before the FHS, 
evidence was already accumulating to implicate T2DM as a risk factor for CVD, but it 
was the FHS analysis that provided empirical confirmation of this relationship (Kannel & 
McGee, 1979a). Several round of analysis confirmed diabetes an independent risk factor 
for CVD, one that conferred a higher risk of CVD mortality and morbidity, with a 
substantial impact on all-cause mortality (Avitabile, Banka, & Fonseca, 2012). Later 
researcher would find that three out of every four diabetics died from heart disease and 
therefore diabetic status should be an important major risk factor in any FRS risk 
assessment function (Qazi & Malik, 2013a). But the strength of other risk factor such as 
cholesterol and hypertension overshadowed diabetes and it would be included 50 years 
after the FHS study began (Bennet, Angelantonio, et al., 2008; Kannel, Gordon, & 
Schwartz, 1971; National Heart & Boston University, 2017; Tsao, 2015). 
Assessing the risk of developing CVD in asymptomatic groups began 
approximately two decades after the data collection for the first FHS cohort started. 
Careful investigation of the data revealed several associated risk factors but only the ones 
with a relatively strong correlation to CVD were used for CVD risk assessment (Dawber 
et al., 1957; Lansing, 1961). Initially, the risk factors were used in cross-classification 
tables to generate a risk level, but as the number of risk factors grew, the tables were 




Anderson et al., 1991). These equation functions were first published in 1967 and 
produced an estimate the risk possessed by each individual subject (Friedman, Hyg, 
Kannel, Dawber, & McNamara, 1967). The risk factors used then were age, gender, total 
cholesterol, left ventricular hypertrophy (LVH), smoking status, and systolic blood 
pressure (SBP). Clinicians used the functions to evaluate each patient and assign those 
with moderate and high risk to relative preventative treatment.  
During the 1970s and the 80s several updates to the FRS model were published 
and the risk equation functions were eventually replaced by a risk factor combination to 
generate a risk profile. This novel risk profile differed in several ways: it distinguished 
between general CVD and its most common type, CHD; there were now 5-year risk and 
10-year risk versions; and it included only variables that had a strong association with a 
CHD event (Gordon & Kannel, 1982; Kannel & McGee, 1979; Kannel, Castelli, Gordon, 
& Mcnamara, 1971). The risk factors were now relegated to those that were 
independently correlated to CHD and whose values were easy to obtain during an office 
visit. By the end of the 1980s, variables like ‘BMI’ values was added but later replaced 
with ‘glucose tolerance test’ (GTT) values; ‘family history’ had been added but removed 
because of the difficulty to accurately determine in most cases; and ‘LVH’ requiring 
expensive, inconvenient test was also removed (D’Agostino et al., 2001a; Qazi & Malik, 
2013a). The new stream-lined formula now included the six variables: age; gender; total 
cholesterol; smoking status; and GTT. 
After several rounds of revisions, the end of the 20th century birthed the latest 




Framing Risk Score would mark the first appearance of ‘diabetes’ (as a dichotomous 
‘yes/no’) as a variable, having replaced ‘GTT’ levels (Wilson, 1998). The new FRS 
assessed the 10-year risk and would go on to have a major impact on the national 
guidelines for treatment for hypercholesterolemia and hypertension. Ironically, this 10-yr 
FRS version was noted for substituting continuous measures of blood pressure and 
cholesterol levels with their risk categories based on the fifth Joint National Committee 
on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V) (Cleeman, 
2001).  
Sometime later, this official 10-year version of the FRS, using the hard CHD 
(coronary deaths, MI and stroke) as the endpoint, was adopted by the third Adult 
Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) 
(Grundy et al., 2002). The classification using the 10-year risk estimates of the FRS 
proved to be more convenient and more accurate, and soon became the basis for the 
cholesterol, blood pressure and dietary rules used by physicians throughout the nation 
(D’Agostino, 2013; Mahmood, 2013). To this basic formula, the American College of 
Cardiology/American Heart Association (ACC/AHA) added cRP and a history of CVD 
to generate the Reynolds risk model, and ‘race’ for the Atherosclerotic Cardiovascular 
Disease (ASCVD) calculator for working with those who have a history of 
atherosclerosis or high LDL (Stone et al., 2013). Despite the existence of other formulas, 
it is the 10-year FRS that is regarded as the official formula in the US and the standard 
used by clinicians and researchers for all their CHD risk assessment needs (Ford, Giles, 




A diagnosis of diabetes became a most important variable in the official 10-year 
FRS. This formula, developed from the first cohort data set, was intended for a relatively 
shorter (than life-time risk) horizon and to have the greatest applicability to the age (30-
74 years) group for whom assessment and prevention therapy would be most beneficial. 
Diabetes testing was already a routine medical assessment, and knowing that positive 
diagnosis imparted a high CHD risk made it critical to the accuracy of the CHD risk 
estimation (Cockram et al., 2001). The ‘diabetic status’ version of the 10-year-FRS 
became a valuable tool to clinicians for classifying new patients and for guiding 
subsequent treatment plans (Coch & Green, 2016; Damkondwar, Rajiv, Suganeswari, 
Kulothungan, & Sharma, 2011; Qazi & Malik, 2013b; Wilson & Meigs, 2008). As one of 
the major modifiable risk factors, ‘diabetic status’ helped in correctly assigning patients 
for either moderate intervention such as education about diet and activity levels, lifestyle 
change; or for stronger intervention like glucose lowering or statin drug prescription 
(Alatawi, Kavookjian, Ekong, & Alrayees, 2016; Brindle et al., 2005). 
It should be noted that the criteria used for a diagnosis of diabetes during the 
initial FHS data collection and analysis was different from that used today. For the first 
cohort, diabetes was diagnosed in one of three ways: (i) by history of hypoglycemic 
(insulin) use; (ii) a casual blood glucose (CBG) level above 150 mg/dL recorded on two 
visits; or (iii) a fasting blood glucose (FBG) level over 140 mg/dL (Wilson et al., 1998). 
By the second cohort, GTT were now part of the examination, and abnormal GTT levels 
was now the fourth way of diagnosing diabetes. But eventually only the fasting blood 




diabetes (Shaw et al., 2000; Wareham, 1998). Even though FBG levels were now more 
routinely obtained, the use of the dichotomous ‘diabetic status’ in the standard 10-year 
FRS, based on an arbitrary threshold, ensured the loss of valuable risk information 
(Bertoluci & Rocha, 2017). Additionally, the risk facing those dealing with ‘prediabetes’ 
would go unrecognized and the risk assessment compromised. Also, further classification 
among those diagnosed with diabetes is important for choosing the appropriate secondary 
treatment and for monitoring the progression (or regression) of the disease in response to 
any of the treatment administered (Kishore et al., 2012). 
Like the other major risk factors, cholesterol and blood pressure, diabetic status 
had a different relative risk for CVD across the genders. FHS data analysis reported that 
T2DM was a significant trait of CVD susceptibility for men and  the strongest risk factor 
for women (Qazi & Malik, 2013b). Additionally, the FHS determined that T2DM was 
associated with a 2 or 4 (male or female respectively) times greater risk of developing 
CVD and it was correlated with an increased risk of dying from CVD-related 
complications (Fox, 2010). We now know that diabetics die mainly from CVDs such as 
MI, CHF, PAD, and stroke, with the increased risk being greater in women than in men 
(Cockram et al., 2001; Huang et al., 2016; Long & Fox, 2016; Tsao & Vasan, 2015a). 
These gender differences were the impetus for separating the 10-year FRS profile into 
distinct gender formulas that improved the sensitivity of the assessment.  
By the turn of the new century, T2DM was not only recognized as a major risk 
factor, but it was believed to be conferring the worst prognosis to CVD patients, with 




Cockram et al., 2001; Raggi, Shaw, Berman, & Callister, 2004). This information led the 
FHS researchers to declare T2DM a CVD risk equivalent and to remove diabetes as a risk 
factor from it’s the official 10-year FRS (Bonow, 2002; NHLBI & NIH, 2002). Instead, 
all diabetic patients were now labelled as having already suffered a CHD event and 
automatically placed in the high-risk category. Subsequently, there were the new 
formulas for ‘global-CHD’ and ‘general-CVD’ risk assessment and they include ‘diabetic 
status’ as a variable (D’Agostino et al., 2008). However, as with previous versions of the 
use of ‘diabetic status’ as a binary limited the accuracy of the FRS. 
Alternative models of the FRS, calculating 20-year, 30-years for long-term and 2-
year and 5-year risk for short-term, were subsequently designed, but the 10-year model 
remained the most commonly used. The 2-year FRS formula is used for patients who had 
already experienced a coronary event (D’Agostino et al., 2000). The 5-year FRS formula, 
being more finely tuned with less generalizability, is usually reserved for the elderly 
(over 75 years) or infirmed as they require a more sensitive test (Laurier, Chau, Cazelles, 
& Segond, 1994; Rodondi et al., 2012; Westendorp et al., 2009). The risk models with 
longer prediction times (20-year, 30-year, and life-time risk) are used for younger 
patients and for those from demographics with a lower incidence of CHD, as the 10-yr 
tool can underestimate the risk for these groups (Levy, Walmsley, & Levenstein, 
1996)(Mccormack, Levine, & Rangno, 1997). The variations of 30-year risk and life-time 
risk usually add the variables ‘BMI’ or ‘use of hypertensive medication’ to the basic 10-




screening for CHD and is therefore most common (PM Brindle et al., 2005; Cleeman, 
2001; Ford et al., 2004; Jahangiry, Farhangi, & Rezaei, 2017; Westendorp et al., 2009).  
Diabetes Over the Years 
At that time there was little understanding of how diabetes was caused, and even 
less attention was placed on how it developed. In addition to the difference in T2DM 
diagnosis protocol and the new FRS inclusion criteria, there have been more volatile 
changes in diabetes prevalence over the years. 
 
Figure 3. Diabetes over the years. Reprinted from Long-term Trends in Diabetes: CDC’s 





The disease was significantly less common 60 years ago than it is now, assuming 
that the prevalence of diabetes at the early stages of the FHS in 1948 was very lower than 
the 0.93% in 1958 (Centers for Disease Control and Prevention, 2017). By the 
publication of the first FRS, diabetes was only at 3.39% (1998) and at 6.29% by the 
second (2008), less than half the 13.5% prevalence it is today (Centers for Disease 
Control and Prevention, 2017). The higher prevalence, the different diagnostic protocols, 
and the rapidly increasing incidence rate are reasons for the complicated role of T2DM in 
the FRS.  
During the last quarter of the 20th century the incidence of diabetes doubled 
among individuals between the ages of 40 to 55 and this was mostly those who were 
obese (Long & Fox, 2016). However, even though the incidence rate of CVD among 
patients with diabetes has fallen by as much as 50% over that same period, the incidence 
of CVD among diabetics is still twice what it is among non-diabetics (Long & Fox, 
2016). These numbers represent an increase in the attributable risk (AR), the difference in 
incidence of CVD for those dealing to diabetes and those who are not, while the relative 
risk (RR) which is a measure of the strength of the association remained the same. This 
increase in AR is an indication of complication and makes early detection and 
stratification even more critical (Fox, 2010). Early detection of T2DM, blood glucose 
control, and early aggressive action are all critical to managing subclinical CVD, and it is 
for this reason for comprehensively assessing the full range (i.e., hypoglycemia, pre-
diabetes/metabolic syndrome and diabetes) of dysglycemia (Coutinho, Gerstein, Wang, & 




Need for Stratifying a Diagnosis of Diabetes in Risk Assessment 
Stratification is necessary for clinicians to identify patients who are at highest risk 
and will therefore be more receptive to, and benefit most from, aggressive treatment. 
Stratification enables the clinicians to more accurately sort patients into additional risk 
categories such as: no-risk, low-risk, intermediate-risk, moderately high-risk and high-
risk. It is also essential for the accuracy of the CVD risk prediction effort, especially 
since atherosclerosis and other CVD risks can remain asymptomatic for years 
(D’Agostino et al., 2013). This facilitates optimal use of time and resources such as 
intensive aggressive treatment including further testing, drug therapy, or surgery for those 
at high risk with moderate monitoring or treatments with a lifestyle emphasis for 
intermediate risk patients and no treatment for those in the low risk group.  
Researchers in the CVD risk prediction field have determined that the risk among 
diabetics is far from homogeneous. In fact, many organizations involved in the diagnosis 
and treatment of heart disease and/or T2DM such as the ACC, the AHA, the ADA, and 
the ESC have rejected the notation that T2DM and CVD are risk equivalent (Bertoluci & 
Rocha, 2017)(Bertoluci & Rocha, 2017). In one study found that there were some 
diabetics who had CAC (coronary artery calcium) scores of zero, essentially the same 
risk level as that of a non-diabetic, especially among younger individuals (Raggi et al., 
2004). Additionally, the AHA has officially recommended further stratification for 
diabetics based on age, particularly for those between 40 and 75 years, and on level of 
LDL in the blood (Ray et al., 2014). The ESC also recommends stratification for 




disease more than 10 years, and on the presence or absence of renal dysfunction and the 
presence of other risk factors (Piepoli et al., 2016). Similarly, the ADA also recommends 
stratification for diabetics based on age, previous CVD status, and the presence of other 
risk factors; facilitating varying therapy recommendations such as intense statin therapy, 
moderate statin therapy, or simply lifestyle modification for some of those at risk (Coch 
& Green, 2016).  
Age, as the strongest non-modifiable risk factor, is important to CVD risk 
stratification because of the synergistic effect it has on other risk factors. The older the 
individual, the greater the accumulation of risk factors and the increased duration and 
thus detrimental effect of the disease on the system (K. M. Anderson et al., 1991). A 
group of Canadian researchers has recommended important ‘transition’ ages that 
clinicians to pay attention to in CVD risk assessment. These age ranges are suspected to 
be when the risk of CVD can go from low/no to moderate or from low/moderate to high, 
and range between 33 to 48 for women and 45 to 52 for men (Booth et al., 2006). It is 
during these ages that newly developed risk factors can appear and serve as a warning or 
as new or additional focus for risk reduction therapy. 
As indicated by the difference in the transition age, gender is another important 
non-modifiable risk factor. The earliest data indicated that men are at a greater risk of 
developing CVD than women (4X for men vs. 2X for women risk of CVD), however 
men have better CVD survival rates (D. Lloyd-Jones et al., 2010). Intriguingly, with a 
diagnosis of T2DM, those differences are reduced, with both genders having similar 




al., 2006)(Amsterdam, 2011). This is believed to be the result of the higher risk profile of 
hyperlipidemia and hypertension in women, combined with the reduced probability of 
diagnosis and treatment of heart disease (D. Lloyd-Jones et al., 2010). Being female and 
having heart disease and diabetes has more severe outcomes for women heart disease is 
recognized less frequently. 
Another variable that provides an opportunity for stratification of the risk of 
developing heart disease is ‘family history of CHD’. The effect of having a family history 
of CHD is proportional to the number of biological relatives affected, and this is reflected 
in the hazard ratio for one blood relative being 1.5 but HR is 1.79 for two relatives with 
CHD (Ray et al., 2014). This increased risk is also dependent on the age of onset for each 
family member and the nature of the relationship (parents, sibling, or cousins, etc. (D. 
Lloyd-Jones et al., 2010; Tsao & Vasan, 2015a). However, although ‘family history’ is a 
better predictor than other biological risk factors, it did not improve the accuracy of the 
FRS and its use is only suggested in the case of older patients- males over 55 and females 
over 65 (Bertoluci & Rocha, 2017). 
Using diabetes as a binary variable in the FRS results in a loss of valuable 
information. The risk level of among diabetics are not the same as there is a significant 
amount of heterogeneity and using the diagnosis as a risk equivalent reduces the accuracy 
power of the formula. Even among those who are non-diabetic there is also range of risk 
levels, as hypoglycemia can confer a higher CVD risk than does a normal glucose level. 
The use of glucose levels as a risk factor provides additional classification and 




Glucose Level as CVD Risk Factor 
Measuring Glucose Levels 
Glucose level is an important CVD risk factor but there are many different 
methods for determining the quantity of glucose in the blood. The most common method 
is the fasting blood glucose (FBG) test, where a blood sample is collected, first thing in 
the morning after abstaining from food for at least 8 hours. The FBG concentration is 
reported either in milligrams (mg) per 100 mL (mg/100mL or mg/dL since 100ml = 1 dL) 
or in millimoles per liter (mmol/L). A FBG above 125 mg/dL (> 5.5 mmol/L) is 
diagnosed as diabetic, between 100-124 mg/dL (5-5.4 mmol/L) is considered pre-
diabetic, 70-100 mg/dL (3.9-4.9 mmol/L) is normal, and below 70 mg/dL (<3.8 mmol/L) 
is hypoglycemic (American Diabetes Association, 2015).  
Blood glucose levels can also be measured under non-fasting conditions by either 
of three ways: the casual blood glucose (CBG) or random blood glucose test; the post-
prandial blood glucose (PPBG) test; or the oral glucose tolerance test (OGTT). The CBG 
is a test of the concentration of a blood sample taken any time of the day, before or after a 
meal, and values above 200 mg/dL (11 mmol/L) are diagnosed as diabetic (Kadowaki et 
al., 2008). However, the CBG test is not as reliable as the FBG since glucose levels are 
subject to normal fluctuations depending on the quantity of carbohydrates consumed in 
the last meal and the time since the meal was eaten. The CBG test is most useful for 
circumstances where the FBG is unavailable or obtaining it would be inconvenient. 
The post-prandial blood glucose (PPBG) test or the oral glucose tolerance test 




two-hour periods. For both tests, a sample of pre-prandial blood is taken, then the patient 
is made to eat a test meal in case of the PPBG or ingest a solution of 75 g of glucose 
dissolved in 8 oz water in the case of the OGTT. For the PPBG, a second blood sample is 
taken after two hours and the difference in the pre-prandial and post-prandial 
concentrations of glucose is determined. For the OGTT, additional blood samples are  
drawn every 30 minutes for the next two hours and plot of concentration over time is 
obtained (American Diabetes Association, 2009). Ultimately, the blood sugar level at the 
end of the two-hours should be <140mg/dl (<7.8 mmol/L) for a normal blood glucose 
response (Saisho, 2014). Values between 140–200 mg/dL (7.8–11.1 mmol/L) indicate 
impaired glucose tolerance (IGT) or prediabetes, while anything above 200 mg/dL (or 
>11.1 mmol/L) is diagnosed as diabetic (American Diabetes Association, 2015). These 
tests were commonly used to check for gestational diabetes in pregnant women, but their 
utility has recently been questioned. 
Lastly, the average glucose concentration during fasting and non-fasting periods 
can be measured using the test of glycated hemoglobin, (the HbA1C) test. This newer 
biochemical test measures the percentage of particular protein molecules (hemoglobin in 
the red blood cells) that have been glycated (i.e., have glucose molecules attached to 
them) (Nolan, Damm, & Prentki, 2011). The higher the prevailing glucose concentration, 
the more glucose molecules bind to proteins, which negatively affects their structure and 
function (Tabák et al., 2012). The results from HbA1C tests reflect the average level of 




6.0% are considered normal; 42–47 mmol/mol (6.0–6.4%) is pre-diabetic; and anything 
above 48 mmol/mol (6.5%) is diabetic (American Diabetes Association, 2015).  
Glucose Levels in Risk Assessment Model 
The Full Range of Glucose Level is Associated with CVD Risk 
The association between high glucose levels (i.e., hyperglycemia) and its 
exacerbation of the many complications of heart disease is well established. However, 
glucose levels just below and even far below the diabetic threshold also have an 
association with heart disease. Bertoluci and Rocha (2017), reported that hypoglycemia 
(FBG of 70-100 mg/dL) or low glucose levels (FBG of 101-125) have a hazard ratio of 
2.64 for CVD and for 6.34 for CVD mortality, respectively. This is believed to be an 
effect of the high levels of insulin in the blood stream simultaneous to insulin resistance, 
that triggers the hypoglycemia and exacerbates the CVD symptoms (Faerch et al., 2012; 
Laakso, 2015; Park et al., 2013). This underscores the complex relationship between the 
predisposition to CVD and the full range of glucose levels from hypo- to normal to 
hyper-glycemia. 
There are several studies that demonstrate the relationship between CVD and the 
full range of glucose levels. One such study is a cross-sectional analysis the data from a 
CVD prevention program that evaluated the CVD risk for 3,739 non-diabetics (Valentino 
et al., 2015). FBG values below 125 mg/dL (non-diabetic) were found to be a marker for 
CVD risk factor clustering and more specifically glucose levels below 100 mg/dL were 
found to be associated with low HDL, high triglycerides, hypertension, abdominal 




interesting aspect of this study was that in cases with similar, healthy cholesterol levels, it 
was the difference in glucose levels that identified the potential CVD risk. Findings like 
these that emphasize the need to include glucose levels in risk assessment as well as in 
risk factor reduction therapy for CVD health promotion. 
Another study with middle-aged African Americans in Florida, looked at the role 
of modifiable and non-modifiable factors in CVD prediction (Carter, Ralston, Young-
Clark, & Ilich, 2016). Information on diabetic indicators (blood glucose and insulin), 
apolipoproteins, adipokines, and lipid profile were collected. Using both the AHA and 
FRS assessment tools they analyzed the data and compared the results for the two 
genders. The results confirmed the higher CVD risk for men, and the negative association 
between the biological markers (except for HDL) and CVD outcomes. Additionally, the 
authors noted that glucose level was the strongest indicator, with the widest applicability 
across the groups, for CVD risk prediction (Carter et al., 2016). 
An Icelandic meta-analysis of several Western prospective studies also indicated 
that glucose levels might be the strongest risk factor associated with vascular outcomes, 
CHD, and stroke (Sarwar et al., 2010). The analysis showed that the inclusion of glucose 
level, measured as HbA1C values, improved risk assessment as well as intervention and 
prevention strategies better than the more simplistic diabetic threshold concept. They also 
noted that the HbA1C test provides information on long-term glucose levels and does not 
require any fasting or post-prandial conditions, but that it is more expensive than standard 




A long-term follow-up study in Japan found that even random blood glucose or 
causal blood glucose (CBG) can be used to predict CVD mortality. Interestingly, 
borderline-high (140-200 mg/dL) and high CBG (above 200 mg/dL), the HR values were 
2.43 to 2.62 respectively (Kadowaki et al., 2008). For normal range of CBG (126 – 140 
mg/dL) the hazard ratio, although predictability lower, was still statistically significant. 
The data also showed that the relationship was not affected by time since the last meal, 
proving that CBG levels can also be used to predict CVD mortality and is a suitable 
substitute in settings where FBG is not available. 
A very large cross-sectional study, involving 500,000 Chinese participants, 
looked at the association of diabetes and blood glucose levels on the risk of CVD 
development (Bragg et al., 2014). Participants age, height, weight, hip and waist 
circumference, and levels of blood pressure and non-fasting blood glucose were recorded. 
The results agreed with previous reports that diabetes doubled the risk of ischemia and 
stroke, but it also showed that among non-diabetics, there was a positive association 
between blood glucose levels and heart disease. For levels below the diabetic threshold, 
every 1 mmol/L increase in blood glucose correlated with a prevalence increase of 4% for 
ischemic heart disease and a 5% increase of ischemic heart attack (Bragg et al., 2014).  
Glucose level vs Cholesterol level in Risk Assessment 
In a South African study, Lammertyn et al. (2011) looked at the many aspects of 
cardiovascular dysfunction among Black Africans. One of the objectives was to compare 
the roles of glucose and cholesterol in predicting cardiovascular function. The 




diastolic blood pressure, total HDL and LDL cholesterol, smoking, and the use of anti-
hypertensive medication. Each of the 200 adults were subjected to an imaging test that 
recorded the carotid intima media thickness (CIMT). An increased CIMT reflects 
“impaired compensatory remodeling of the arterial wall and atheroma progression” 
following damage and is prevalent in diabetics, predisposing them to stroke and 
myocardial infarctions (Lammertyn et al., 2011). The analysis showed a negative 
correlation between CIMT and HDL:TC, a positive correlation between glucose and 
hypertension, but FBG proved to be the better candidate for CVD prediction. 
A study conducted by Faeh et al. (2013) verified that replacing cholesterol levels 
with the long-term measure of hyperglycemia, produced a more accurate risk prediction 
model. Using the NHANNES III data set and the ESC SCORE formula, they compared 
four different models (HDL:TC ratio, cholesterol, and glucose) and found that the 
glucose values provided better prediction of CVD mortality compared with the other two 
variables, even when below the diabetes threshold values (Faeh et al., 2013). The 
researchers added that when the FRS and other models use only diabetes (yes/no) that it 
insufficiently maps the potential impact of blood glucose on CVD. 
A swiss study that followed 6,095 adults for 32 years, compared the ability of 
glucose levels to that of cholesterol levels to predict fatal CVD event (Braun et al., 2013). 
Measures of age, gender, blood pressure, smoking, and FBG or total cholesterol were 
used in the ESC-SCORE model. The models were cross-validated with another data set 
and the area under the receiver-operating characteristic curve (AUC) and integrated 




researchers found that not only did both low and high glucose levels generate a more 
accurate prediction than did cholesterol, but in a joint model (i.e., both cholesterol and 
glucose) only the coefficient for glucose was statistically significant (Braun, 2013). 
Another study among African Americans looked at the role of fasting blood 
glucose and the different components of serum cholesterol in predicting the reactivity to 
stress associated with CHD development. Patients were exposed to a prescribed stressful 
situation and measurements were taken prior to, during, and while recovering from the 
stressful period. The analysis revealed a negative association between HDL and high 
blood pressure, and that FBG was better than cholesterol in predicting cardiovascular 
stress (Clark et al., 2015). The authors stated that excess insulin was associated with high 
glucose concentration and was the mediator of the stress response (Clark et al., 2015). 
Glucose Lowering in CVD Treatment 
Anti-diabetic drugs failed to show efficacy in cardiovascular treatment because 
they were producing insulin, which deleterious to the vascular system. Several clinical 
studies that sought to reduce CVD risk by aggressive glucose lowering failed or worse-
had to be aborted due to increased morbidity and mortality in the treatment group 
(Ginsberg, 2011; Nordestgaard et al., 2013; Reaven et al., 2009; The ACCORD Study 
Group, 2011; Zoungas et al., 2009). What these trials had in common was the use of 
either insulin supplementation or drugs that stimulated the pancreas to produce more 
insulin. Not only did that approach fail to lower the HbA1C, but the CVD outcomes were 




hormone itself has many deleterious effects on the vascular system (Faerch et al., 2012; 
Laakso, 2015; Sah et al., 2016).  
As further proof that glucose lowering was not the source of the problem, trials 
that used non-insulin elevating intervention to lower glucose levels obtain greater success 
in reducing the participants CVD risk (Kishore et al., 2012; Xu & Rajaratnam, 2017). In 
fact, the use of metformin, a drug that lowers glucose while at the same time increasing 
insulin sensitivity was shown to confer significant CVD benefits to diabetics (Roumie et 
al., 2012; Skov et al., 2014). These studies confirm that the focus on glucose level is not 
misplaced and that association with CVD events is an important one. The strength of the 
glucose level association with risk of CVD emphasizes the need for its inclusion not just 
in CVD treatment but in CVD screening and risk assessment as well. 
Summary 
The incidence of cardiovascular disease began rising after WWII and rapidly 
became an epidemic in the middle of the last century. Despite a slight decline in the 
rising rate by the end of the century, it remains the deadliest of all the chronic diseases 
and the number cause of death in most developed and developing countries. The 
Framingham Heart Study (FHS), initiated by the US Government in response to the 
epidemic of heart disease, was a several decades long prospective study of over 5,000 
adults living in Framingham, MA. The FHS successfully identified several of the major 
risk factors and encouraged the idea of disease prevention by reducing the incidence and 




The FHS also developed and risk assessment model, the ubiquitous Framingham 
Risk Score (FRS), based on the risk factors of CHD and used to predict the probability of 
developing the disease over a given time period. The FRS, though useful and effective is 
limited in its accuracy and as such has undergone several rounds of optimization. The 
inclusion of diabetic status as a risk factor in the FRS formula has been challenged over 
the years and is now considered a CHD equivalent. However, using this risk factor 
dichotomously results in a loss of very important risk information and limits the 
performance of the FRS formula. Moreover, because CHD is a cardiometabolic disease, 
the continuous variable ‘glucose levels’ inclusion in the FRS model increases the 





Chapter 3: Research Methodology 
Introduction 
Overview  
This chapter includes an outline of the methods I used to answer the three 
research questions formulated in the first chapter of the dissertation. Each of the 
questions is examined in detail and the research design used to generate an answer is 
explained. The chapter begins with a description of the comprehensive research design, 
followed by details on the secondary data set chosen, including how the subjects were 
selected, how sample data were originally obtained, and how the data were ultimately 
handled in preparation of the statistical analysis. Also included in this chapter are the 
definitions of the outcome variable and all the explanatory variables featured in the 
analyses, along with their operationalization for inclusion in the model. The chapter ends 
with a presentation of the three research questions, each followed by the specifics of the 
statistical test used and determination of the statistical significance for each. 
Study Objective 
The purpose of this study was to investigate the effect that the inclusion of FBG 
levels, as a risk factor variable, has on the accuracy of the FRS formula in predicting 10-
year CHD event. The second chapter detailed the history of the FRS formula as 
documented in the literature and the many studies that focused on performance 
optimization for this formula. One aspect of the FRS performance optimization that has 




that I sought to fill. MLR analysis was used to generate formula pairs (for FBG level and 
DM2 status) and the performance in representing the data compared. 
Before the multivariate formulas was generated for performance comparison, the 
relative risk (as odds ratio or OR) of each of the two factors (FBG and DM2), for the 
CHD event outcome, was determined using univariate analysis, along with their 
respective confidence intervals. Following the univariate OR comparison, the 
multivariate formulas, containing the various cofactors (AGE, SEX, HDL, SMOKING, 
BMI and either FBG or DM2) was generated and the ORs of each compared the 
appropriate goodness-of-fit tests were used to compare the performance. Finally, the 
interaction between the each of the covariates Sys BP, BMI, and HDL and FBG was also 
assessed. The effect of the potential moderators (SBP, BMI, and HDL) was evaluated by 
the creation of three interaction variables (HDLxFBG, SBPxFBG, and BMIxFBG), that 
were included in the MLR formula. An evaluation of OR and significance of the 
interaction terms and the performance of the overall performance model was evaluated. 
Research Questions 
RQ1: Is the relative risk of glucose level higher than that of diabetic status for the 
development of CHD in the FHS data set? 
H01: There is no difference between the relative risk of glucose level and that of 
diabetic status for the development of CHD in the FHS data set. 
Ha1: The relative risk of glucose level is higher than that of diabetic status for the 
development CHD in the FHS data set. 




diabetic status formula in the FRS-CHD 10-year risk prediction model? 
H02: There is no difference between the measure of accuracy for glucose level 
and diabetic status versions of the FRS-CHD 10-year risk prediction formula. 
Ha2: The measure of accuracy for glucose level formula is higher than that for 
diabetic status version of the FRS-CHD 10-year risk prediction formula. 
RQ3: Is the measure of accuracy for the glucose level formula independent of age, 
BMI, cholesterol level, or blood pressure level in the CHD 10-year CHD prediction 
model? 
H03: The measure of accuracy for glucose level is independent of age, BMI, 
cholesterol level, or blood pressure level in the 10-year CHD prediction. 
Ha3: The measure of accuracy for glucose level is dependent on age, BMI, 
cholesterol level, or blood pressure level in the CHD 10-year CHD prediction. 
Research Study Design 
Choosing the FHS Data Set 
The data set used in this study was the third generation of FHS, a longitudinal 
study originating several decades ago to collect information in understanding the factors 
that predispose individuals to heart disease. The FHS was a prospective cohort study, 
where the exposure or risk factors levels are measured before the disease develops 
(D’Agostino et al., 2013). All the subjects were followed over a decade and information 
on their risk factors and their disease outcome (whether they developed heart disease or 




allows for greater accuracy concerning the risk of exposure and it is ideal for 
investigating causal relationship (Kannel & Boston, 1990).  
The data set is made up of participants from the third generation of the FHS 
cohort (FHS-GenIII), combined with the OMNI2 and the new offspring spouses (NOS). 
The FHS III data accounts for 4,578 adults, who are the grandchildren of the FHS I, 
along with an additional 101 of their non-FHS parents who had not been included in any 
of the previous FHS cohorts (Splanksy, 2007). The OMNI2 are the children of the 
original OMNI cohort, introduced to include a more racially and ethnically diverse 
sample set, but they numbered only 405 (Tsao & Vasan, 2015a). The NOS (New Off-
Spring) cohort, also added to increase genetic diversity, was made up of the spouses of 
the OMNI2 and consisted of only 101 subjects (Govindaraju et al., 2008). The sample 
size of the raw data was 4,578 that was reduced to about 60% (2,670) after the filtering 
process detailed in data handling section of Chapter 4 of this dissertation. 
In the original FHS cohort, several risk factors were measured and recorded for 
each of the subjects and analysis of the data uncover the risk factors that were linked to 
CVD. This led to the development of risk prediction strategies and to the prominence of 
primary prevention effort in response to the rise of CHD and other CVDs (Wilson et al., 
1998). The FHS data have been used extensively over 5 decades to provide additional 
insight into the association between a variety of risk factors and the probability of 
developing CVD . Despite its limitations, the large, randomly selected data set is still 




FHS, the FRS remains the most widely used CVD prediction formula ( Garg et al., 2017), 
making it ideal for studying the role of major risk factors such as FBG. 
Experimental Validity 
External Validation. External validity is a measure of the generalizability of the 
research findings beyond the current data set (Stoltzfus, 2011). The risk formula 
developed by the FHS team faced issues of validity from the beginning. The first 
concerns were who were the truly at-risk individuals, on which aspect of CVD should the 
prediction focus, and how would this outcome be defined. The decision was made to 
focus on the prediction of CHD, the most common CVD and with the highest clinical 
relevance specific to death and disability (Mahmood et al., 2014). For original FRS 
formula generation, the development of the first hard CHD (originally called 
atherosclerotic heart disease or ASHD), defined as coronary death or myocardial 
infraction, were the events was chosen as the outcome of interest (D’Agostino et al., 
2013). With the endpoint decided, the issue was now who was considered at risk and who 
should be included in the study and how they would be selected. For the sake of 
simplicity, the first cohort was made up of individuals who were at the time free of any 
CVD and had not had a previous CVD event (D’Agostino et al., 2013).  
The remaining issues of validity included what risk factors should be measured 
and what should be the cut-off for follow-up time. The decision about the time was 
easier, and a period of 10-year was decided as adequate for CHD risk prediction, but to 
ensure all events were captured, 12 years of data was collected on each subject 




the researchers decided that data on all factors making up a regular clinical exam (gender, 
age, height, and weight) along with suspected predisposing factors (BP, HDL, smoking 
status, and diabetes) would be collected (Dawber et al., 1957). The debate over which 
risk factors should be included continues to be part of the optimization research, but 
focus has always been on keeping the formula simple and convenient yet effective as 
possible. As a result, more definitive factors that were difficult to assess, were excluded. 
An additionally important decision was to the selection of the mathematical 
model that would serve as the best risk estimation function for the data set. The ideal 
model should not only adequately estimate the risk for the period in question, but it 
should also provide some measure of the relative risk for each of the risk factor. The first 
model was based on the discriminant analysis, but was replaced by the more robust and 
more flexible logistic regression model as soon as its existence was known to the FRS 
team (D’Agostino et al., 2013). Over the years, other analyses like the Cox proportional 
hazard regression and accelerated failure models were considered (see D’Agostino et al., 
2013). However, the absolute risk at t=10 years provided by the simpler logistic 
regression analysis became the preferred measure on which to make important treatment 
decisions. 
Once I selected the model it became essential that its suitability and performance 
be evaluated. At the top of the list of requirements were powers of  discrimination and 
calibration, the former reflecting the ability to separate between cases and noncases, and 
the later measuring the accuracy of estimating an absolute risk probability (see Dawber et 




as it describes the sensitivity and the specificity of a function and indicates the ability of 
the function to rank an individual’s risk (see Bertoluci & Rocha, 2017). For calibration 
evaluation, the FHS researchers first used a specifically designed chi-squared test 
combined with Kaplan Meier (K-M) estimates to quantify the difference between the 
predicted probability and those reflected in the data (D’Agostino et al., 2013). The K-M 
test was suitable for the time-to-event risk estimation models used in the beginning but it 
was replaced by the Hosmer-Lemeshow test which more accurately evaluates the 
goodness-of-fit for logistic regression models (Giancristofaro & Salmaso, 2003).  
Internal validation. Internal validation refers to the replicability of the test 
findings and reflects the veracity of the inferred results and a minimization of systematic 
error (Eichler et al., 2007; Kones, 2011). Internal validation should ideally be done on a 
different data set to avoid overfitting, but suitable alternatives include bootstrapping, 
cross validation, or simply split-sample validation (Giancristofaro & Salmaso, 2003). The 
10-fold split was the first validation technique for the FRS formula, where the sample 
was split into deciles and nine models (developed on different sample sets) were 
developed and each tested on the unused 10th sample (Steyerberg et al., 2010). The C-
statistics and calibration plot comparisons are performed for each of the nine models to 
select the one that best described the data. Fortunately, the calibration models were not 
significantly different from each other or the one generated on the entire data set, making 
this method futile (Steyerberg et al., 2010).  
Despite the congruency in the internal validation procedure, the researchers 




completely independent data set. However in a 1999 study, the NLBI had determined that 
the FRS performed relatively well on the data from other prospective studies and should 
be used with confidence in other populations across the United States (Kannel et al., 
1999). It had also been verified as suitable for other populations across Europe, Asia, and 
regions of the Mediterranean, subsequent to adequate recalibration, but that would later 
be challenged by European experts in the field of cardiology (D’Agostino et al., 2001a). 
Given the racial bias of the original cohort, the FRS’s performance on other populations 
of has always been questioned. Researchers discovered that after a recalibration process 
the FRS was able to distinguish the high-risk individuals from those at low risk in non-
Framingham populations in predicting hard CHD (O’Donnell & Elosua, 2008). This 
recalibration, which included adjusting the intercepts for the formula and replacing the 
disease incidence with that of the current population, was found to worked well with non-
Framingham populations (D’Agostino et al., 2008). This method is the basis of many 
recalibration methods used by those who use the FRS in communities outside the United 
States. 
Secondary Data Set 
FHS Data Set: Cohort III, OMNI & NOS 
The data used in this study was obtained from the FHS group, and made up of the 
third generation of the original cohort that started in 1948 (Lansing, 1961). I requested 
permission from the institutional review board (IRB) to contact the FHS researchers and 
obtain a copy of the relevant data file. The FHS is a longitudinal, retrospective cohort and 




with discovering all the major, now established, and minor risk factors of cardiovascular 
disease (Mahmood et al., 2014). This data set was used to develop the renowned formula 
used effectively to predict the likelihood of developing cardiovascular disease over a 10-
year period (Eichler et al., 2007). FHS data has been the basis for 1,000s of published 
research articles on the subject related to heart disease and other related illnesses. 
The long natural history of the CVD necessitated a prospective, observation-type, 
epidemiological cohort study. In the first cohort, the need was to explore the relationship 
between the disease and the predisposing factors, while at the same time collect important 
data on the disease’s prevalence, incidence and prognosis (Dawber et al., 1951). 
Influenced by the enthusiastic physicians of the area and the previous success of the 6-
year TB study there, participants were recruited through a random sampling of the 
residents from the now infamous town of Framingham, MA (Dawber & Lansing, 1966; 
Mahmood et al., 2014). To ensure that all the possible subject’s data were accounted for, 
an extended follow-up period of data collection was adopted (D’Agostino et al., 2008). 
The study continues today, some 70 years after it began, with the second and third 
generation of the FHS cohorts. 
Sample Selection 
Initial recruitment for the FHS began with letters being sent out to two of every 
three (randomly selected) of the 10,000 families living in Framingham, MA, inviting 
anyone between 30 and 59 years of age to participate (Dawber et al., 1959; Tsao & 
Vasan, 2015). This group was believed to be representative of the adult U.S. population 




exam to all. News of the study spread, mostly by word of mouth, from first few recruits 
who were honored to be involved, and soon 100s of participants turned into several 
1,000s (Tsao & Vasan, 2015a). Of the 6,507 contacts made, 2,336 men and 2,873 women 
responded to make up the original cohort 5,209 ( Long & Fox, 2016; Tsao & Vasan, 2015 
). The data from this original cohort was intended for use in the analysis for the research, 
but due to concerns about the age (over 60 years) of the data set, the data from the third 
generation (most recent) was chosen instead. 
The community-based structure of the FHS study enabled the identification of 
aggregation of the traits among family or communal groups (Tsao & Vasan, 2015a). The 
detection of shared family traits led the researchers to start recruiting the second 
generation participants from the children and their spouses of the original husband and 
wife pairs in 1972 (Tsao & Vasan, 2015a). The off-springs and their spouses of the 
second generation (grandchildren of the original cohort participants) made up the third 
FHS generation enrolled in 2002 (Mahmood et al., 2014; Tsao & Vasan, 2015). These 
groups provided many invaluable insight including who were susceptible, the effects of a 
shared environments, and most importantly, the familial and multigenerational genetic 
factors involved (Long & Fox, 2016; Mahmood et al., 2014). The first FHS offspring 
(second generation) study was organized in 1971, with 5,124 participants and consisting 
of the children of the original cohort participants and their spouses (Tsao & Vasan, 
2015a). 
The smaller OMNI1 and OMNI2, started in 1994 and 2003 respectively, focused 




white (of European descent) participants that made up the first three (original, second 
generation and third generation) cohorts (Long & Fox, 2016; Tsao & Vasan, 2015a). All 
the succeeding cohorts now include state of the arts health data collection methods like 
ECG, imaging, and genotyping and have contributed valuable temporal trend and 
genotypic. Data on other diseases such as cancer, COPD, diabetes, epilepsy, arthritis, 
Parkinson’s, and Alzheimer’s is also included (Tsao, 2015). The factors measured have 
expanded from the original dozen or so to include almost twice as many with the addition 
of blood tests for insulin, HbA1C, thyroid hormones, liver function tests, c-RP, and 
testing for specific genes, etc. Add summary and synthesis to fully conclude the section.  
Sample Size Determination 
Statistical power analysis is a method used to determine the sample size required 
to bestow sufficient power to the research result (Rudestam & Newton, 2014). The 
statistical power reflects the probability of the Type II error (β) for the analysis, which is 
the failure to reject the null hypothesis when it is in fact false. This power is equal to 1 
minus probability of the Type II error (Power = 1- β), thus as the probability of error 
increases, the power of the study or the significance of the results decreases. It is for this 
reason that the power of a model is inversely proportional to the number of factors, and 
formulas with the lower number of variables are preferred (Sperandei, 2014). 
The statistical power not only depends on the level of Type II error, but on the 
effect size and the sample size as well. The effect size is a measure of the treatment effect 
and is usually calculated by dividing the difference of the means by the standard 




(Fuller, 2009). There are many formulas (some more complicated than others) that use 
the effect size, the sample size, and the probability of Type II error to calculate the 
statistical power. In other cases, a reverse calculation is performed, and the appropriate 
sample size is determined from the desired statistical power, the estimated effect size, and 
the predetermined probability of Type II error (Pearl, Glymour, & Jewell, 2016). 
Calculating the sample size for a multivariate logistic regression is challenging. 
First, there is the issue of the nonlinear correlation that is represented by the odds ratio, 
which describes the relationship between the independent variable and the dependent 
variable. Second, there isn’t one independent but several independent variables, with non-
zero interaction between them, and each having a different probability value in the 
population. Choosing from among the many possible coefficients can be difficult, 
however, simulation using the G*Power application has simplified the process (Faul, 
Erdfelder, Lang, & Buchner, 2007). This app allows you to choose among several 
different types of test, including F tests, t tests, chi-squared tests, and z test, etc., and the 
input parameters include, but are not limited to, “Tails”, “Odds ratio”, “Power”, and 
“R2”. I used generic values of 1.3 for the “Odds Ratio”, 0.05 for the “error”, and 0.8 for 
the “Power” and a value of 962 was returned for the “Total Sample Size”. For the data set 
in question, with over 5000 participants, the sample size is more than adequate for 
statistically significant effect size determination. 
Data Collection 
 Traditionally, the FHS data were collected by the biennial follow-up exams and 




comprised physical and medical data, including blood pressure, blood glucose, height and 
weight (Long & Fox, 2016). For the original cohort, those determined to have a history of 
CVD were excluded from the study, but for subsequent cohorts, their data were included 
and their information collected. Originally the researchers wanted to focus only on those 
who were free of any cardiovascular complications at baseline so as not to confound the 
data (D’Agostino et al., 2013; Kannel et al., 1999). But they later realized that a history 
of CVD was a strong risk factor for a future CVD event, and this eventually became one 
of the factors recorded for each subject in subsequent cohort (Kannel et al., 1999).  
Each of the biannual exam began with a written informed consent form along 
with a questionnaire on the patient’s medical and family history (see Appendix A). The 
data collection included but was not limited to information on: family history, medical 
history, current symptoms, medication, personal and dietary habits, weight, biometrics, 
cardiac exam, x-ray, ECG, blood (Hb, cholesterol, uric acid, glucose, syphilis) and a 
urinalysis (Dawber et al., 1951). A complete physical, targeted at the cardiovascular 
health, as well as collection of blood and urine samples followed the written portion of 
the exam. These exams were mostly conducted at the designated sites, otherwise staff 
members visited home-bound participants. Included in the medical consent was 
permission for the FHS group to access the diagnostic and chart records from clinics and 
doctors’ offices and hospitals, medical examiners’ reports, physician’s files, and death 
certificates (Friedman, Hyg, Kannel, Dawber, & McNamara, 1967).  
For each case, chart data were eventually compared to the original clinical 




most common CVD subtype- CHD (Tsao & Vasan, 2015a). The frequency of the exams 
fostered relationships between the participants and the researchers and helped retention, 
while the comprehensive nature of the follow-up exams minimized the possibility of 
collection bias (Friedman et al., 1967). The dedication of the participants and the 
perceived value of the ‘free’ medical exams resulted in high retention rate, contributing to 
the exceptional quality of the FHS data and setting a high standard that continued with 
subsequent cohorts. Of the 5209 participants in recruited between 1948 and 1952, event 
data on 4,439 participants were collected over three exam cycles from 1956 to 1968 
(Sorlie & Coady, 2004). That is a retention rate of 85%, which high by most standards. 
Data Handling 
The first step in handling any data set is the cleaning process, which entails 
detecting and removing or replacing all corrupt, inaccurate, or incomplete records. The 
FHS data set was assessed for missing data, incorrect data and outliers, and each variable 
was evaluated to ensure that no more than 10% of the data is missing, as missing data 
could the produce incorrect analysis (Field, 2013). In the case of missing or incorrect 
data, the use of mean or weighted values can be generated to compensate, depending on 
the nature of the variable being measured, but there was no need for this. Box or Whisker 
plots with the interquartile range determination was used to detect for any outlier values 
that may have required the removal of all corresponding for offending subject (Field, 
2013). However, the potential outliers were tested and determined to be legitimate 




The data was received in the statistical analytical system (SAS) form, which was 
downloaded from the NIH website following the granting of permission (password) to 
access. The SAS zip files (FHSIII, OMNI2 and NOS2) were saved on my hard drive and 
unzipped for use. The relevant SAS files (CHD event, lab tests, general health screen, 
etc.) were opened in SPSS and working version will be created for selecting of the 
appropriate variables. The files were combined into one, utilizing the unique patient 
unique identification number, and assessed for errors then filtered, as described in chapter 
four. All variables will be checked to ensure that the SPSS type, length and description in 
SPSS matched that listed in the data dictionary provided, and data set was filtered to 
remove those with a history of heart disease. Following the filter, the variables were 
subjected to comprehensive descriptive and correlation analyses before the inferential 
analyses were conducted (Lani, 2015). 
Ethical Considerations 
Permission was obtained from the Institutional Review Board (IRB #: 10-18-18-
0031692) of Walden University to request access to the FHS data set, and since it is a 
secondary analysis an exempt status requested. The data set from the FHS is distributed 
minus any personal information or any unique identifiers, ensuring participants’ 
confidentiality. This guarantees the individuals’ privacy and compliance with the Health 
Insurance Portability and Accountability act (HIPPA). The FHS data is available for 
research and analysis purposes and has been used for 100s of invaluable studies over the 




Operational Definition of the Variables  
Dependent Variable: Disease Outcome 
The FHS was the first epidemiological study of its kind and it led the way in 
identifying CVD risk factors. The risk factors identified were then made the subject of 
many clinical trials that revealed the efficacy of risk factor reduction in CVD prevention 
strategies (Nieto, 1999a). The researchers realized that CHD was the most common CVD 
event, with the most lethal consequences, so they decided to focus on the risk factors for 
CHD in the risk assessment formula (Truett et al., 1967). However, in 2008, the FHS 
team decided that a more global formula was also needed and developed a formula, with 
a comprehensive FRS to include predictions of CVD that included cerebrovascular 
disease, intermittent claudication and congestive heart failure (Kones, 2011). The more 
commonly used formula however, estimates the 10-year absolute probability of  
developing the risk of hard CHD, where coronary death or myocardial infraction was the 
outcome (D’Agostino et al., 2013). The formula returns three categories of risk: high risk 
for a 10-year risk score >20%; moderate risk for a score between below 20% but above 
10%; and low risk for a score below 10% (Pedersen, 2002). This analysis used CHD as 
determined by the FHS team and recorded as the dichotomous nominal ‘1’ or a CHD 
event and ‘0’ for no-CHD event.  
Independent Variables: The Risk Factors 
 The FHS is credited with uncovering the multifactorial nature of CVD and with 
the recognition of interactions between the risk factors, leading to the creation of the 




age, systolic blood pressure (SBP), HDL cholesterol (HDL), body mass index (BMI), 
smoking behavior (SMKG) and ‘diabetes status’ (DM2)- all comprise the current 
algorithm that is used as the Framingham Risk Score (FRS) for estimating a patient’s 
CHD. There have been changes in the way a few of the variables are measured and 
utilized in the formula, namely blood glucose, which although measured for determining 
diabetic status it was not included in the FRS formula; and HDL values replacing total 
cholesterol by the second cohort as technological advancement facilitated it 
determination, and only systolic BP (SBP) as being a better predictor of CHD than 
diastolic BP (DBP). The following section will take an in-depth look at the factors in the 
FRS formula and the role they each play in predicting CHD. 
 
The Risk Factors Measured in FHS Cohort 1, 2, and 3. (Govindaraju et al., 2008). 
 
Cholesterol. Cholesterol is a fatty substance transported in the blood as small 
bundles of proteins and fat molecules, aka lipoproteins. The two major types of 
lipoproteins are high-density lipoproteins (HDL) and low-density lipoproteins (LDL) and 
are named based on the ratio of lipid to protein. HDL, the larger, heavier molecule, has a 




(Chowdhury et al., 2014). Cholesterol is carried to the tissues as LDL, which why it is 
found deposited on the arterial walls and is the major component of plaque (National 
Heart Lung & Blood Institute, 2013). High levels of LDL are associated with an 
increased risk of CHD, heart attack and stroke (Srikanthan et al., 2016). Cholesterol is 
removed from the arteries and tissues by HDL molecules and taken to the liver for 
expulsion (National Heart Lung & Blood Institute, 2013). High levels of HDL are 
associated with a reduced risk of CHD, making it the “good/healthy” cholesterol.  
Blood Pressure. Blood pressure is a measure of the force exerted on the walls of 
the arteries as by the blood flowing through it. The pumping of the heart pumps forces 
blood to move through the blood vessels delivering oxygen and nutrients to the cells and 
tissues of the body. Damaged arteries, narrowed by plaque deposits, require extra force or 
higher pressure to overcome the increased resistance. This persistent high blood pressure 
or hypertension is overworks the heart muscles, and together with the damaged arteries, if 
left untreated, leads to heart disease (Franklin & Wong, 2013). High blood pressure is 
referred to as the “silent killer” as it develops slowly and can go undetected for many 
years. Fortunately, the FHS discovered that systolic blood pressure (SBP) is more 
strongly associated with CVD than is diastolic blood pressure (DBP), and the FRS only 
includes the former (Kannel, Gordon, et al., 1971). Hypertension, now defined as an SBP 
above 140 mmHg, and is associated with an increased risk of CHD (Pedersen, 2002).  
Diabetic Status. Diabetes Mellitus II (DM2) or hyperglycemia describes the 
condition of persistently high concentration glucose in the blood. Normally, ingested 




the cells energy need. However, when the supply of glucose supply is excessive, the cells 
become unresponsive to insulin and this excess glucose remains dissolved in the blood 
(Sah et al., 2016). This increased glucose causes an upsurge in the pancreas’ insulin 
production (Faerch et al., 2012), and it is this elevated levels of glucose and insulin is 
known to damage the walls of the arteries and increase the risk of heart disease (Faerch et 
al., 2012; Laakso, 2015; Tostes & et al., 2009). For first FHS cohort, diabetic status was 
made by either of three determinations: (i) the use of insulin; or (ii) two separate 
incidents of a glucose level >150mg/dL; or (iii) an abnormal glucose tolerance test (Qazi 
& Malik, 2013a). It was the FHS researchers who first reported the link between diabetes 
and CVD (Kannel & McGee, 1979a), a link that was confirmed by many subsequent 
studies (Carter et al., 2016; Cockram et al., 2001; Ray et al., 2014; Zhang et al., 2014). 
Although elevated glycated hemoglobin (HbA1c) is becoming more popular in 
diagnosing DM2, in many cases a FBG above 120 mg/dL is also used. 
Glucose Level.  
In the original FHS study, glucose level was used only for the determination of 
diabetic status. Fortunately, the raw values of fasting blood glucose (FBG) have always 
been recorded for all cohorts and are available for use in the current analysis. High FBG 
is now recognized as being a strong risk factor for CVD as well as other diseases such as 
diseases of the kidney, the eye, the brain, and the central and peripheral nervous (Ismail-
Beigi, Moghissi, Kosiborod, & Inzucchi, 2008; Laakso, 2015). However, the only 
established glucose level threshold is that used for the diagnosis of diabetes, and glucose 




to other disease (Sarwar et al., 2010). But the threshold for diabetes diagnosis was not 
based on the risk of CHD and that threshold may not relevant to the risk of a CHD 
outcome. In fact, research now shows that the link between glucose and atherosclerosis 
and cardiovascular disease may extends below the diabetes threshold (Braun et al., 2013; 
Desouza, Raghavan, & Fonseca, 2010; Valentino et al., 2015). Low levels, intermediate 
(impaired glucose tolerance) levels, and low-normal (pre-diabetes) levels of glucose have 
all been shown to be associated with a risk of developing CHD (Coutinho et al., 1999; 
Desouza et al., 2010; Faerch, Vistisen, Borup, Marit, & Jørgensen, 2014; Park et al., 
2013; Valentino et al., 2015). For this reason, this study contends that FBG, a continuous 
and modifiable CHD risk factor, can improve the efficacy of the CHD risk prediction. 
Body Mass Index. An overweight person is one whose weight is above what is 
considered normal or healthy. Body mass index or BMI is a measure of overweight and is 
calculated by dividing the weight in kilograms (Kg) by the square of the height in meters 
(m2). i.e. BMI = Kg/ m2 (Herman & Rothberg, 2015). For adults, a BMI below 25 is 
normal, above 25 is overweight, and above 29 is obese (American Diabetes Association, 
2015). A person increasing BMI is an indication of an increasing dysfunction in their 
body’s ability to metabolize glucose (Srikanthan et al., 2016). The high BMI in 
overweight and obese persons is usually associated other CHD risk factors such as high 
blood cholesterol, high blood pressure, and hyperglycemia, making an elevated BMI 
strong risk factor CHD and heart attack (Grundy et al., 2002). 
Smoking. Cigarettes or tobacco smoking or exposure to secondhand smoke 




These toxins cause damage the blood vessels, mainly to the lungs and heart first, which 
initiates a buildup of plaque and the formation of blood clots in the arteries (Huxley et al., 
2011). Smoking is also associated with a lower level of the healthy HDL, exacerbating 
the development of heart disease risks. Smoking as a CHD risk is dependent on the how 
long the individual has smoked and how many packs are smoked per day (Mannan, 
Stevenson, Peeters, Walls, & McNeil, 2010). Ideally, smoking should be used as a 
continuous risk factor (number of cigarettes or number of packs per day, or a similar 
measure), and some optimized versions of the FRS do so. However, the current FRS 
formula used for purposed of CHD risk screening uses as a binary (yes/no) factor of 
current smoking status and will be similarly used in this study.  
Age. As the body ages so does the blood vessels and older blood vessels are less 
supple and more susceptible to damage. Both the buildup of plaque in response to any 
damage and the loss in flexibility makes blood flow more difficult, resulting in the need 
for increase in blood pressure from the heart (Rodondi et al., 2012). Over time, these 
conditions combined with an extended exposure to other harmful influences makes heart 
disease more common as subjects get older. Persons in an older age group are more likely 
to die from heart disease than those in a younger age group, in fact over 80% of the 
people who die from CHD are over 65 years and (Mozaffarian, Benjamin, Arnett, et al., 
2015). Older people are not only more likely to develop heart disease they are also more 
likely to die from it, making age a major CHD risk factor (Tsao, 2015). The age of the 




Gender. Being female is somehow heart protective, relative to make, and women are less 
likely to develop CHD. Not only is there is a lower prevalence of the heart disease among 
women but and women also tend to develop CHD at a later age than men (Franklin & 
Wong, 2013). Unfortunately, there are gender specific factors such as preeclampsia 
during pregnancy or menopause, that do increase women’s predisposition to CHD risk 
factors such as atherosclerosis and hypertension (Hosseini, 2015). Additionally, the risk 
posed by cigarette smoking is more harmful to women and furthermore women have 
greater incidences of metabolic dysfunction (obesity, prediabetes, diabetes) than do men 
(Huxley et al., 2011; Moore et al., 2017). Moreover, the major CVD risk factors affect 
the female body differently than it does the male, for example diabetes raises the risk of 
CVD for both genders, but it does so to a greater extent for women than it does for men 
(Hosseini, 2015; Qazi & Malik, 2013b). Diabetic women tend to have a greater burden of 
risk as well as a higher risk of developing CHD, making gender another important non-
modifiable risk factor (Amsterdam, 2011; Booth et al., 2006). All these factors combined, 
makes gender or sex a major risk factor for CHD and in some instances, separate gender-
specific formulas are used for screening purposes (Çevik et al., 2015). Here gender was 
included as a nominal dichotomous variable along with the other risk factors in the 
multivariate formula.  
Data Analysis 
This study sought to use statistical analysis of the FHS data set to answer the 




Research Question 1: 
Is the relative risk of ‘glucose level’ higher than that of ‘diabetic status’ for the 
development of CHD in the FHS data set? 
Null Hypothesis. There is no difference between the relative risk of ‘glucose 
level’ and that of ‘diabetic status’ for the development of CHD in the FHS data set. 
Alternative Hypothesis. The relative risk of ‘glucose level’ is higher than that of 
‘diabetic status’ for the development CHD in the FHS data set. 
Statistical Analysis. This first question compared the strength of the association 
between the two predictors, FBG and DM2, and the outcome. Given the binary outcome 
variable (10-year CHD event), a logistic regression is most suitable for this analysis. Here 
two different univariate logistic regression formulas were generated, one for ‘diabetic 
status’ (DM2) and one for ‘glucose level’ (FBG), and the odds ratio (OR) for each was 
recorded. The OR is a measure of the change in odds for the outcome (CHD) 
corresponding with a unit change in the predictor, and an OR > 1 implies that the 
presence of predictor or exposure increases the odds or the probability of the outcome 
event (Tripepi, Jager, Dekker, Wanner, & Zoccali, 2007). This ORs from each of the 
formulas, which indicated the crude or unadjusted measure of association for the 
outcome, was used to compare the relative strength of two independent variables and to 
make a determination of which was the stronger (Field, 2013). 
Logistic regression (LR) analysis generates a regression coefficient for the 
predictor variable, and the OR is calculated by finding the exponential or inverse-logit 




the outcome violates the regular assumption of linearity, but the relationship between the 
predictor variables and the logit of the outcome variable is assumed to be linear (Lani, 
2015). The statistical significance of the OR is based on both the p-value and the 95% 
confidence interval (CI). A α level of 0.05 was used and an OR with a p-value less than 
0.05 was considered statistically significant. The CI reflects the range within which the 
OR value can be found 95% of the times the test is run on this data set, (Giancristofaro & 
Salmaso, 2003; Sullivan, n.d.) The precision with which the OR was estimated from the 
width of the CI and a ranges that did not cross “1” (a pair of positive numbers of a pair of 
negative numbers) was considered statistically significant (Field, 2013; Sullivan, n.d.). 
Research Question 2:  
Is the measure of accuracy higher for the ‘glucose level’ formula than that for 
‘diabetic status’ formula in the FRS-CHD 10-year risk prediction model? 
Null Hypothesis. There is no difference between the measure of accuracy for 
‘glucose level’ and ‘diabetic status’ versions of the FRS-CHD 10-year risk prediction 
formula. 
Alternative Hypothesis. The measure of accuracy for ‘glucose level’ formula is 
higher than that for ‘diabetic status’ version of the FRS-CHD 10-year risk prediction 
formula. 
Statistical Analysis. This second question dealt with the relative performance of 
the two versions of the Multivariate Logistic regression (MLR) model. An MLR is used 
to describe a data set containing several predictor variables and one dichotomous 




controlling for confounding effects makes it the analysis of choice for medical research 
(Stoltzfus, 2011). MLR analysis is common with longitudinal data, which is collected on 
the various risk factors believed to be associated with a disease or medical event. Here 
the independent or predictor variables can be categorical, or continuous, but the outcome 
must be binomial (Stoltzfus, 2011). For this research question, two MLRs were 
generated, one with FBG and another with DM2, and both included the other independent 
variables including- age, gender, HDL, SBP, smoking status, and BMI. The dependent 
variable was the presence or absence (yes/no) of a 10-year CHD event outcome. 
For assessing the performance of screening models, there are several tests that can 
used, depending on whether the goal is prediction, selection, or causal modeling 
(Steyerberg et al., 2010). In this study the goodness-of-fit or modeling power was 
assessed using three parameters: the pseudo-R2 values, the Hosmer-Lemeshow test, and 
the maximum likelihood function in the form of chi-square values. The pseudo-R2 
measures the amount of variance in the dependent variable explained by the independent 
variables and provides a measure of the model’s discriminatory capability (Field, 2013). 
The maximum likelihood function estimates the how likely is the inclusion of the 
variable (or variables) in the model, relative to not including it, to make the correct 
outcome prediction (Hu, 2007). The Hosmer-Lemeshow (H-L) chi-squared test is another 
goodness-of-fit test that measures the model’s calibration, giving an average of fit for the 
sub-groups within the data set when divided into deciles of predicted risk values (Demler, 
Paynter, & Cook, 2015; Stoltzfus, 2011). Unlike the chi-square values for the maximum 




the null hypothesis assumes that the model is a good fit of the data (Giancristofaro & 
Salmaso, 2003). 
Assumption/Rationale. As a regression analysis, the MLR does not depends on 
the ordinary least square algorithms required in general linear models. A linear 
relationship between the independent variable (IV) and outcome is not required, neither is 
a normal distribution of the residuals (homoscedasticity), nor that the dependent variable 
should be an interval or ratio scale (Lani, 2015). The assumptions for the MLR instead 
include: independence of little or no multicollinearity among the variables and linearity 
between the variable log odds measure for the outcome (Stoltzfus, 2011). Additionally, 
the MLR should be generated from a large enough sample size, with a minimum of 10 
cases for each IV, to avoid overfitting of the data (Sperandei, 2014; Stoltzfus, 2011). The 
maximum number of variables in the main multivariate formula was seven (when gender, 
and BMI were included), requiring a minimum of 70 cases, which was far exceeded by 
the sample size of over 2,600 after filtering. Pearson correlation coefficient (for 
continuous IVs) and the Chi-Square Cramer’s V values (dichotomous IVs and continuous 
IVs as groupings) were used to analyze the strength of the association among the 
variables. The pairs that were deemed strongly correlated were used to create interaction 
terms, which were then tested for significance by including in the MLR formula.  
Statistical Significance. 
Determining the statistical significance of a logistic regression is relatively 
straightforward, as the model results are generated with a corresponding p-value and CI 




value of 0.05 then the term, and by extension the association between the predictor and 
the outcome, is considered significant (Giancristofaro & Salmaso, 2003). The size or 
strength of the association is based from the odds ratio, which is generated with a 95% 
CI. If the p-value is less than 0.05 and the OR is outside of one, statistical significance is 
accepted and the null hypothesis is rejected (Cook & Sheikh, 2000; Sullivan, n.d.). 
Since this research question focuses on the model’s performance or how well the 
model fits the data, it is important to evaluate the goodness-of-fit results. The goodness-
of-fit test tells the extent to which the predicted probabilities deviate from that recorded 
in the data (Demler et al., 2015). For logistic regression, pseudo-R2 can be used as a 
goodness-of-fit test, that reflects the model’s predictive power, as a measure of variation 
accounted for by the variable included. There is no established threshold of significance 
for this measure, but when used to compare models, the greater the R2 value the better the 
fit of the model (Steyerberg et al., 2010). The maximum likelihood measure does not test 
the model independently, but compares the fit of models generated from the same data set 
and each is reported with a corresponding p-value (Burnham & Anderson, 2004). For the 
H-L test, unlike in the logistic regression test on which it is based, the alternative 
hypothesis assumes a poor match between the observed and the predicted, and therefore a 
χ2 < 20 and ap > 0.05 is considered statistically significant (Demler et al., 2015).. 
Research Question 3:  
Is the measure of accuracy for the ‘glucose level’ formula independent of ‘age’, 





Null Hypothesis. The measure of accuracy for ‘glucose level’ is independent of 
‘age’, ‘BMI’, ‘cholesterol level’ or ‘blood pressure level’ in the 10-year CHD prediction. 
Alternative Hypothesis. The measure of accuracy for ‘glucose level’ is 
dependent on ‘age’, ‘BMI’, ‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-
year CHD prediction. 
Statistical Analysis. This third question evaluates extent to which the interaction 
between the independent variables moderates the association between ‘glucose level’ and 
the 10-year CHD outcome. The variables chosen for interaction testing were considered 
factors involved  metabolism and are thus connected in the cardiometabolic hypothesis of 
CVD development. For the moderation analysis, the FBG model in addition to the 
respective interaction items (a product of the moderator and the predictor) (Field, 2013). 
Since the FBG itself was determined to have an insignificant relationship with the 
outcome, the FBG-group variable was created, and this was used to generate the 
interaction terms. Since the correlation coefficient between these variables were all below 
0.350, there was no need for centering of the variables.  
Statistical Significance. To determine the statistical significance of the 
interaction term, the properties of its coefficient was evaluated (Newsom, 2016). Like 
with the other ORs, a p-value that is less than α and a 95% CI that does not include “1” 
indicate statistical significance for the interaction terms. The statistical significance of the 
overall model, as well as the p-value  and CI for each of the interaction and non-
interaction variables of the model was evaluated for comparing the accuracy of the 




(Newsom, 2016). The relevant performance analyses will also be compared for the new 
‘interaction’ model against that for FBG model without interaction terms to determine if 
the interaction terms provide any improvement to the model.  
Summary 
The goal of this study was to measure the effect of fasting blood glucose (FBG) 
levels on the performance of the Framingham Risk Score (FRS). The FRS was designed 
from the FHS data, from the first cohort of which originating several decades ago, and 
the more commonly used current version includes the major CHD risk factors; age, 
gender, HDL cholesterol, systolic blood pressure, smoking behavior and diabetic status. 
The 10-year FRS score is a measure of an individual’s probability of succumbing to a 
CHD event over the next 10-years. Limits to the generalizability and discriminatory 
power of the FRS has led to customization and optimization of the formula over the past 
four decades, with goal of improving its performance and widening is applicability in a 
diversity of populations. 
 In this study, multivariate logistic regression (MLR) model was the statistical 
analysis of choice, as it was the method used to first develop the FRS model. Using the 
data from the third generation (most recent) of the FHS cohort as secondary data, 
univariate and multivariate regression analyses was performed to evaluate and compare 
the predictive power of the ‘diabetic status’ (DM2) model with that of the FBG model. 
The strength of the relationship between the respective variables and the outcome, the 
predictive power of the two models, and the effect of interactions (in the FBG model) 




the odds ratio for each. The goodness-of-fit parameters were employed included the odds 
ratio or OR (assessed the unadjusted strength of the association), the pseudo-R2 (how well 
the variance in the outcome is accounted for by the predictive factors), the Chi-square 
values (the extent to which the model predictions matches the recorded data), and the 
Hosmer-Lemeshow test (the average of the fit of model for each decile of the outcome 
variable). The next chapter will provide specific details of the steps involved in the 
statistical analysis performed to answer the three research questions and whether the null 






Research Question Statistical Test Assumptions Interpretation Significance 
RQ1: Strength of 
Association 
 




Outcome matches test 
Correct labeling of outcome 
Large sample size 
Estimated from OR 
ORDM2 > ORFBG? 
p < α 
 
RQ2: Model Comparison 
 






Outcome matches test 
Correct labeling of outcome 
Only meaningful variables 
No/little collinearity 
Large sample size 
R2DM2 > R2FBG p < α 
DM2 χ2 > FBG χ2  
 
Hosmer-Lemeshow Test p > α* 
RQ3: Model Comparison 
 






Same as MLR 
Minimal collinearity  
Coefficient of interaction term 
OR from MLRG+Ms  




Chapter 4: Results 
 Overview 
The objective of this quantitative analysis was to assess the contribution of the 
variable FBG level compared to that of DM2 diagnosis as a predictor for (CHD in the 
FHS cohort dataset. The variables were compared unadjusted, adjusted and then 
possible interactions tested, in the three research questions examined. The research 
questions and the related null and alternative hypotheses are as follows:  
RQ1: Is the relative risk for glucose level higher than that for diabetic status in 
the CHD 10-year risk prediction? 
H01: There is no difference between the relative risk for glucose level and that 
for diabetic status’ in the CHD 10-year risk prediction.  
Ha1: The relative risk for glucose level is higher than that for diabetic status in 
the CHD 10-year risk prediction. 
RQ2: Is the measure of accuracy for glucose level higher than that for diabetic 
status in the CHD 10-year risk prediction formula? 
H02: There is no difference between the measure of accuracy for glucose level 
and diabetic status in the CHD 10-year risk prediction formula. 
Ha2: The measure of accuracy for glucose level is higher than that for diabetic 
status in the CHD 10-year risk prediction formula. 
RQ3: Is the measure of accuracy for glucose level independent of age, BMI, 




H03: The measure of accuracy for glucose level is independent of age, BMI, 
cholesterol level or blood pressure level in the CHD 10-year risk prediction formula. 
Ha3: The measure of accuracy for glucose level is dependent on age, BMI’, 
cholesterol level or blood pressure level in the CHD 10-year risk prediction formula. 
This chapter outlines the data collection (obtaining access to the secondary data) 
process, how the data was treated and analyzed, and the results of the statistical 
analyses. The data I analyzed is from the third generation of the original cohort 
(GenIII), combined with data from the OMNI2 and the NOS cohorts. The reporting of 
results begins with the descriptive analyses performed on the dependent variable as 
well as all the independent variables included in the study. This is followed by the 
results of each of the logistic regression analysis conducted to answer the specific 
research questions. Finally, the chapter summary highlights the overall findings as it 
relates to the objective of the study.  
Data Collection 
The data analysis for this study was conducted using secondary data obtained 
from the FHS, via the BioLINCC division of the NHBLI. The data set from the third 
cohort (FHSIII), as this was the most recent, were collected from the grandchildren of 
the participants of the original cohort (FHSI) beginning in 2001. The recruitment and 
response rates were described in detail in chapter three. Following IRB approval 
received from Walden University (Appendix B), I was granted access to the data from 
the BioLINC website according the signed agreement (Appendix C) for third party 




and opened to separate folders containing the data, the documentation, and the data 
dictionary. The data set folders contained two folders each, one with the data in CSV 
(Excel files) and the other with a SAS duplicate of all the files. The CSV files were 
opened in the SPSS application, subjected to several data screening and data cleaning 
steps before being used for the data analyses described below. 
Preanalysis Data Cleaning 
I combined several pertinent files in SPSS to create a new file that contained 
only the variables of interest. This involved duplicating the main file (CHD outcome, 
CHD date, etc.), deleting unwanted variables (CVD, CHF outcomes, etc.) and then 
merging into one file (based on the ID numbers) that included the predictor variables 
(age, sex, HDL, glucose, smoking status, BP, DM status and CHD outcome). Some of 
the variables were renamed (e.g. age @ exam 1 to simply AGE) for clarity, others 
required reformatted (e.g. CDH update status to 10-year update status) or used to create 
new variables (age groups, HDL groups, etc.). This file was then filtered twice, first to 
remove all those who had a history of CHD and then to remove those whose CHD 
event happened after more than 10 years. The filtered file was saved as the working file 
and used to perform the descriptive and inferential analyses. 
Results of Data Analysis 
Descriptive Analysis 
Valid Number of Sample Size. After filtering, a total of 2,677 participants 




2,649 after accounting for the missing values from some (BP, FBG, HDL and DM) of 
the variables (See Table 1).  
Table 1 
 
Valid Number of Variables 
                N 
 Valid Missing 
Sex of participant 2,677 0 
Age (years) 2,677 0 
Diastolic blood pressure  2,675 2 
Fasting blood glucose (FBG) 2,652 25 
HDL cholesterol  2,676 1 
Diabetes Mellitus Status (DM2) 2,674 3 
CHD status 2,677 0 
Valid N (listwise) 2,649  
 
Measures of central tendency (Continuous Variables). The average age of 
the sample of participants was 40 years and 6 months, with the youngest being 19 and 
the oldest being 82 years old. As the histogram of the age distribution shows (Figure 4), 
there is a right shift, as there are fewer persons at the extreme end (elderly) than are at 
the left (<25 years). Despite this skewness, the trend line of frequency distribution 
indicates that the assumption of normalcy is met. Similarly, with the distribution of 
FBG levels, some very high values cause right skewness, but overall the distribution is 





Figure 4. Histogram of AGE distribution. 
The mean value of FBG was 94.43 but the median was only 92.00, confirming 
the presence of very high FBG values causing the shift in the mean to the right of the 
median (See Figure 5). The relatively large SE also suggests that the sample mean may 
be greater than the true population mean, but still within range. As can be seen in Table 
2, the other continuous variables, BMI and SysBP, were also normally distributed, with 
respective means 26.7 and 116.8 (mmHg). The BMI was calculated based on weight 
and height measures, and like all other measurement, were based at the initiation exam 






Measures of Central Tendency of CHD Risk Factors 
 Mean S.E. Mean Median Std. Dev Min Max 
Age (years) 40.51 .176 41.00 9.102 19 82 
Systolic Blood Pressure  116.80 .278 115.00 14.403 81 192 
Body mass index  26.684 .105 25.720 5.440 16 59 
Fasting blood glucose  94.43 .322 92.00 16.588 64 357 
HDL Cholesterol  54.87 .316 53.00 16.352 19 206 
 
 
Figure 5. Histogram of fasting blood glucose (FBG) levels. 
Distribution of CHD risk factors. In the case of the nonmodifiable risk factors, 
Age and Sex, there was an equal representation of the major groups. There were 271 




Table 3). And all the participants were adults (at least 19 years old), but the two largest 
groups were those between 26 and 40 (44.0%) and those between 41 and 55 (46.4%). 
Those younger than 25 and those older than 56 years made up a little less than 10% 
(combined) of the total sample. This distribution of age is consistent with the fact that 
most of the participants that make up this sample were from the third generation of the 
original FHS participants. The rest of the sample was made up from the second 








Distribution of Risk Factors 
 Frequency Percent Cumulative Percent 
Sex of participant    
Male 1204 45.0 45.0 
Female 1473 55.0 100.0 
Age Groups    
< 25 156 5.8 5.8 
26 - 40 1178 44.0 49.8 
41 - 55 1241 46.4 96.2 
56 - 70 90 3.4 99.6 
> 70 12 .4 100.0 
HDL Chol Group    
< 41 (Risk) 504 18.8 18.8 
41-60 (Boderline) 1301 48.6 67.4 
> 60 (Optimal) 872 32.6 100.0 
Systolic Blood Pressure Group    
<91 (Low) 23 .9 .9 
91-120 (Normal) 1728 64.5 65.4 
121-140 (Prehypertensive) 748 27.9 93.4 
>140 (HyperTension) 178 6.6 100.0 
Smoking Status    
Non-Smoker 2334 87.2 87.3 
Smoker 341 12.7 100.0 
FBG Groups    
        <81 Hypo 143 5.3 5.3 
81 - 100 Normal 2017 75.3 80.7 
101 - 125 PreDM2 443 16.5 97.2 
126 - 150 Boderline DM2 27 1.0 98.2 
151 - 200 High DM2 9 .3 98.6 
 >200 Very High DM2 13 .5 99.1 
Missing 25 .9 100.0 
BMI Groups    
        <18 Underweight 19 .7 .7 
18 - 24.9 Normal   1117 41.7 42.4 
25 - 39.9 Overweight 1443 53.9 96.3 






Pearson correlation of risk factor. The correlation between the risk factors 
measured as continuous variables (age, HDL, BMI, FBG and SysBP) were statistically 
significant, with p values less than 0.000. The Pearson correlation values were all 
positive, except for HDL, as was expected, which was negatively correlated with BMI 
(-0.321), FBG (-0.200), and SysBP (-0.128). Since the strongest correlation was 
between BMI and SysBP (0.384) all the correlations were determined relatively weak 
or negligible.  
Table 4 
 
Pearson Correlation Between Variables 





















p-value  .000 .000 .000 .000 












p-value .000  .000 .000 .000 












p-value .000 .000  .000 .000 












p-value .000 .000 .000  .000 

















Association between risk factor groups across gender. When comparing the 
distribution of risk factors across genders, the differences in age group and smoking 
status were not statistically significant and the differences among the other variables 
were. The 17% (200) excess of females (1,204 males and 1,473 females) was reflected 
in all of the age groups. Similarly, despite there being more male smokers than female 
smokers, the difference in male (177) smokers compared female smokers (164) was not 
statistically significant (p = 0.215). Advanced age and smoking are the strongest, 
modifiable risk factors for CHD, and both they were both found to be equally 
distributed across the genders in this data set.  
All the other risk factors demonstrated a statistically significant difference in 
association across the genders, with all p-values less than or equal to 0.001. However, 
for the effect size of the gender difference for diabetic status was considered weak 
(Cramer’s V = 0.062), while the effect size for HDL, BP, and BMI and FBG were 
moderate in effect, with HDL being the largest (Cramer’s V values of 0.431, 0.207, 
0.312, 0.431, and 0.265 respectively). The effect sizes of these association did not 
warrant the centering of the variables prior to the interaction study, but it did justify 







Chi-square Analysis of Association 
 Male Female χ2 p-value Cramer’s V 
Age   2.494 0.646 0.031 
<25 67 89    
26- 40 545 633    
41 - 55 546 695    
56 - 70 39 51    
>70 7 5    
Diabetic Status   10.226 0.001 0.062 
Non-Diabetic 1160 1447    
Diabetic 43 24    
Smoking Status   1.539 0.215 0.024 
Non-Smoker 1039 1295    
Smoker 164 177    
HDL Chol   497.074 0.000 0.431 
<41 (Risk) 396 108    
41 – 60 (Normal) 650 651    
>60 (Optimal) 158 714    
Sys Blood Press   114.982 0.000 0.207 
<90 (Low) 2 21    
91-120 (Normal 660 1068    
121-140 (Prehypertensive) 446 302    
>40 (Hypertension) 96 82    




 Male Female χ2 p-value Cramer’s V 
BMI    260.973 0.000 0.312 
<18 (Underweight) 2 17    
18 – 24.9 (Normal) 315 802    
25 – 39.9 (Overweight) 855 588    
>= 40 (Morbid Obesity) 32 66    
Blood Glucose   188.646 0.000 0.265 
< Hypoglycemic 15 128    
81- 100 (Normal) 842 1175    
101 – 125 (PreDM2) 306 137    
126 – 150 (Borderline DM2) 19 8    
151 – 200 (High DM2) 5 4    
> 200 (Very High DM2) 6 7    
 
Distribution of Risk Factors Across Diabetic Status 
The other set of bivariate analyses conducted, were the distribution of the risk 
factors across the diabetic status groups (DM2 and Non-DM2). The chi-square analyses 
(Table 6) indicated that there was a statistically significant difference between the two 
groups for all the risk factors, with the exception of Smoking status (p = 0.201). In the 
case of Age, HDL, SysBP, and BMI, even though the differences were statistically 
significant, the value of the Cramer’s V were all below 0.200, with the largest effect 
seen across the age groups (Cramer’s V=0.198). The percent of diabetics increased with 
age, with an average of 0.6% for those younger than 40, increasing to 3.7% between the 




Table 6). Similar trends occur in the risk factors that are also negatively predictive, 
such as SysBP and BMI, with the percentage of diabetics increasing as the value of the 
risk factor increases, e.g. from Normal BMI to Overweight BMI or from Normal SysBP 
to Hypertensive SysBP. The converse happens with HDL, which is the only factor that 
is positively predictive (of a reduced risk) of CHD. As the HDL value goes up from one 
group to the next, the percentage diabetics in the group goes down.  
Table 6 
 
Association of Risk Factor Groups Across Diabetic Status 
 
Diabetic Non-Diabetic χ2 p-value Cramer’s V 
Age   105.124 0.000 0.198 
<25 1 155    
26- 40 7 1170    
41 - 55 45 1195    
56 - 70 10 80    
>70 4 7    
Smoking Status   1.636 0.201 0.025 
Non-Smoker 55 2276    
Smoker 12 329    
HDL Chol   30.842 0.000 0.107 
<41 (Risk) 30 474    
41 – 60 (Normal) 25 1274    
>60 (Optimal) 12 859    
Sys Blood Press   51.338 0.000 0.139 





Diabetic Non-Diabetic χ2 p-value Cramer’s V 
91-120 (Normal 19 1708    
121-140 (PreHyperT) 33 713    
>140 (Hpertension) 15 163    
BMI    93.053 0.000 0.187 
<18 (Underweight) 0 19    
18 – 24.9 (Normal) 8 1107    
25 – 39.9 (Overweight) 43 1399    
>= 40 (Morbid Obesity) 16 82    
Blood Glucose   1957.410 0.000 0.856 
< Hypoglycemic 1 141    
81- 100 (Normal) 2 2015    
101 – 125 (PreDiabetic) 14 429    
126 – 150 (Borderline Diabetic) 27 0    
151 – 200 (High Diabetic 9 0    
> 200 (Very High Diabetic) 13 0    
 
Expectedly, the association between fasting blood glucose (FBG) group and 
DM2 was statistically significant with a very large effect size (Cramer’s V=0.856). As 
can be seen from the Table 6, all those with very high blood glucose levels (above 126 
mg/dL) belonged to the diabetic group. But surprisingly, all of the very high glucose 
levels were with the younger diabetics, while many the older diabetics have blood 
glucose levels closer to that of the Non-Diabetic (See Figure 6). Also, of note is the 
association between those who those who had a CHD event and those who didn’t, 




with those whose blood glucose levels were within the normal range. According to 
Figure 6, the majority of diabetics were 40 years and older, but as can be seen in Figure 
7, those for whom a CHD event was recorded, the ages were both above and below 40 
years, but mostly in the normal FBG region. These findings would have an impact on 





Figure 6. Scatterplot of fasting blood glucose (FBG) vs. AGE by diabetic status (DM2). 
 







Research Question 1 
Research Question 1: Is the relative risk of ‘glucose level’ higher than that of 
‘diabetic status’ for the development of CHD in the FHS data set? 
Null Hypothesis. The relative risk of ‘glucose level’ is less than that of ‘diabetic 
status’ for the development of CHD in the FHS data set. 
Alternative Hypothesis. The relative risk of ‘glucose level’ is higher than that of 
‘diabetic status’ for the development CHD in the FHS data set. 
Two univariate binary logistic regression analyses were conducted to answer 
this first research question. The dichotomous outcome variable was the occurrence of a 
CHD event over the 10-year period. In this unadjusted model, Diabetic Status (DM2) 
was predictive of CHD as the model was statistically significant, with the χ2 = 24.652, p 
= .000 and the pseudo-R2 = 0.043 (See Table 7). In a similar unadjusted model, fasting 
blood glucose (FBG) was also statistically significant, with the χ2 = 14.649, p = .000 
and the pseudo-R2 = 0.025. The larger pseudo-R2 of the DM2 model would imply that 
it is a superior representation of the variance in the CHD outcome than the FBG model. 
Table 7 
 
Comparison of the Unadjusted Models of the Odds for CHD 
 χ2 Pseudo- R2 p-value 
DM2 Model 24.652 0.043 0.000 
FBG Model 14.649 0.025 0.000 
 
With respect to predicting CHD, the odds ratio (OR) for glucose level was 
1.015, 95% CI [1.009, 1.022], suggesting that for each unit level increase in FBG the 




17.015], implying that on average, a diagnosis of diabetes increases the likelihood of 
CHD by 848%. According to the results from the two models, in the absence of 
adjusting for any other risk factor, DM2 status is shown to have a higher OR and is 
therefore a better predictor of CHD. The relative risk of an increasing FBG level, for 
one each unit change, is lower than that for change in DM2 Status, from non-diabetic to 
diabetic. The results of the analysis indicate that the null hypothesis cannot be rejected 
and that the relative predictive value of FBG is less (based on OR measures) than that 
of DM2 for the probability of CHD, in this FHS data set. 
Table 8 
 
Two Models of Odds of CHD Relative to Diabetic Status or Fasting Blood Glucose 
 B S.E. Wald df Sig. Exp(B) 
95% C.I. 
Lower Upper 
DM2 Model 2.138 .355 36.249 1 .000 8.483 4.229 17.015 
FBG Model .015 .003 21.060  1 .000 1.015 1.009 1.022 
 
Research Question 2 
Research Question 2: Is the measure of accuracy higher for the ‘glucose level’ 
formula than that for ‘diabetic status’ formula in the FRS-CHD 10-year risk prediction 
model? 
Null Hypothesis. There is no difference between the measure of accuracy for 





Alternative Hypothesis. The measure of accuracy for ‘glucose level’ formula is 
higher than that for ‘diabetic status’ version of the FRS-CHD 10-year risk prediction 
formula. 
For answering this second research question, a multivariate logistic regression 
was used. The variables SEX, AGE, HDL, SysBP, Smoking Status, and BMI were 
entered as the cofactors, but SEX proved to be a statistically insignificant predictor and 
was eliminated from subsequent formulations. The adjusted DM2 model (Table 9), was 
statistically significant, with χ2 = 100.242, p = .000 and a pseudo-R2 = .171, as was the 
adjusted FBG model (Table 10), with χ2 = 92.098, p = .000, and the pseudo-R2 = .163. 
The adjusted OR for DM2 (Table 9), dropped to 2.295 (from 8.483), 95% CI [1.035, 
5.087] but it remained statistically significant (p = .041). However, in the case of FBG 
(Table 10), the OR decreased to 1.008 (from 1.015) and was no longer a statistically 
significant predictor, as p = .079. 
Table 9 
 
Odds of Diabetic Status for CHD Adjusted for Age, Smoking Status, HDL, and SysBP 




Age  .089 .015 36.985 1 .000 1.093 1.062 1.125 
Smoking Status .921 .301 9.351 1 .002 2.512 1.392 4.533 
HDL cholesterol -.026 .009 8.506 1 .004 .974 .957 .991 
Systolic blood  .021 .008 7.395 1 .007 1.022 1.006 1.037 
DM2  .831 .406 4.182 1 .041 2.295 1.035 5.087 







Odds of FBG for CHD adjusted for Age, Smoking Status, HDL, and SysBP 




Age  .093 .015 41.080 1 .000 1.098 1.067 1.129 
Smoking Status .884 .307 8.279 1 .004 2.422 1.326 4.423 
HDL cholesterol  -.028 .009 8.973 1 .003 .972 .955 .990 
Systolic blood .018 .008 5.119 1 .024 1.018 1.002 1.035 
FBG  .008 .004 3.077 1 .079 1.008 .999 1.017 
Constant -9.504 1.154 67.788 1 .000 .000   
 
To evaluate and compare the performance of the two models relative to each 
other, various performance parameters were used. In the case of the predictive power 
(the Log Likelihood and the Wald statistics), and for the discriminating power (pseudo 
R-squared) the values for the DM2 model were greater than these of FBG model (See 
Table 11) suggesting a superior DM2 performance. For the goodness-of-fit measure, as 
determined by the Hosmer-Lemeshow values, the FBG model had the lower chi-square 
and the higher p-value indicating the FBG superiority over the DM2. These seemingly 
contradiction in performance measures and the lack of statistical significance of the 
actual FBG variable in its model, were considered evidence that the FBG model was 
not an improvement to the DM2 model. Consequently, the null hypothesis was rejected 
as there was no significant difference between the measure of accuracy for ‘glucose 






Comparison of Model’s Performance 
 
DM2 Model FBG Model 
 χ 2 p-value χ2 p-value 
Overall Model     
Log Likelihood  547.800 .000 532.995 0.000 
Wald 891.077 .000 871.000 0.000 
Goodness-of-fit     
Hosmer-Lemeshow 8.115 .422 6.524 0.589 
     
      Coefficient of Determination 
Pseudo-R-square  





Research Question 3:  
Is the measure of accuracy for the ‘glucose level’ formula independent of 
‘BMI’, ‘HDL’ or ‘SysBP’ in the CHD 10-year CHD prediction model? 
Null Hypothesis. The measure of accuracy for ‘glucose level’ is independent of 
‘BMI’, ‘HDL’ or ‘SysBP’ in the 10-year CHD prediction. 
Alternative Hypothesis. The measure of accuracy for ‘glucose level’ is 
dependent on ‘BMI’, ‘HDL’ or ‘SysBP in the CHD 10-year CHD prediction. 
In answering this third research question, instead of using the fasting blood 
glucose level as a continuous variable it was used as an ordinal variable. The sample 
was divided into blood glucose level group (FBG group) variable, which was first run 




When the FBG group variable was entered in the model, the model was also 
statistically significant, as χ2 = 100.781, p = 0.000 and the pseudo R-square = 0.172 
(Table 12). All the variables, including the FBG groups were shown to be statistically 
predictive on a CHD event, with the FBG being the strongest predictor (0R = 1.360, p = 
0.01, 95% CI [1.076, 1.720].  
The introduction of interaction the terms, FBGxHDL, FBGxBMI, and 
FBGxSysBP (created from the metabolically linked factors), did produce a statistically 
significant overall model, with χ2 = 102.407, p = 0.000 and the pseudo R-square = 
0.175 (Table 13). However, the only variables that remained statistically significant in 
this new ‘interaction’ model were Age, and Smoking status. All the other variables, 
including the interaction variables along with HDL and SysBP, were no longer 
statistically significant in this model. 
Table 12 
 
Odds of FBG Groups for CHD Adjusted for Age, Smoking Status, HDL, and SysBP 
 
 B  S.E. Wald df Sig. Exp(B) 
95% C.I. 
Lower Upper 
 Age (years) .085 .014 35.940 1 .000 1.088 1.059 1.119 
Smoking Status .951 .300 10.016 1 .002 2.588 1.436 4.664 
HDL cholesterol  -.025 .009 8.020 1 .005 .975 .958 .992 
Sys blood pressure  .021 .008 7.025 1 .008 1.021 1.005 1.037 
FBG Groups .308 .120 6.610 1 .010 1.360 1.076 1.720 







Odds FBG Groups and Interaction Variables for CHD Adjusted for Age, Smoking 
Status, HDL, BMI, and SysBP 




Age (years) .085 .014 35.802 1 .000 1.089 1.059 1.119 
Smoking Status .955 .301 10.074 1 .002 2.600 1.441 4.689 
HDL cholesterol  -.036 .023 2.479 1 .115 .964 .921 1.009 
Sys blood pressure -.002 .020 .009 1 .925 .998 .959 1.039 
FBG Groups -.831 1.060 .614 1 .433 .436 .055 3.481 
FBG_SysBP .009 .007 1.494 1 .222 1.009 .995 1.023 
FBG_HDL .004 .008 .199 1 .655 1.004 .988 1.020 
FBG_BMI -.004 .008 .326 1 .568 .996 .981 1.011 
Constant -6.157 2.921 4.441 1 .035 .002   
 
The comparison of the measures of performance statistics of the two FBG 
Group model (with and without the interaction variables) demonstrated very little 
difference. As shown in Table 14, the Log Likelihood value did go down from 547.368 
to 545.376 with the addition of the interaction terms (representing a decrease in 
performance), the Hosmer-Lemeshow value also went up from 9.319 to 10.881 
(representing a slight increase in performance). Collectively, the very small changes in 
these values and the contradiction from one performance maker to another renders the 
results insignificant. Together with the results of the logistic regression model, it can be 




groups) and the metabolic terms of HDL, BMI and SysBP. The null hypothesis cannot 
be rejected, and it is assumed that the measure of accuracy of the prediction of the 
CHD, in the FRS-CHD 10-year risk prediction formula, by FBG level groups is not 
influenced the interaction terms. 
Table 14 
 
Comparing the Performance of the FBG Group Models 
 
Non-Interaction Model Interaction Model 
 χ2 p-value χ2 p-value 
Overall Model 
    
Log Likelihood  547.368 0.000 545.376 0.000 
Wald 891.474 0.000 891.276 0.000 
Goodness-of-fit     
Hosmer-Lemeshow 9.319 0.316 10.881 0.209 
     
 Coefficient of Determination  
Pseudo R-square 
 






For this research, the outcome variable was the binary measure of the presence 
or absence of a CHD event within a 10-year period. The dichotomous nature of the 
outcome warranted the use of a binary logistic regression analysis to answer the 
research question. For the first question, where the relative risk of a diagnosis of 
Diabetes was compared with the relative risk of a measure of Fasting Blood glucose 




both variables were statistically significant predictors, but the OR for Diabetes was 
8.483 and that for glucose was 1.015. This suggests that the odds of a CHD event for a 
Diabetic is approximately 8.5 times that of the odds for a non-diabetic, while the odds 
of a CHD event go up by 0.015 for each unit increase in blood glucose level. While the 
glucose would appear to give a more precise measure of risk, the results of the χ2-value 
(24.652 vs 14.649) and the pseudo R-square (0.043 vs 0.025) would indicate that a 
diagnosis of diabetes (in the absence of other risk factors) is a superior predictor.  
For the second question, the other risk factors (Age, Sex, SysBP, HDL and 
Smoking Status) were included in the model and each of the variables (glucose/FBG 
and diabetes/DM2) tested separately. Here both models were statistically significant, 
but the OR for diabetes dropped considerably (OR = 2.295, 95% CI [1.035, 5.087] with 
adjustment, and glucose level was rendered statistically insignificant in the formula. 
The performance measures also confirmed the superiority of the Diabetes model and 
the null hypothesis was not rejected as ‘Diabetic’ FRS-CHD 10-year risk prediction 
formula as there was no difference between the measure of accuracy for ‘glucose level’ 
and ‘diabetic status’ versions of the FRS-CHD 10-year risk prediction formula. 
The third research question investigate the impact of any possible interaction 
between glucose and the metabolic risk factors (HDL, BMI and SysBP). For this 
analysis, the glucose level was transformed into an ordinal variable of groups of 
glucose levels. This variable was statistically significant predictive of CHD, with a 
OR=1.36, p = 0.010 and 95% CI [1.076, 1.720]. The addition of the interaction terms 




and Smoking Status, all the other risk factors, along with the interaction term, were not 
statistically significant for the outcome (p-values > 0.05). Based on these results the 
null hypothesis was not rejected, and the interaction terms were considered to not 
influence the relationship between glucose (when used as FBG levels group) and the 





Chapter 5: Discussion, Recommendations 
Introduction 
Purpose of the Study 
CVDs continue to be the leading cause of death in developed and developing 
countries around the world . Despite the efforts in the field of medicine and public 
health, these diseases continue to threaten the lives of many, and causing serious 
debilitation in others, while costing several billions of dollars in health care cost 
annually . Screening for CVDs has proven to be an effective means of curbing the 
spread and slowing the continued growth among the many affected communities 
around the world. Identifying those at risk and exposing them to health care 
intervention methods has reduced the incidence as well as the devastating effect of all 
the major CVDs. 
The FRS is still the most common screening tool used by health care providers 
to identify those at risk and allocate resources to help prevent CVD or minimize its 
effects on affected individuals . The risk factors included in the FRS have proven to be 
very strong predictors and their combination in the multivariate FRS makes this model 
most effective. The FRS was developed over 50 years ago and its usefulness 
effectiveness notwithstanding, it has undergone optimization and customization that has 
made it more specific the various people groups for whom it is used. The optimization 
methods have focused on either the inclusion of additional risk factors or altering the 
measuring of current risk factors based on novel information from research in the fields 




This present study deals with the optimization of the FRS formula based on the 
use of FBG levels as a risk factor in the place of a diagnosis of DM2. Other derivations 
of the FRS that were developed in for other countries, with different populations, have 
seen an increase in the sensitivity of the screening formula when similar changes were 
made (see citation). The objective of this study was to carry out this substitution and 
compare the models using various performance evaluation methods. Additionally, the 
interaction between glucose and the metabolically significant risk factors were assessed 
for the FBG model. Pairs of the univariate-, multivariate-, and the interaction-models 
were all generated for the both FBG and the DM2, and the respective odds ratios, the 
pseudo-R2 values, and the model-fit parameters (Log Likelihood, Wald, and Hosmer-
Lemeshow statistics) were compared for each pair. 
The data set used for this study was a combination of the Gen III (third 
generation of the Framingham cohort), together with the OMNI II and the NOS cohort. 
This is  prospective data, collected based on a series of exams over many years, 
beginning in 2001 and continuing  today . Before beginning the analysis, the data was 
streamlined to remove those with a history of heart disease, leaving only those whose 
heart disease developed within 10-years period following the original exam when the 
baseline data was collected. The risk factors glucose level and DM2 diagnosis along 
with smoking status (dichotomous), HDL-cholesterol (continuous), systolic blood 
pressure (continuous), gender (nominal) and age (continuous) were included. The 
outcome variable was the dichotomous measure of coronary heart disease (CHD =1, no 




inferential statistics to answer the research questions. Before conducting the inferential 
statistics, descriptive statistics on the predictor variables was carried out, the results of 
which are presented in Chapter 4 of this dissertation.  
Results and Findings 
RQ1: Is the relative risk for glucose level higher than that for diabetic status in 
the CHD 10-year risk prediction? 
H01: There is no difference between the relative risk for glucose level and that 
for diabetic status in the CHD 10-year risk prediction.  
Ha1: The relative risk for glucose level is higher than that for diabetic status in 
the CHD 10-year risk prediction. 
RQ2: Is the measure of accuracy for glucose level higher than that for diabetic 
status in the CHD 10-year risk prediction formula? 
H02: There is no difference between the measure of accuracy for glucose level 
and diabetic status in the CHD 10-year risk prediction formula. 
Ha2: The measure of accuracy for glucose level is higher than that for 
 diabetic status in the CHD 10-year risk prediction formula. 
RQ3: Is the measure of accuracy for glucose level independent of age, BMI, 
cholesterol level, or blood pressure level in the CHD 10-year risk prediction formula? 
H03: The measure of accuracy for glucose level is independent of age, BMI, 





Ha3: The measure of accuracy for glucose level is dependent on age,  BMI, 
cholesterol level, or blood pressure level in the CHD 10-year risk prediction 
formula? 
Descriptive Statistics: How This Data Set Compares with Others 
Comparing Nonmodifiable Risk Factors. The descriptive analysis conducted 
on this data set revealed that the distribution of the gender reflects that of most other 
data sets used for this type of study, as well as that of the distribution in the general 
population (Center for Health Statistics, 2017; D’Agostino, Grundy, Sullivan, & 
Wilson, 2001b; Jahangiry et al., 2017). In the current study, there was almost an equal 
balance, with slightly more female (55%) than males, similar to the distribution in the 
original FHS cohort, and in the subsequent (FHSII) cohort ( Lloyd-Jones et al., 2002; 
Tsao & Vasan, 2015b). This distribution is also reflective of the distribution of the 
sexes in the general population according to the U. S. Census Bureau (U. S. Department 
of Commerce, n.d.). 
Unlike the distribution of the genders, the racial distribution in this data set does 
not reflect that of the general population but is considered like the original FHS cohort 
(mostly White), given that most of the subjects were descendants of the original FHS 
participants. This current data set is made up of three groups, the FHS III, the OMNI II, 
and the NOS cohorts. The FHS III data accounts for 4,578 adults, who are the 
grandchildren of the FHS I, along with an additional 101 of their non-FHS parents who 
had not been included in any of the previous FHS cohorts (Splanksy, 2007). The OMNI 




and ethnically diverse sample set, but they numbered only 405 (Tsao & Vasan, 2015a). 
The NOS cohort also added to increase genetic diversity, was made up of the spouses 
of the OMNI2 and consisted of only 101 subjects (Govindaraju et al., 2008). 
Unfortunately, the ethnically diverse participants made up no more 10% of the total 
sample size, in its original iteration. However, that percentage was reduced with each 
subsequent generation, and race data was only collected for the OMIN2 participants, so 
race was not included in any of these analyses.  
The age values followed a normal distribution of adults (over 19 years), with an 
average of the sample being slightly above 40 years, and 93.8% of the subject between 
26 and 55 years old. In the original cohort, the age range (30 to 62) was narrower that 
the current 20 to 92 and this could have impacted the results of the data analysis. Age is 
not only a major CHD risk factor; it influences the prevalence of other risk factors as 
well and thus the overall reliability of the model. Other risk model optimization studies 
used data sets with older subjects and shorter age ranges, e.g. 45 to 64 (Conroy et al., 
2003), or 35 to 74 (Hippisley-Cox et al., 2007), or 30 to 74 (D’Agostino et al., 2001b). 
A 10-year CHD prediction formula is less accurate for younger adults than it is for 
older adults and this is one of the reasons why formula optimization is preferred with a 
age distribution with smaller standard deviation (Booth et al., 2006). 
Comparing Modifiable Risk Factors. The results of the prevalence evaluation 
of the various risk factors among the participants in this data set revealed that some of 
the prevalences were similar to the national prevalence but most were lower. For 




national average of 17.1% (Zwald, 2017), but the prevalence of hypertension (>140 m) 
was 6.6%, compared to a 29% national average (Paulose-Ram, 2017). In this data set, 
only 1.3% of the subject were reported as diabetic as baseline, which is much lower 
than the national average of 9.4% (or even 7.4% for Whites) ( Benjamin et al., 2017). 
And while it is not known how many patients developed DM2 during the 10-year 
period, those who were classified as prediabetic made up 16.5%, almost half of what is 
the average percentage nationally- 33.9% ( Benjamin et al., 2017). The prevalence of 
overweight/obesity is also a lot less 57.6% compared to the 65.7% reported by the CDC 
at the time of the initial exam (Health E Stats, 2003-4). Based on these analyses, the 
current data set was made up of subjects with lower prevalence of the major risk 
factors. 
The descriptive analyses revealed that the people making up had a lower risk of 
heart disease than the general population average and this was reflected in the CHD 
outcome. After 10 years, only 2.6% had a CHD event, 4.7% CVD in general, which is 
much less than in previous decades, 18.09% for men and 10.08% women for the 
(D’Agostino et al., 2008), or the 15.9% men and 6.9% women for CVD for the two 
previous FHS cohorts (Ford, 2014). The rate of CHD across the U.S. population has 
gone from 10.3% (2001-2), down to 8.0% (2011-12) (Yoon, 2016), and currently is at a 
national average of 3.9%, but ranges from WV’s 7.4% to HI’s 2.5% (CDC BRFSS, 
2017). This low CHD prevalence in this data set countered the effectiveness of the 




outcomes (Giancristofaro & Salmaso, 2003; Stoltzfus, 2011) and made the formula 
development more challenging. 
Bivariate Analysis: Gender Differences 
Historically, the distribution of heart disease and its risk factors have always 
differed across the genders (Amsterdam, 2011; Hosseini, 2015; Tunstall-Pedoe, 
Woodward, Tavendale, Brook, & Mccluskey, n.d.). In the present study also, there 
were more almost twice as many male diabetics (n=43) as female diabetics (n=23) 
contrasted with the more than four times as many women (n=714) than men (n=158) 
with optimal HDL measures. These findings were also congruent with others, including 
that the fact that the overweight/obese men (887 or 73.7%) outnumbered the 
overweight/obese women (654 or 44.4%). The association between gender and the 
various groups of systolic blood pressure was also significant, (p = .000) with 45% of 
men being hypertensive compared to 22% of the women. These findings are consistent 
with previous research where men had higher prevalence of CVD risk factors 
(D’Agostino et al., 2013, 2008; Fawwad et al., 2016). A related study that used 
electronic health records (EHR) to compare the performance of three CVD risk score 
functions (FRS, ASCVD and QRISK), found that 82% of the men were overweight or 
obese compared to 63% of the women; 14% of men were diabetic compared with 9% of 
women; and ultimately 8% of the men and 4% of the women had a CVD event during 
the 10-year follow-up (Pike et al., 2016). These gender differences in the current study 
were ultimately reflected in the CHD rate outcome as 3.25% of men and 1.31% of 




were adjusted for in the formula, gender was not a statistically significant predictor. 
This lack of effectiveness of gender in the CHD outcome has been reported in previous 
research (Jahangiry et al., 2017; Kozakova et al., 2017). 
Bivariate Analysis: Diabetics versus Nondiabetics 
The bivariate analysis of this data set confirmed the association between DM2 
and the other cardiometabolic risk factors. Increasing BMI, Sys BP, and age, and 
decreasing HDL were all associated with an increased probability of a DM2 diagnosis 
(see Table 6). The older the subjects the higher the percentage of diabetes, going from 
3.76% of those 41 - 55, to 12.5% for 56 - 70, and to 57.2% of those over 70 years old. 
Similarly, only 1.1% of the nonhypertensive (Sys BP < 120) were diabetic, but 9.2% of 
the hypertensive were diabetic; only 0.7% of the normal/underweight (BMI < 25) were 
diabetic but 3.98% of the overweight or obese were. Only 1.3% of those with optimal 
HDL levels were diabetic, but of those with low (not-optimal) HDL, 3.15% were 
diabetic. These results are similar to those found in other DM2-CVD risk factor 
correlation studies (Bragg et al., 2014; Haregu et al., 2016; Qazi & Malik, 2013a; 
Selvin et al., 2010). The Chi-square analysis of all these association, proved they were 
all statistically significant (p = .000), and based on the Cramer’s V, relatively strong, 
measuring 0.107, 0.139 and 0.187 for HDL, SBP and BMI respectively. Despite these 
values, however, in the multivariate formula, BMI was not predictive, and the 
interaction variables for each of HDL and SBP were not statistically significant. 
Smoking is traditionally the strongest CVD risk factor (CDC, 2014; Mannan et 




DM2 (p = 0.201). In this analysis, smokers were no more likely to be diagnosed as 
diabetic than nonsmokers. This is probably an indication that though both smoking and 
DM2 increases the risk of developing CVD, the mechanism by which these two factors 
cause damage to the cardiovascular system are different. Smoking introduces toxins 
and external sources of oxidative stress that ultimately damages the endothelial and this 
precipitates atherosclerosis (CDC, 2014; Huxley et al., 2011). On the other hand, as a 
disorder of metabolism, DM2-driven CVD is mediated by the internally produced 
biochemicals, namely excessive insulin, that eventually generates ROS and the 
associated tissue damage then leads to atherosclerosis and (Faerch et al., 2012; Kumar 
et al., 2019; Laakso, 2015). These differences may be a possible explanation for 
absence of association between the variables at baseline. 
The etiology of CVD as a cardiometabolic disease that has been postulated in 
many prospective epidemiological studies, though not clearly defined, is increasing 
being supported by the clinical and genetic research (Holmes, Pulit, & Lindgren, 2017; 
Nichols et al., 2012; Wilson & Meigs, 2008). One such study is the comprehensive 
meta review of over 100,00 cases that used gene analysis to research the causal role of 
central/general obesity in several CVD outcomes (Dale et al., 2017. The results suggest 
that patients with a genetic disposition to metabolic disorder, of which central or 
abdominal obesity is symptomatic, are more susceptible to both DM2 and CVD (Dale 
et al., 2017). Another genetic study of over 26,000 Finnish subjects verified the causal 
role of metabolic disruption and rising insulin as the source of heart damage and that 




et al., 2016). Another study, conducted with 1.3 million obese or overweight (BMI > 
25), nondiabetic adults on the distribution of four metabolic risk factors -elevated blood 
pressure, low HDL, elevated triglycerides and prediabetes- found the number and 
prevalence of the CVD increased significantly with each age group indicating a 
progression of the risk factors culminating in CVD (Assmann et al., 2008). This may 
also explain, the correlation between BMI in a univariate model, but no statistical 
significance in the multivariate model, when adjustments are made for other more 
strongly predictive risk factors. 
Answer to Research Questions  
RQ1: Is the relative risk for glucose level higher than that for diabetic status in 
the CHD 10-year risk prediction? 
H01: There is no difference between the relative risk for glucose level and that 
for diabetic status in the CHD 10-year risk prediction.  
Ha1: The relative risk for glucose level is higher than that for diabetic status in 
the CHD 10-year risk prediction. 
Comparison of Unadjusted Odds Ratio. The results of the univariate analyses 
do indicate that a DM2 diagnosis is stronger predictor of CHD risk than is a measure of 
fasting glucose level. However, it is difficult to compare these results, as one variable is 
dichotomous, and the other is continuous. The odds ratio indicate that a diabetic person 
has an almost 850% (OR = 8.483) increased risk of CHD compared to a non-diabetic. 
On the other hand, every unit increase in FBG confers an increased risk of 1.5% (OR = 




(OR = 1.161), and a 20-unit FBG increase confers a 35% (OR = 1.347) increased CHD 
risk. Despite the large discrepancy in the odds for DM2 and FBG, they were both 
predictive, but the difference in odds is mainly due to the way the variables are 
measured as both are statistically significant (p-value < 0.001). 
This minimal effect in the predictive value of FBG may be further explained by 
a number of reasons, including (a) the formula used for evaluating; (b) the cohort used 
to generate the formula; and (c) the method of comparison. Firstly, previous studies that 
have evaluated the performance of glucose included models that were based on 
different (optimized) variations of the FRS than the one used in this study (Collins & 
Altman, 2009; Rücker et al., 2016), or other studies used hazard ratio (HR) measures 
instead of OR for comparison of the variables (Demler et al., 2015; Kadowaki et al., 
2008; Sarwar et al., 2010), or still others compared classification categories for CHD 
risk outcomes and not the goodness of fit parameters (Conroy et al., 2003; Garg et al., 
2017). Secondly, the Framingham cohort is known to be made up of predominantly 
White subjects and as have been confirmed by many studies race dose play a role risk 
of heart disease (see Nichols et al., 2012; Pike et al., 2016; Sarwar et al., 2010; Singhal, 
Tien, & Hsia, 2016). Two such study in particular found that glucose level was a strong 
predictor of CVD risk than blood pressure and cholesterol values, for African 
Americans (Carter et al., 2016). These factors may have impacted the performance of 
the model in this study and thus render the model optimization futile. 
Other explanations for the apparent underperformance of the glucose level as a 




variables. The coefficient and the corresponding odds ratio for each independent 
variable approximates the relationship. One of the assumptions of the logistic 
regression is that the predictor has a linear relationship with the log of the outcome, else 
the strength and significance of the relationship is underestimated (Lani, 2015; 
Sperandei, 2014). For example, a few studies have reported that the (log odds) 
relationship between glucose level and heart disease risk follows a J-shaped curve, 
representing that the glucose level associated with a reduced risk is only a narrow 
range, and an increased CVD risk for levels below and above that range (Mongraw-
Chaffin et al., 2019; Park et al., 2013; Selvin et al., 2010). In the present study, when 
the FBG was turned into a categorical variable (FBG groups) the odds ratio varied 
considerably among the groups, but the relationship was not linear. Other studies have 
reported that the strength of the relationship between glucose and CHD decrease with 
the age of the subjects, as other CHD risk factors become more prominent (Booth et al., 
2006; Conroy et al., 2003). This combined with the fact that CHD prevalence in the 
population increases with age, are the main reasons why the hazard ratio is the 
preferred method of risk evaluation. With the current study, the only age range within 
which glucose remained statistically significant in the model was between 56 and 70 
years. Using ORs as was done in here, may complicate and even preclude the 
relationship necessary for formula optimization.  
RQ2: Is the measure of accuracy for ‘glucose level’ higher than that for ‘diabetic 




H02: There is no difference between the measure of accuracy for ‘glucose level’ 
and ‘diabetic status’ in the CHD 10-year risk prediction formula. 
HA2: The measure of accuracy for ‘glucose level’ is higher than that for 
‘diabetic status’ in the CHD 10-year risk prediction formula. 
Comparison of Adjusted Odds Ratios 
 Although both factors (glucose level and diabetic status) were significant in 
their respective univariate models, only DM2 remained statistically significant after 
adjusting for the other cofactors. In comparing the two models, the various parameters 
indicated that the both models performed similarly, with the glucose model being 
slightly weaker model than that for DM2 model. Looking at the chi-square (measure of 
the association between the observed and the expected probabilities) values for the 
multivariate models, shows that the DM2 model is slightly superior fit to the overall 
data (χ2: 547.800DM2 vs 532.995FBG); and similarly the pseudo R-square values 
indicating that the DM2 model has marginally better predictive power (0.171 DM2 vs 
0.163 FBG). Based on these two parameters, there is no advantage gained by using blood 
glucose level instead of diabetic status in the FRS model when screening for CHD risk 
in asymptomatic clients. 
The Hosmer-Lemeshow (H-L) test tells a similar story about the similarity of 
the models, with one interesting caveat. It should be noted that with the H-L test, which 
gives an average of the chi-square for deciles of the outcome probability, unlike the 
Omnibus test, a lower chi-square and higher p-values are preferred (Giancristofaro & 




superior to the diabetic status model, as indicated by the lower chi-square values (H-L: 
6.524 FBG vs 8.115 DM2) and the higher p-values (0.589 FBG vs 0.422 DM2). This points to 
the superiority of the glucose model as a better fit (predicted versus observed) for the 
data when divided into sections (Moons et al., 2012.; Peng, Lee, & Ingersoll, 2002). 
The H-L results lend further support to the recommendation that model performance 
evaluation is best estimated only after dividing the data into various strata. 
RQ3: Is the measure of accuracy for ‘glucose level’ independent of ‘age’, ‘BMI’, 
‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-year risk prediction 
formula? 
H03: The measure of accuracy for ‘glucose level’ is independent of ‘age’, 
‘BMI’, ‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-year risk prediction 
formula. 
HA3: The measure of accuracy for ‘glucose level’ is dependent on ‘age’, ‘BMI’, 
‘cholesterol level’ or ‘blood pressure level’ in the CHD 10-year risk prediction formula. 
Assessing the Interaction Variables 
Testing the interaction variables in the given formula proved futile, as the FBG 
variable itself was not statistically significant in the multivariate model. Consequently, 
different interaction terms were created with the ‘FBG-groups’ variable, which was 
statistically significant, but again the interaction variables were not statistically 
significant. Though only the age and smoking status variables remained significant in 
this new interaction-included model, the addition of the interaction terms had very little 




version, the model only accounted for 17.2% of the variability in the outcome, and the 
low prevalence of the disease conferred an already high accuracy (~97.4%) to the null 
(no variable) model leaving very little room for improvement. The area under curve 
(AUC) values, which assesses the classification power of the models, were 0.816 for 
DM2 and 0.813 for glucose; with the DM2 model have a slightly higher specificity and 
sensitivity, at the 20%-CHD risk cut off point, 14.3% vs 11.7% and 1.0% vs. 0.9% 
respectively. The UC values are similar to those found in previous studies, higher than 
some, 0.69 – 0.71 (Pike et al., 2016), 0.809-0.834 (Pandya, Weinstein, & Gaziano, 
2011) and lower than others, 0.811 -0.819 (Günaydın et al., 2016). However, based on 
the confidence intervals for the present AUC values (overlapping CIs), the differences 
between the two models were not considered significant. 
Limitations of the Findings 
This study presented insight into the performance of the FRS formula, but there 
are some specific limitations to the generalizability of the findings. Firstly, the main 
limitation of these findings relates to the uniqueness of all the FHS cohorts, which is 
specific to a particular population, namely White American of European descent, 
connected to the Framingham, MA region. As other studies have proven, FRS findings 
are sometimes not applicable to the other population that include other ethnicities, and 
require recalibration prior to application (Elosua, 2014; Hemann et al., 2007; Rücker et 
al., 2016). Furthermore, this FRS III cohort is the most recent version and was chosen 
for that reason, but it should be noted that there were differences between this and the 




diagnosis has changed since the 1950s, and was mentioned before, many more diabetes 
were previously diagnosed and receiving treatment than was the case with the 
participants of the FRS I. 
Another important limitation relates to the FRS formula used here was restricted 
to very specific risk factors, namely Age, Sex, Sys BP, HDL, DM2 and FBG and did 
not include others. This model did not account for factors, such as family history of 
heart disease, presence of other diseases (chronic kidney or liver disease or 
inflammatory disease), level of physical activity, etc., all of which have been proven to 
impact CHD risk levels (Kones, 2011; Ray et al., 2014; Sarwar et al., 2010; Tsao, 2015; 
Tsao & Vasan, 2015b; Wilson et al., 1998; Woodward et al., 2007). The presence of 
these attenuating factors for some participants, but not included in the analysis, may 
have weakened the measure of the association between the outcome and the risk factors 
being assessed. 
A most important issue in this model is that it did not include relevant 
information on patient medication, especially glucose lowering medications for the 
diabetics, including sulfonylureas, biguanides, alpha glucosides inhibitors or exogenous 
insulin. Like with other medications, this was not included for the sake parsimony of 
the model, but it should be noted that doing so limits the model’s accuracy. In this 
study, almost 25% of the diabetics had FBG levels below the threshold (see Table 6), 
which could be the results of medication, or lifestyle, or both. The lowered FBG for 




FBG levels and the CHD outcome, thereby reducing the predictive power of 
dysglycemia on a CHD event, reducing the reliability of the results. 
There are several other limitations related to all disease risk score studies in 
general that are also worth mentioning. Any disease risk score, based on cross-sectional 
data, can only be considered as risk estimation and cannot be used for causality 
determination (Dahlöf, 2010; Nieto, 1999b). Also, all risk formula should be carefully 
validated by applying and testing them to a data set other than the one used to develop 
it. Relying of statistical significance or internal calibration is not enough, for this type 
of one-time measurement of risk factors that are known to fluctuate and interact with 
each other in unpredictable ways (Collins & Altman, 2009). Finally, an issue that is 
common to risk estimation studies, is the imprecision and low sensitivity of the 
formulas generated. These models tend to have very low sensitivity and specificity 
values and should only be used for general classification of asymptomatic patients. This 
is advised to reduce the reported cases of underestimation of high-risk patients going 
undetected and therefore untreated (Collins & Altman, 2012; Rücker et al., 2016; 
Steyerberg et al., 2010; Tsao & Vasan, 2015b). The CVD risk prediction models have 
been very effective in predicting risk probability and stratifying individuals into risk 
groups, but because of their many limitations then cannot be used in place of a 
thorough medical examination. 
Recommendations for Future Research 
The unexpected findings in this study point to the need for additional research 




heart health. The next step in this type of study would be to conduct similar 
performance estimation with a cohort from a different, more diverse population. For 
example, the results may be different in African Americans populations, given that 
glucose level have be shown to have on the strong predictive association with CVD risk 
and that there is a higher the prevalence of CHD as well (Carter et al., 2016; Clark et 
al., 2015; Marshall, 2005). The prevalence of the different types of CVD as well as the 
prevalence of the risk factors vary among the different population types and these 
prevalence difference have been shown to impact the performance of the risk models 
(Al-Nooh, Abdulabbas Abdulla Alajmi, & Wood, 2014; Nichols et al., 2012; Yosaputra 
et al., 2010). 
Another area of future research is the model evaluation generated with different 
stratifications of the same data set. There are several ways that the data could be 
stratified, including by gender, age groups, diabetic status, smoking status, etc. Other 
risk assessment models have been known to have variation in their performance for 
different strata of the same population (Mendis, 2010; Steyerberg et al., 2010). In this 
data set, as in others reported, the prevalence of CHD is twice as high as it is for 
women, consequently some forms of the risk models are sex-specific (Amsterdam, 
2011; Jahangiry et al., 2017; Wilson et al., 1998). Separating the data set into different 
groups or sections could potentially reveal any nuances in the performance of the 
models across the groups that may be affecting overall performance. 
Another important recommendation for future research is the use of other 




namely glycated hemoglobin. A supplementary analysis of this data set was conducted, 
replacing glucose with insulin or HbA1C values. Insulin levels were not statistically 
significant but HbA1C was found to be a statistically significant predictor, even having 
a stronger predictive relationship (with an OR = 1.378, p =0.039), than all the other risk 
factors, except for smoking. A previous study found HbA1C to be a stronger predictor 
of CHD risk than total cholesterol or total cholesterol/HDL ratio, with OR of 1.23, 
1.047 and 1.073 respectively (Faeh et al., 2013). Several other studies also determined 
that HbA1C has a greater association with CVD risks than does glucose (Ahn, 2017; 
Carson et al., 2015; Sarwar et al., 2010; Selvin et al., 2010). Others have suggested that 
HBA1C levels could replace glucose in screening for both DM2 and CVD (Danesh, 
2014), or it could even be used a single parameter in determining CVD risk for non-
diabetics (Garg et al., 2014). All these studies point to a strong rationalization to 
including HbA1C in risk models, or at least testing the merit of its inclusion. 
The final recommendation as it relates to CVD risk estimation is the use of a 
different type of regression modeling to represent the prospective data. The models that 
have been traditionally used are based on Logistic Regression and the Cox Proportional 
Hazard, both of which are parametric analyses and therefore rely on various 
assumptions about the underlying data. The Logistic regression assumes that there is a 
linear relationship between the variable and the log odds of the outcome (Lani, 2015), 
and the Cox Hazard assumes that the ratio of the hazard of the succumbing to the 




not be true in the case of CVD and its many risk factors, making models based on them 
unreliable. 
Non-parametric modeling are free of assumptions and are able to account for 
the structure in the data and generate more accurate representation of the data (Austin, 
Tu, & Alter, 2003). Methods such as decision/classification tree analysis; structural 
equation model (SEM); non-parametric path analysis; as well as data mining and big 
data analysis techniques are transforming medical disease modeling (Dunson, Xing, & 
Associate, 2012)(Kennedy, Wiitala, Hayward, & Sussman, n.d.) (Dunson et al., 2012). 
These novel techniques are outperforming older modeling approaches with increased 
accuracy and improved reliability as well as providing causal inferences from 
prospective data. These types of models allowing improved patient classification and 
clinical treatment decision making (Vistisen et al., 2016). The combination of large 
quantities of patient data, both epidemiological and HER, and the sophisticated 
computer application tools may make traditional modeling obsolete.  
General Conclusion 
This study was the first of its kind to assess the performance of the Framingham 
Risk Score model on the third generation of FHS cohort (FHS III). The present analysis 
confirmed that both glucose and diabetic status had a significant association with the 
outcome of a CHD event. The findings, however, indicate that there was no statistically 
significant difference and no improvement in performance of the FRS model when 
DM2 replaces FBG levels. The study did also corroborate the predictive value of the 




pressure. Specific to this data set, factors of gender and BMI were not statistically 
significant to the outcome, however, it should be noted that this data set, like all other 
FHS cohorts, is made up of unique population of relatively heart-healthy participants. 
As such further research into the accuracy and reliability of the results, along with 
responsible validation studies, are needed before generalizable application of these 
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